Help:Needs review/Stale reviews

This is a list of all content pages that are marked reviewed, but after the review it was subsequently edited. Presumably these pages need to be reviewed again.

3900 reviews are up to date. 2732 reviews are stale and are listed below.

• The gut microbiota in conventional and serrated precursors of colorectal cancer
• The gut microbiota in conventional and serrated precursors of colorectal cancer/Experiment 1
• The gut microbiota in conventional and serrated precursors of colorectal cancer/Experiment 2
• The gut microbiota in conventional and serrated precursors of colorectal cancer/Experiment 3
• The gut microbiota in conventional and serrated precursors of colorectal cancer/Experiment 4
• The gut microbiota in conventional and serrated precursors of colorectal cancer/Experiment 5
• The gut microbiota in conventional and serrated precursors of colorectal cancer/Experiment 5/Signature 1
• The gut microbiota in conventional and serrated precursors of colorectal cancer/Experiment 6
• The gut microbiota in conventional and serrated precursors of colorectal cancer/Experiment 7
• Microbiomic differences in tumor and paired-normal tissue in head and neck squamous cell carcinomas
• Microbiomic differences in tumor and paired-normal tissue in head and neck squamous cell carcinomas/Experiment 1
• Microbiomic differences in tumor and paired-normal tissue in head and neck squamous cell carcinomas/Experiment 2
• Fecal Microbiota, Fecal Metabolome, and Colorectal Cancer Interrelations
• Fecal Microbiota, Fecal Metabolome, and Colorectal Cancer Interrelations/Experiment 1
• Gut microbiome alterations in patients with stage 4 hepatitis C
• Gut microbiome alterations in patients with stage 4 hepatitis C/Experiment 1
• The lung microbiome in moderate and severe chronic obstructive pulmonary disease
• The lung microbiome in moderate and severe chronic obstructive pulmonary disease/Experiment 1
• The lung microbiome in moderate and severe chronic obstructive pulmonary disease/Experiment 2
• Gut Microbiome-Based Metagenomic Signature for Non-invasive Detection of Advanced Fibrosis in Human Nonalcoholic Fatty Liver Disease
• Gut Microbiome-Based Metagenomic Signature for Non-invasive Detection of Advanced Fibrosis in Human Nonalcoholic Fatty Liver Disease/Experiment 1
• Pyrosequencing study of fecal microflora of autistic and control children
• Pyrosequencing study of fecal microflora of autistic and control children/Experiment 1
• Gut microbiota in human adults with type 2 diabetes differs from non-diabetic adults
• Gut microbiota in human adults with type 2 diabetes differs from non-diabetic adults/Experiment 1
• A comprehensive analysis of breast cancer microbiota and host gene expression
• A comprehensive analysis of breast cancer microbiota and host gene expression/Experiment 1
• Analysis of the cervical microbiome and potential biomarkers from postpartum HIV-positive women displaying cervical intraepithelial lesions
• Analysis of the cervical microbiome and potential biomarkers from postpartum HIV-positive women displaying cervical intraepithelial lesions/Experiment 1
• Analysis of the cervical microbiome and potential biomarkers from postpartum HIV-positive women displaying cervical intraepithelial lesions/Experiment 2
• Analysis of the cervical microbiome and potential biomarkers from postpartum HIV-positive women displaying cervical intraepithelial lesions/Experiment 2/Signature 1
• Analysis of the cervical microbiome and potential biomarkers from postpartum HIV-positive women displaying cervical intraepithelial lesions
• Analysis of the cervical microbiome and potential biomarkers from postpartum HIV-positive women displaying cervical intraepithelial lesions/Experiment 1
• Association of cervical microbial community with persistence, clearance and negativity of Human Papillomavirus in Korean women: a longitudinal study
• Association of cervical microbial community with persistence, clearance and negativity of Human Papillomavirus in Korean women: a longitudinal study/Experiment 1
• Association of cervical microbial community with persistence, clearance and negativity of Human Papillomavirus in Korean women: a longitudinal study/Experiment 2
• Association of cervical microbial community with persistence, clearance and negativity of Human Papillomavirus in Korean women: a longitudinal study/Experiment 3
• Association of cervical microbial community with persistence, clearance and negativity of Human Papillomavirus in Korean women: a longitudinal study/Experiment 4
• The direct and indirect association of cervical microbiota with the risk of cervical intraepithelial neoplasia
• The direct and indirect association of cervical microbiota with the risk of cervical intraepithelial neoplasia/Experiment 1
• The direct and indirect association of cervical microbiota with the risk of cervical intraepithelial neoplasia/Experiment 2
• The tongue microbiome in healthy subjects and patients with intra-oral halitosis
• The tongue microbiome in healthy subjects and patients with intra-oral halitosis/Experiment 1
• The tongue microbiome in healthy subjects and patients with intra-oral halitosis/Experiment 1/Signature 2
• The Placental Microbiota Is Altered among Subjects with Gestational Diabetes Mellitus: A Pilot Study
• The Placental Microbiota Is Altered among Subjects with Gestational Diabetes Mellitus: A Pilot Study/Experiment 1
• Melatonin prevents obesity through modulation of gut microbiota in mice
• Melatonin prevents obesity through modulation of gut microbiota in mice/Experiment 1
• Melatonin prevents obesity through modulation of gut microbiota in mice/Experiment 2
• Altered gut microbiota profile in patients with generalized anxiety disorder
• Altered gut microbiota profile in patients with generalized anxiety disorder/Experiment 1
• Altered gut microbiota profile in patients with generalized anxiety disorder/Experiment 2
• High-fat feeding rather than obesity drives taxonomical and functional changes in the gut microbiota in mice
• High-fat feeding rather than obesity drives taxonomical and functional changes in the gut microbiota in mice/Experiment 1
• High-fat feeding rather than obesity drives taxonomical and functional changes in the gut microbiota in mice/Experiment 2
• High-fat feeding rather than obesity drives taxonomical and functional changes in the gut microbiota in mice/Experiment 3
• High-fat feeding rather than obesity drives taxonomical and functional changes in the gut microbiota in mice/Experiment 3/Signature 2
• Analysis of gut microbiota diversity and auxiliary diagnosis as a biomarker in patients with schizophrenia: A cross-sectional study
• Analysis of gut microbiota diversity and auxiliary diagnosis as a biomarker in patients with schizophrenia: A cross-sectional study/Experiment 1
• The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota
• The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota/Experiment 1
• The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota/Experiment 2
• 16S gut community of the Cameron County Hispanic Cohort
• 16S gut community of the Cameron County Hispanic Cohort/Experiment 1
• Analysis of Gut Microbiota in Patients with Parkinson's Disease
• Analysis of Gut Microbiota in Patients with Parkinson's Disease/Experiment 1
• Gut microbiome alterations in Alzheimer's disease
• Gut microbiome alterations in Alzheimer's disease/Experiment 1
• Gut microbiome alterations in Alzheimer's disease/Experiment 1/Signature 1
• Gut microbiome alterations in Alzheimer's disease/Experiment 1/Signature 2
• Chronic fatigue syndrome patients have alterations in their oral microbiome composition and function
• Chronic fatigue syndrome patients have alterations in their oral microbiome composition and function/Experiment 1
• Microbiome dynamics of human epidermis following skin barrier disruption
• Microbiome dynamics of human epidermis following skin barrier disruption/Experiment 1
• Intestinal Microbiota Is Influenced by Gender and Body Mass Index
• Intestinal Microbiota Is Influenced by Gender and Body Mass Index/Experiment 1
• Intestinal Microbiota Is Influenced by Gender and Body Mass Index/Experiment 2
• Maternal omega-3 fatty acids regulate offspring obesity through persistent modulation of gut microbiota
• Maternal omega-3 fatty acids regulate offspring obesity through persistent modulation of gut microbiota/Experiment 1
• Maternal omega-3 fatty acids regulate offspring obesity through persistent modulation of gut microbiota/Experiment 2
• Reduced diversity and altered composition of the gut microbiome in individuals with myalgic encephalomyelitis/chronic fatigue syndrome
• Reduced diversity and altered composition of the gut microbiome in individuals with myalgic encephalomyelitis/chronic fatigue syndrome/Experiment 1
• Altered fecal microbiota composition in patients with major depressive disorder
• Altered fecal microbiota composition in patients with major depressive disorder/Experiment 1
• Altered fecal microbiota composition in patients with major depressive disorder/Experiment 2
• High-throughput 16S rRNA gene sequencing reveals alterations of intestinal microbiota in myalgic encephalomyelitis/chronic fatigue syndrome patients
• High-throughput 16S rRNA gene sequencing reveals alterations of intestinal microbiota in myalgic encephalomyelitis/chronic fatigue syndrome patients/Experiment 1
• High-throughput 16S rRNA gene sequencing reveals alterations of intestinal microbiota in myalgic encephalomyelitis/chronic fatigue syndrome patients/Experiment 2
• High-throughput 16S rRNA gene sequencing reveals alterations of intestinal microbiota in myalgic encephalomyelitis/chronic fatigue syndrome patients/Experiment 3
• Fecal metagenomic profiles in subgroups of patients with myalgic encephalomyelitis/chronic fatigue syndrome
• Fecal metagenomic profiles in subgroups of patients with myalgic encephalomyelitis/chronic fatigue syndrome/Experiment 1
• Fecal metagenomic profiles in subgroups of patients with myalgic encephalomyelitis/chronic fatigue syndrome/Experiment 1/Signature 2
• Fecal metagenomic profiles in subgroups of patients with myalgic encephalomyelitis/chronic fatigue syndrome/Experiment 2
• Fecal metagenomic profiles in subgroups of patients with myalgic encephalomyelitis/chronic fatigue syndrome/Experiment 2/Signature 2
• Fecal metagenomic profiles in subgroups of patients with myalgic encephalomyelitis/chronic fatigue syndrome/Experiment 3
• Fecal metagenomic profiles in subgroups of patients with myalgic encephalomyelitis/chronic fatigue syndrome/Experiment 3/Signature 1
• Microbiota in anorexia nervosa: The triangle between bacterial species, metabolites and psychological tests
• Microbiota in anorexia nervosa: The triangle between bacterial species, metabolites and psychological tests/Experiment 1
• Comparison of the gut microbiota composition between obese and non-obese individuals in a Japanese population, as analyzed by terminal restriction fragment length polymorphism and next-generation sequencing
• Comparison of the gut microbiota composition between obese and non-obese individuals in a Japanese population, as analyzed by terminal restriction fragment length polymorphism and next-generation sequencing/Experiment 1
• A step ahead: Exploring the gut microbiota in inpatients with bipolar disorder during a depressive episode
• A step ahead: Exploring the gut microbiota in inpatients with bipolar disorder during a depressive episode/Experiment 1
• A step ahead: Exploring the gut microbiota in inpatients with bipolar disorder during a depressive episode/Experiment 2
• A step ahead: Exploring the gut microbiota in inpatients with bipolar disorder during a depressive episode/Experiment 3
• A step ahead: Exploring the gut microbiota in inpatients with bipolar disorder during a depressive episode/Experiment 4
• A step ahead: Exploring the gut microbiota in inpatients with bipolar disorder during a depressive episode/Experiment 5
• A step ahead: Exploring the gut microbiota in inpatients with bipolar disorder during a depressive episode/Experiment 6
• A step ahead: Exploring the gut microbiota in inpatients with bipolar disorder during a depressive episode/Experiment 7
• A step ahead: Exploring the gut microbiota in inpatients with bipolar disorder during a depressive episode/Experiment 8
• A step ahead: Exploring the gut microbiota in inpatients with bipolar disorder during a depressive episode/Experiment 9
• A step ahead: Exploring the gut microbiota in inpatients with bipolar disorder during a depressive episode/Experiment 10
• A step ahead: Exploring the gut microbiota in inpatients with bipolar disorder during a depressive episode/Experiment 11
• Molecular analysis of oral microflora in patients with primary Sjögren's syndrome by using high-throughput sequencing
• Molecular analysis of oral microflora in patients with primary Sjögren's syndrome by using high-throughput sequencing/Experiment 1
• Gut Microbiota Markers in Obese Adolescent and Adult Patients: Age-Dependent Differential Patterns
• Gut Microbiota Markers in Obese Adolescent and Adult Patients: Age-Dependent Differential Patterns/Experiment 1
• Gut Microbiota Markers in Obese Adolescent and Adult Patients: Age-Dependent Differential Patterns/Experiment 2
• Gut Microbiota Markers in Obese Adolescent and Adult Patients: Age-Dependent Differential Patterns/Experiment 3
• Gut Microbiota Markers in Obese Adolescent and Adult Patients: Age-Dependent Differential Patterns/Experiment 4
• Gut Microbiota Markers in Obese Adolescent and Adult Patients: Age-Dependent Differential Patterns/Experiment 5
• Gut Microbiota Markers in Obese Adolescent and Adult Patients: Age-Dependent Differential Patterns/Experiment 6
• Dysbiosis signature of fecal microbiota in colorectal cancer patients
• Dysbiosis signature of fecal microbiota in colorectal cancer patients/Experiment 1
• Understanding the microbial basis of body odor in pre-pubescent children and teenagers
• Understanding the microbial basis of body odor in pre-pubescent children and teenagers/Experiment 1
• Understanding the microbial basis of body odor in pre-pubescent children and teenagers/Experiment 1/Signature 1
• Understanding the microbial basis of body odor in pre-pubescent children and teenagers/Experiment 1/Signature 2
• Understanding the microbial basis of body odor in pre-pubescent children and teenagers/Experiment 2
• Understanding the microbial basis of body odor in pre-pubescent children and teenagers/Experiment 3
• Understanding the microbial basis of body odor in pre-pubescent children and teenagers
• Understanding the microbial basis of body odor in pre-pubescent children and teenagers/Experiment 1
• Understanding the microbial basis of body odor in pre-pubescent children and teenagers/Experiment 2
• Understanding the microbial basis of body odor in pre-pubescent children and teenagers/Experiment 3
• Understanding the microbial basis of body odor in pre-pubescent children and teenagers/Experiment 4
• Understanding the microbial basis of body odor in pre-pubescent children and teenagers/Experiment 5
• Understanding the microbial basis of body odor in pre-pubescent children and teenagers/Experiment 6
• Gut microbiome in ADHD and its relation to neural reward anticipation
• Gut microbiome in ADHD and its relation to neural reward anticipation/Experiment 1
• Analysis of microbiota in first episode psychosis identifies preliminary associations with symptom severity and treatment response
• Analysis of microbiota in first episode psychosis identifies preliminary associations with symptom severity and treatment response/Experiment 1
• Analysis of microbiota in first episode psychosis identifies preliminary associations with symptom severity and treatment response/Experiment 1/Signature 2
• Alterations of Gut Microbiota in Cholestatic Infants and Their Correlation With Hepatic Function
• Alterations of Gut Microbiota in Cholestatic Infants and Their Correlation With Hepatic Function/Experiment 1
• Sequencing of 16S rRNA reveals a distinct salivary microbiome signature in Behçet's disease
• Sequencing of 16S rRNA reveals a distinct salivary microbiome signature in Behçet's disease/Experiment 1
• Sequencing of 16S rRNA reveals a distinct salivary microbiome signature in Behçet's disease/Experiment 2
• Pediatric obesity is associated with an altered gut microbiota and discordant shifts in Firmicutes populations
• Pediatric obesity is associated with an altered gut microbiota and discordant shifts in Firmicutes populations/Experiment 1
• An intermittent hypercaloric diet alters gut microbiota, prefrontal cortical gene expression and social behaviours in rats
• An intermittent hypercaloric diet alters gut microbiota, prefrontal cortical gene expression and social behaviours in rats/Experiment 1
• Relative Abundance in Bacterial and Fungal Gut Microbes in Obese Children: A Case Control Study
• Relative Abundance in Bacterial and Fungal Gut Microbes in Obese Children: A Case Control Study/Experiment 1
• Diet, physical activity and screen time but not body mass index are associated with the gut microbiome of a diverse cohort of college students living in university housing: a cross-sectional study
• Diet, physical activity and screen time but not body mass index are associated with the gut microbiome of a diverse cohort of college students living in university housing: a cross-sectional study/Experiment 1
• Diet, physical activity and screen time but not body mass index are associated with the gut microbiome of a diverse cohort of college students living in university housing: a cross-sectional study/Experiment 2
• Diet, physical activity and screen time but not body mass index are associated with the gut microbiome of a diverse cohort of college students living in university housing: a cross-sectional study/Experiment 2/Signature 2
• Obesity Alters the Microbial Community Profile in Korean Adolescents
• Obesity Alters the Microbial Community Profile in Korean Adolescents/Experiment 1
• Obesity Alters the Microbial Community Profile in Korean Adolescents/Experiment 2
• Obesity Alters the Microbial Community Profile in Korean Adolescents/Experiment 3
• Obesity Alters the Microbial Community Profile in Korean Adolescents/Experiment 4
• Obesity Alters the Microbial Community Profile in Korean Adolescents/Experiment 5
• Obesity Alters the Microbial Community Profile in Korean Adolescents/Experiment 6
• Characterization of the salivary microbiome in people with obesity
• Characterization of the salivary microbiome in people with obesity/Experiment 1
• Characterization of the salivary microbiome in people with obesity/Experiment 1/Signature 1
• Structural segregation of gut microbiota between colorectal cancer patients and healthy volunteers
• Structural segregation of gut microbiota between colorectal cancer patients and healthy volunteers/Experiment 1
• Gut microbiota in patients after surgical treatment for colorectal cancer
• Gut microbiota in patients after surgical treatment for colorectal cancer/Experiment 1
• Gut microbiota in patients after surgical treatment for colorectal cancer/Experiment 2
• Bacterial Diversity of Intestinal Microbiota in Patients with Substance Use Disorders Revealed by 16S rRNA Gene Deep Sequencing
• Bacterial Diversity of Intestinal Microbiota in Patients with Substance Use Disorders Revealed by 16S rRNA Gene Deep Sequencing/Experiment 1
• Bacterial Diversity of Intestinal Microbiota in Patients with Substance Use Disorders Revealed by 16S rRNA Gene Deep Sequencing/Experiment 2
• Changes in Gut and Plasma Microbiome following Exercise Challenge in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)
• Changes in Gut and Plasma Microbiome following Exercise Challenge in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)/Experiment 1
• Human gut colonisation may be initiated in utero by distinct microbial communities in the placenta and amniotic fluid
• Human gut colonisation may be initiated in utero by distinct microbial communities in the placenta and amniotic fluid/Experiment 1
• Human gut colonisation may be initiated in utero by distinct microbial communities in the placenta and amniotic fluid/Experiment 2
• Human gut colonisation may be initiated in utero by distinct microbial communities in the placenta and amniotic fluid/Experiment 2/Signature 1
• Gut microbiota composition is correlated to grid floor induced stress and behavior in the BALB/c mouse
• Gut microbiota composition is correlated to grid floor induced stress and behavior in the BALB/c mouse/Experiment 1
• Diversified microbiota of meconium is affected by maternal diabetes status
• Diversified microbiota of meconium is affected by maternal diabetes status/Experiment 1
• Diversified microbiota of meconium is affected by maternal diabetes status/Experiment 2
• Diversified microbiota of meconium is affected by maternal diabetes status/Experiment 3
• The microbiome of the oral mucosa in irritable bowel syndrome
• The microbiome of the oral mucosa in irritable bowel syndrome/Experiment 1
• The microbiome of the oral mucosa in irritable bowel syndrome/Experiment 2
• The early infant gut microbiome varies in association with a maternal high-fat diet
• The early infant gut microbiome varies in association with a maternal high-fat diet/Experiment 1
• The early infant gut microbiome varies in association with a maternal high-fat diet/Experiment 2
• Exposure to Titanium Dioxide Nanoparticles During Pregnancy Changed Maternal Gut Microbiota and Increased Blood Glucose of Rat
• Exposure to Titanium Dioxide Nanoparticles During Pregnancy Changed Maternal Gut Microbiota and Increased Blood Glucose of Rat/Experiment 1
• Association between blood microbiome and type 2 diabetes mellitus: A nested case-control study
• Association between blood microbiome and type 2 diabetes mellitus: A nested case-control study/Experiment 1
• Association between blood microbiome and type 2 diabetes mellitus: A nested case-control study/Experiment 2
• Effect of mother's weight on infant's microbiota acquisition, composition, and activity during early infancy: a prospective follow-up study initiated in early pregnancy
• Effect of mother's weight on infant's microbiota acquisition, composition, and activity during early infancy: a prospective follow-up study initiated in early pregnancy/Experiment 1
• Effect of mother's weight on infant's microbiota acquisition, composition, and activity during early infancy: a prospective follow-up study initiated in early pregnancy/Experiment 2
• Effect of mother's weight on infant's microbiota acquisition, composition, and activity during early infancy: a prospective follow-up study initiated in early pregnancy/Experiment 3
• Effect of mother's weight on infant's microbiota acquisition, composition, and activity during early infancy: a prospective follow-up study initiated in early pregnancy/Experiment 4
• Sensitive Quantitative Analysis of the Meconium Bacterial Microbiota in Healthy Term Infants Born Vaginally or by Cesarean Section
• Sensitive Quantitative Analysis of the Meconium Bacterial Microbiota in Healthy Term Infants Born Vaginally or by Cesarean Section/Experiment 1
• Sensitive Quantitative Analysis of the Meconium Bacterial Microbiota in Healthy Term Infants Born Vaginally or by Cesarean Section
• Sensitive Quantitative Analysis of the Meconium Bacterial Microbiota in Healthy Term Infants Born Vaginally or by Cesarean Section/Experiment 1
• Sensitive Quantitative Analysis of the Meconium Bacterial Microbiota in Healthy Term Infants Born Vaginally or by Cesarean Section/Experiment 2
• Sensitive Quantitative Analysis of the Meconium Bacterial Microbiota in Healthy Term Infants Born Vaginally or by Cesarean Section/Experiment 3
• Investigation of the effect of type 2 diabetes mellitus on subgingival plaque microbiota by high-throughput 16S rDNA pyrosequencing
• Investigation of the effect of type 2 diabetes mellitus on subgingival plaque microbiota by high-throughput 16S rDNA pyrosequencing/Experiment 1
• Investigation of the effect of type 2 diabetes mellitus on subgingival plaque microbiota by high-throughput 16S rDNA pyrosequencing/Experiment 2
• Investigation of the effect of type 2 diabetes mellitus on subgingival plaque microbiota by high-throughput 16S rDNA pyrosequencing/Experiment 3
• Investigation of the effect of type 2 diabetes mellitus on subgingival plaque microbiota by high-throughput 16S rDNA pyrosequencing/Experiment 4
• Investigation of the effect of type 2 diabetes mellitus on subgingival plaque microbiota by high-throughput 16S rDNA pyrosequencing/Experiment 5
• Subgingival biodiversity in subjects with uncontrolled type-2 diabetes and chronic periodontitis
• Subgingival biodiversity in subjects with uncontrolled type-2 diabetes and chronic periodontitis/Experiment 1
• Meconium microbiome associates with the development of neonatal jaundice
• Meconium microbiome associates with the development of neonatal jaundice/Experiment 1
• Meconium microbiome associates with the development of neonatal jaundice/Experiment 2
• New evidences on the altered gut microbiota in autism spectrum disorders
• New evidences on the altered gut microbiota in autism spectrum disorders/Experiment 1
• New evidences on the altered gut microbiota in autism spectrum disorders/Experiment 2
• New evidences on the altered gut microbiota in autism spectrum disorders/Experiment 3
• New evidences on the altered gut microbiota in autism spectrum disorders/Experiment 4
• A taxonomic signature of obesity in a large study of American adults
• A taxonomic signature of obesity in a large study of American adults/Experiment 1/Signature 1
• A taxonomic signature of obesity in a large study of American adults/Experiment 1/Signature 2
• A taxonomic signature of obesity in a large study of American adults/Experiment 2
• A taxonomic signature of obesity in a large study of American adults/Experiment 2/Signature 2
• A taxonomic signature of obesity in a large study of American adults/Experiment 3
• A taxonomic signature of obesity in a large study of American adults/Experiment 3/Signature 2
• A taxonomic signature of obesity in a large study of American adults/Experiment 4
• A taxonomic signature of obesity in a large study of American adults/Experiment 4/Signature 2
• A taxonomic signature of obesity in a large study of American adults/Experiment 5
• A taxonomic signature of obesity in a large study of American adults/Experiment 5/Signature 2
• A taxonomic signature of obesity in a large study of American adults/Experiment 6
• A taxonomic signature of obesity in a large study of American adults/Experiment 6/Signature 2
• Body Mass Index Differences in the Gut Microbiota Are Gender Specific
• Body Mass Index Differences in the Gut Microbiota Are Gender Specific/Experiment 1
• Body Mass Index Differences in the Gut Microbiota Are Gender Specific/Experiment 2
• Body Mass Index Differences in the Gut Microbiota Are Gender Specific/Experiment 3
• Body Mass Index Differences in the Gut Microbiota Are Gender Specific/Experiment 4
• Composition of gut microbiota in obese and normal-weight Mexican school-age children and its association with metabolic traits
• Composition of gut microbiota in obese and normal-weight Mexican school-age children and its association with metabolic traits/Experiment 1
• Composition of gut microbiota in obese and normal-weight Mexican school-age children and its association with metabolic traits/Experiment 2
• Composition of gut microbiota in obese and normal-weight Mexican school-age children and its association with metabolic traits/Experiment 3
• Meconium microbiome analysis identifies bacteria correlated with premature birth
• Meconium microbiome analysis identifies bacteria correlated with premature birth/Experiment 1
• Meconium microbiome analysis identifies bacteria correlated with premature birth/Experiment 2
• Analysis of gut microbiota profiles and microbe-disease associations in children with autism spectrum disorders in China
• Analysis of gut microbiota profiles and microbe-disease associations in children with autism spectrum disorders in China/Experiment 1
• Gut Microbiota and Predicted Metabolic Pathways in a Sample of Mexican Women Affected by Obesity and Obesity Plus Metabolic Syndrome
• Gut Microbiota and Predicted Metabolic Pathways in a Sample of Mexican Women Affected by Obesity and Obesity Plus Metabolic Syndrome/Experiment 1
• Gut Microbiota and Predicted Metabolic Pathways in a Sample of Mexican Women Affected by Obesity and Obesity Plus Metabolic Syndrome/Experiment 2
• Human intestinal microbiota composition is associated with local and systemic inflammation in obesity
• Human intestinal microbiota composition is associated with local and systemic inflammation in obesity/Experiment 1
• Human intestinal microbiota composition is associated with local and systemic inflammation in obesity/Experiment 2
• Human intestinal microbiota composition is associated with local and systemic inflammation in obesity/Experiment 3
• Human intestinal microbiota composition is associated with local and systemic inflammation in obesity/Experiment 4
• Disordered microbial communities in the upper respiratory tract of cigarette smokers
• Disordered microbial communities in the upper respiratory tract of cigarette smokers/Experiment 1
• Disordered microbial communities in the upper respiratory tract of cigarette smokers/Experiment 2
• Disordered microbial communities in the upper respiratory tract of cigarette smokers/Experiment 3
• Disordered microbial communities in the upper respiratory tract of cigarette smokers/Experiment 4
• Imbalance of Fecal Microbiota at Newly Diagnosed Type 1 Diabetes in Chinese Children
• Imbalance of Fecal Microbiota at Newly Diagnosed Type 1 Diabetes in Chinese Children/Experiment 1
• Interaction Between Atypical Antipsychotics and the Gut Microbiome in a Bipolar Disease Cohort
• Interaction Between Atypical Antipsychotics and the Gut Microbiome in a Bipolar Disease Cohort/Experiment 1
• Effects of surgical and dietary weight loss therapy for obesity on gut microbiota composition and nutrient absorption
• Effects of surgical and dietary weight loss therapy for obesity on gut microbiota composition and nutrient absorption/Experiment 1
• Effects of surgical and dietary weight loss therapy for obesity on gut microbiota composition and nutrient absorption/Experiment 2
• Fecal microbiota imbalance in Mexican children with type 1 diabetes
• Fecal microbiota imbalance in Mexican children with type 1 diabetes/Experiment 1
• Roux-en-Y gastric bypass surgery of morbidly obese patients induces swift and persistent changes of the individual gut microbiota
• Roux-en-Y gastric bypass surgery of morbidly obese patients induces swift and persistent changes of the individual gut microbiota/Experiment 1
• Roux-en-Y gastric bypass surgery of morbidly obese patients induces swift and persistent changes of the individual gut microbiota/Experiment 2
• Metagenomic sequencing of the human gut microbiome before and after bariatric surgery in obese patients with type 2 diabetes: correlation with inflammatory and metabolic parameters
• Metagenomic sequencing of the human gut microbiome before and after bariatric surgery in obese patients with type 2 diabetes: correlation with inflammatory and metabolic parameters/Experiment 1
• Metagenomic sequencing of the human gut microbiome before and after bariatric surgery in obese patients with type 2 diabetes: correlation with inflammatory and metabolic parameters
• Metagenomic sequencing of the human gut microbiome before and after bariatric surgery in obese patients with type 2 diabetes: correlation with inflammatory and metabolic parameters/Experiment 1
• Metagenomic sequencing of the human gut microbiome before and after bariatric surgery in obese patients with type 2 diabetes: correlation with inflammatory and metabolic parameters
• Metagenomic sequencing of the human gut microbiome before and after bariatric surgery in obese patients with type 2 diabetes: correlation with inflammatory and metabolic parameters/Experiment 1
• Evolution in fecal bacterial/viral composition in infants of two central African countries (Gabon and Republic of the Congo) during their first month of life
• Evolution in fecal bacterial/viral composition in infants of two central African countries (Gabon and Republic of the Congo) during their first month of life/Experiment 1
• Evolution in fecal bacterial/viral composition in infants of two central African countries (Gabon and Republic of the Congo) during their first month of life/Experiment 2
• Evolution in fecal bacterial/viral composition in infants of two central African countries (Gabon and Republic of the Congo) during their first month of life/Experiment 3
• Evolution in fecal bacterial/viral composition in infants of two central African countries (Gabon and Republic of the Congo) during their first month of life/Experiment 4
• Colonization and Succession within the Human Gut Microbiome by Archaea, Bacteria, and Microeukaryotes during the First Year of Life
• Colonization and Succession within the Human Gut Microbiome by Archaea, Bacteria, and Microeukaryotes during the First Year of Life/Experiment 1
• Colonization and Succession within the Human Gut Microbiome by Archaea, Bacteria, and Microeukaryotes during the First Year of Life/Experiment 2
• Colonization and Succession within the Human Gut Microbiome by Archaea, Bacteria, and Microeukaryotes during the First Year of Life/Experiment 3
• Colonization and Succession within the Human Gut Microbiome by Archaea, Bacteria, and Microeukaryotes during the First Year of Life/Experiment 4
• Colonization and Succession within the Human Gut Microbiome by Archaea, Bacteria, and Microeukaryotes during the First Year of Life/Experiment 5
• Colonization and Succession within the Human Gut Microbiome by Archaea, Bacteria, and Microeukaryotes during the First Year of Life/Experiment 6
• Colonization and Succession within the Human Gut Microbiome by Archaea, Bacteria, and Microeukaryotes during the First Year of Life/Experiment 7
• Colonization and Succession within the Human Gut Microbiome by Archaea, Bacteria, and Microeukaryotes during the First Year of Life/Experiment 8
• Gut Microbiota Differs in Composition and Functionality Between Children With Type 1 Diabetes and MODY2 and Healthy Control Subjects: A Case-Control Study
• Gut Microbiota Differs in Composition and Functionality Between Children With Type 1 Diabetes and MODY2 and Healthy Control Subjects: A Case-Control Study/Experiment 1
• Gut Microbiota Differs in Composition and Functionality Between Children With Type 1 Diabetes and MODY2 and Healthy Control Subjects: A Case-Control Study/Experiment 2
• Reduced Abundance of Butyrate-Producing Bacteria Species in the Fecal Microbial Community in Crohn's Disease/Experiment 1/Signature 1
• Delivery Mode and the Transition of Pioneering Gut-Microbiota Structure, Composition and Predicted Metabolic Function
• Delivery Mode and the Transition of Pioneering Gut-Microbiota Structure, Composition and Predicted Metabolic Function/Experiment 1
• Delivery Mode and the Transition of Pioneering Gut-Microbiota Structure, Composition and Predicted Metabolic Function/Experiment 2
• Initial meconium microbiome in Chinese neonates delivered naturally or by cesarean section
• Initial meconium microbiome in Chinese neonates delivered naturally or by cesarean section/Experiment 1
• Altered gut microbial energy and metabolism in children with non-alcoholic fatty liver disease
• Altered gut microbial energy and metabolism in children with non-alcoholic fatty liver disease/Experiment 1
• Altered gut microbial energy and metabolism in children with non-alcoholic fatty liver disease/Experiment 2
• Altered gut microbial energy and metabolism in children with non-alcoholic fatty liver disease/Experiment 3
• Maternal influence on the fetal microbiome in a population-based study of the first-pass meconium
• Maternal influence on the fetal microbiome in a population-based study of the first-pass meconium/Experiment 1
• Maternal influence on the fetal microbiome in a population-based study of the first-pass meconium/Experiment 2
• Maternal influence on the fetal microbiome in a population-based study of the first-pass meconium/Experiment 3
• Maternal influence on the fetal microbiome in a population-based study of the first-pass meconium/Experiment 4
• Characterization of the Gut Microbial Community of Obese Patients Following a Weight-Loss Intervention Using Whole Metagenome Shotgun Sequencing
• Characterization of the Gut Microbial Community of Obese Patients Following a Weight-Loss Intervention Using Whole Metagenome Shotgun Sequencing/Experiment 1
• Characterization of the Gut Microbial Community of Obese Patients Following a Weight-Loss Intervention Using Whole Metagenome Shotgun Sequencing/Experiment 2
• Characterization of the Gut Microbial Community of Obese Patients Following a Weight-Loss Intervention Using Whole Metagenome Shotgun Sequencing/Experiment 3
• Gut microbiota and overweight in 3-year old children
• Gut microbiota and overweight in 3-year old children/Experiment 1
• Comparison of the gut microbial community between obese and lean peoples using 16S gene sequencing in a Japanese population
• Comparison of the gut microbial community between obese and lean peoples using 16S gene sequencing in a Japanese population/Experiment 1
• Differential composition of gut microbiota among healthy volunteers, morbidly obese patients and post-bariatric surgery patients
• Differential composition of gut microbiota among healthy volunteers, morbidly obese patients and post-bariatric surgery patients/Experiment 1
• Differential composition of gut microbiota among healthy volunteers, morbidly obese patients and post-bariatric surgery patients/Experiment 2
• Differential composition of gut microbiota among healthy volunteers, morbidly obese patients and post-bariatric surgery patients/Experiment 3
• Differential composition of gut microbiota among healthy volunteers, morbidly obese patients and post-bariatric surgery patients/Experiment 4
• Blood Microbiome Profile in CKD : A Pilot Study
• Blood Microbiome Profile in CKD : A Pilot Study/Experiment 1
• Blood Microbiome Profile in CKD : A Pilot Study/Experiment 1/Signature 1
• Blood Microbiome Profile in CKD : A Pilot Study/Experiment 1/Signature 2
• Gut microbiome and serum metabolome alterations in obesity and after weight-loss intervention/Experiment 1
• Gut microbiome and serum metabolome alterations in obesity and after weight-loss intervention/Experiment 1/Signature 2
• Gut Microbiota in Patients with Different Metabolic Statuses: Moscow Study
• Gut Microbiota in Patients with Different Metabolic Statuses: Moscow Study/Experiment 1
• Gut Microbiota in Patients with Different Metabolic Statuses: Moscow Study/Experiment 2
• Obesity-associated gut microbiota is enriched in Lactobacillus reuteri and depleted in Bifidobacterium animalis and Methanobrevibacter smithii
• Obesity-associated gut microbiota is enriched in Lactobacillus reuteri and depleted in Bifidobacterium animalis and Methanobrevibacter smithii/Experiment 1
• The stool microbiota of insulin resistant women with recent gestational diabetes, a high risk group for type 2 diabetes
• The stool microbiota of insulin resistant women with recent gestational diabetes, a high risk group for type 2 diabetes/Experiment 1
• Sex differences in gut microbiota in patients with major depressive disorder
• Sex differences in gut microbiota in patients with major depressive disorder/Experiment 1
• Sex differences in gut microbiota in patients with major depressive disorder/Experiment 2
• Prevotella and Klebsiella proportions in fecal microbial communities are potential characteristic parameters for patients with major depressive disorder
• Prevotella and Klebsiella proportions in fecal microbial communities are potential characteristic parameters for patients with major depressive disorder/Experiment 1
• Prevotella and Klebsiella proportions in fecal microbial communities are potential characteristic parameters for patients with major depressive disorder/Experiment 2
• Prevotella and Klebsiella proportions in fecal microbial communities are potential characteristic parameters for patients with major depressive disorder/Experiment 3
• The gut microbiome composition associates with bipolar disorder and illness severity
• The gut microbiome composition associates with bipolar disorder and illness severity/Experiment 1
• The gut microbiome composition associates with bipolar disorder and illness severity/Experiment 1/Signature 1
• Gut microbiota composition in patients with newly diagnosed bipolar disorder and their unaffected first-degree relatives/Experiment 1/Signature 1
• Gut microbiota composition in patients with newly diagnosed bipolar disorder and their unaffected first-degree relatives/Experiment 2
• Gut microbiota composition in patients with newly diagnosed bipolar disorder and their unaffected first-degree relatives/Experiment 2/Signature 1
• The Intestinal Microbiota in Acute Anorexia Nervosa and During Renourishment: Relationship to Depression, Anxiety, and Eating Disorder Psychopathology/Experiment 1
• The Intestinal Microbiota in Acute Anorexia Nervosa and During Renourishment: Relationship to Depression, Anxiety, and Eating Disorder Psychopathology/Experiment 1/Signature 1
• The Intestinal Microbiota in Acute Anorexia Nervosa and During Renourishment: Relationship to Depression, Anxiety, and Eating Disorder Psychopathology/Experiment 1/Signature 2
• The Intestinal Microbiota in Acute Anorexia Nervosa and During Renourishment: Relationship to Depression, Anxiety, and Eating Disorder Psychopathology/Experiment 2/Signature 1
• The Intestinal Microbiota in Acute Anorexia Nervosa and During Renourishment: Relationship to Depression, Anxiety, and Eating Disorder Psychopathology/Experiment 2/Signature 2
• Gut Dysbiosis in Patients with Anorexia Nervosa/Experiment 1
• Weight gain in anorexia nervosa does not ameliorate the faecal microbiota, branched chain fatty acid profiles, and gastrointestinal complaints/Experiment 2/Signature 2
• Gut microbiota profiles in treatment-naïve children with attention deficit hyperactivity disorder/Experiment 1
• Gut microbiota profiles in treatment-naïve children with attention deficit hyperactivity disorder/Experiment 1/Signature 1
• Gut microbiota profiles in treatment-naïve children with attention deficit hyperactivity disorder/Experiment 1/Signature 2
• Gut microbiota in children with type 1 diabetes differs from that in healthy children: a case-control study
• Gut microbiota in children with type 1 diabetes differs from that in healthy children: a case-control study/Experiment 1
• Dysbiosis of upper respiratory tract microbiota in elderly pneumonia patients/Experiment 1
• Dysbiosis of upper respiratory tract microbiota in elderly pneumonia patients/Experiment 1/Signature 2
• Dysbiosis of upper respiratory tract microbiota in elderly pneumonia patients/Experiment 2
• The Perturbation of Infant Gut Microbiota Caused by Cesarean Delivery Is Partially Restored by Exclusive Breastfeeding
• The Perturbation of Infant Gut Microbiota Caused by Cesarean Delivery Is Partially Restored by Exclusive Breastfeeding/Experiment 1
• The Perturbation of Infant Gut Microbiota Caused by Cesarean Delivery Is Partially Restored by Exclusive Breastfeeding/Experiment 1/Signature 1
• The Perturbation of Infant Gut Microbiota Caused by Cesarean Delivery Is Partially Restored by Exclusive Breastfeeding/Experiment 2
• Gut microbiota varies by opioid use, circulating leptin and oxytocin in African American men with diabetes and high burden of chronic disease
• Gut microbiota varies by opioid use, circulating leptin and oxytocin in African American men with diabetes and high burden of chronic disease/Experiment 1
• Gut microbiota varies by opioid use, circulating leptin and oxytocin in African American men with diabetes and high burden of chronic disease/Experiment 2
• Gut microbiota varies by opioid use, circulating leptin and oxytocin in African American men with diabetes and high burden of chronic disease/Experiment 3
• Gut microbiota composition in male rat models under different nutritional status and physical activity and its association with serum leptin and ghrelin levels
• Gut microbiota composition in male rat models under different nutritional status and physical activity and its association with serum leptin and ghrelin levels/Experiment 1
• Gut microbiota composition in male rat models under different nutritional status and physical activity and its association with serum leptin and ghrelin levels/Experiment 2
• Subgingival Microbiome of Gingivitis in Chinese Undergraduates
• Subgingival Microbiome of Gingivitis in Chinese Undergraduates/Experiment 1
• Subgingival Microbiome of Gingivitis in Chinese Undergraduates/Experiment 1/Signature 1
• High fat diet alters gut microbiota but not spatial working memory in early middle-aged Sprague Dawley rats
• High fat diet alters gut microbiota but not spatial working memory in early middle-aged Sprague Dawley rats/Experiment 1
• The combination of sport and sport-specific diet is associated with characteristics of gut microbiota: an observational study
• The combination of sport and sport-specific diet is associated with characteristics of gut microbiota: an observational study/Experiment 1
• The combination of sport and sport-specific diet is associated with characteristics of gut microbiota: an observational study/Experiment 2
• The combination of sport and sport-specific diet is associated with characteristics of gut microbiota: an observational study/Experiment 3
• Analysis of oral microbiota in Japanese oral cancer patients using 16S rRNA sequencing
• Analysis of oral microbiota in Japanese oral cancer patients using 16S rRNA sequencing/Experiment 1
• Changes in the salivary microbiota of oral leukoplakia and oral cancer
• Changes in the salivary microbiota of oral leukoplakia and oral cancer/Experiment 1
• Changes in the salivary microbiota of oral leukoplakia and oral cancer/Experiment 2
• Changes in the salivary microbiota of oral leukoplakia and oral cancer/Experiment 3
• Mucosal microbiome dysbiosis in gastric carcinogenesis/Experiment 1
• Mucosal microbiome dysbiosis in gastric carcinogenesis/Experiment 2
• Mucosal microbiome dysbiosis in gastric carcinogenesis/Experiment 3
• Multiple sclerosis patients have a distinct gut microbiota compared to healthy controls/Experiment 1/Signature 1
• Multiple sclerosis patients have a distinct gut microbiota compared to healthy controls/Experiment 1/Signature 2
• Influence of food consumption patterns and Galician lifestyle on human gut microbiota
• Influence of food consumption patterns and Galician lifestyle on human gut microbiota/Experiment 1
• Influence of food consumption patterns and Galician lifestyle on human gut microbiota/Experiment 2
• Influence of food consumption patterns and Galician lifestyle on human gut microbiota/Experiment 3
• Influence of food consumption patterns and Galician lifestyle on human gut microbiota/Experiment 4
• Influence of food consumption patterns and Galician lifestyle on human gut microbiota/Experiment 5
• Influence of food consumption patterns and Galician lifestyle on human gut microbiota/Experiment 6
• Influence of food consumption patterns and Galician lifestyle on human gut microbiota/Experiment 7
• Influence of food consumption patterns and Galician lifestyle on human gut microbiota/Experiment 8
• Daily Consumption of Orange Juice from Citrus sinensis L. Osbeck cv. Cara Cara and cv. Bahia Differently Affects Gut Microbiota Profiling as Unveiled by an Integrated Meta-Omics Approach
• Daily Consumption of Orange Juice from Citrus sinensis L. Osbeck cv. Cara Cara and cv. Bahia Differently Affects Gut Microbiota Profiling as Unveiled by an Integrated Meta-Omics Approach/Experiment 1
• Daily Consumption of Orange Juice from Citrus sinensis L. Osbeck cv. Cara Cara and cv. Bahia Differently Affects Gut Microbiota Profiling as Unveiled by an Integrated Meta-Omics Approach/Experiment 2
• Daily Consumption of Orange Juice from Citrus sinensis L. Osbeck cv. Cara Cara and cv. Bahia Differently Affects Gut Microbiota Profiling as Unveiled by an Integrated Meta-Omics Approach/Experiment 2/Signature 1
• Daily Consumption of Orange Juice from Citrus sinensis L. Osbeck cv. Cara Cara and cv. Bahia Differently Affects Gut Microbiota Profiling as Unveiled by an Integrated Meta-Omics Approach/Experiment 3
• Daily Consumption of Orange Juice from Citrus sinensis L. Osbeck cv. Cara Cara and cv. Bahia Differently Affects Gut Microbiota Profiling as Unveiled by an Integrated Meta-Omics Approach/Experiment 3/Signature 1
• Daily Consumption of Orange Juice from Citrus sinensis L. Osbeck cv. Cara Cara and cv. Bahia Differently Affects Gut Microbiota Profiling as Unveiled by an Integrated Meta-Omics Approach/Experiment 4
• Daily Consumption of Orange Juice from Citrus sinensis L. Osbeck cv. Cara Cara and cv. Bahia Differently Affects Gut Microbiota Profiling as Unveiled by an Integrated Meta-Omics Approach/Experiment 5
• Daily Consumption of Orange Juice from Citrus sinensis L. Osbeck cv. Cara Cara and cv. Bahia Differently Affects Gut Microbiota Profiling as Unveiled by an Integrated Meta-Omics Approach/Experiment 6
• Impact of Agaricus bisporus Mushroom Consumption on Gut Health Markers in Healthy Adults
• Impact of Agaricus bisporus Mushroom Consumption on Gut Health Markers in Healthy Adults/Experiment 1
• Microbial enterotypes, inferred by the prevotella-to-bacteroides ratio, remained stable during a 6-month randomized controlled diet intervention with the new nordic diet
• Microbial enterotypes, inferred by the prevotella-to-bacteroides ratio, remained stable during a 6-month randomized controlled diet intervention with the new nordic diet/Experiment 1
• Microbial enterotypes, inferred by the prevotella-to-bacteroides ratio, remained stable during a 6-month randomized controlled diet intervention with the new nordic diet/Experiment 2
• Microbiome Responses to an Uncontrolled Short-Term Diet Intervention in the Frame of the Citizen Science Project
• Microbiome Responses to an Uncontrolled Short-Term Diet Intervention in the Frame of the Citizen Science Project/Experiment 2
• Association of Oral Microbiome With Risk for Incident Head and Neck Squamous Cell Cancer
• Association of Oral Microbiome With Risk for Incident Head and Neck Squamous Cell Cancer/Experiment 1
• Association of Oral Microbiome With Risk for Incident Head and Neck Squamous Cell Cancer/Experiment 1/Signature 1
• Association of Oral Microbiome With Risk for Incident Head and Neck Squamous Cell Cancer/Experiment 1/Signature 2
• Association of Oral Microbiome With Risk for Incident Head and Neck Squamous Cell Cancer/Experiment 2
• Association of Oral Microbiome With Risk for Incident Head and Neck Squamous Cell Cancer/Experiment 2/Signature 1
• Association of Oral Microbiome With Risk for Incident Head and Neck Squamous Cell Cancer/Experiment 3
• Association of Oral Microbiome With Risk for Incident Head and Neck Squamous Cell Cancer/Experiment 3/Signature 1
• Association of Oral Microbiome With Risk for Incident Head and Neck Squamous Cell Cancer/Experiment 4
• Association of Oral Microbiome With Risk for Incident Head and Neck Squamous Cell Cancer/Experiment 4/Signature 1
• Association of Oral Microbiome With Risk for Incident Head and Neck Squamous Cell Cancer/Experiment 4/Signature 2
• Alterations of the human gut microbiome in multiple sclerosis/Experiment 1
• Alterations of the human gut microbiome in multiple sclerosis/Experiment 2
• Alterations of the human gut microbiome in multiple sclerosis/Experiment 3
• Alterations of the human gut microbiome in multiple sclerosis/Experiment 4
• Alterations of the human gut microbiome in multiple sclerosis/Experiment 5
• Alterations of the human gut microbiome in multiple sclerosis/Experiment 6
• 16S rRNA amplicon sequencing identifies microbiota associated with oral cancer, human papilloma virus infection and surgical treatment
• 16S rRNA amplicon sequencing identifies microbiota associated with oral cancer, human papilloma virus infection and surgical treatment/Experiment 1
• 16S rRNA amplicon sequencing identifies microbiota associated with oral cancer, human papilloma virus infection and surgical treatment/Experiment 1/Signature 1
• 16S rRNA amplicon sequencing identifies microbiota associated with oral cancer, human papilloma virus infection and surgical treatment/Experiment 2
• 16S rRNA amplicon sequencing identifies microbiota associated with oral cancer, human papilloma virus infection and surgical treatment/Experiment 3
• The Human Mesenteric Lymph Node Microbiome Differentiates Between Crohn's Disease and Ulcerative Colitis
• The Human Mesenteric Lymph Node Microbiome Differentiates Between Crohn's Disease and Ulcerative Colitis/Experiment 1
• The Human Mesenteric Lymph Node Microbiome Differentiates Between Crohn's Disease and Ulcerative Colitis/Experiment 2
• Air pollution during the winter period and respiratory tract microbial imbalance in a healthy young population in Northeastern China/Experiment 1
• Air pollution during the winter period and respiratory tract microbial imbalance in a healthy young population in Northeastern China/Experiment 1/Signature 2
• Air pollution during the winter period and respiratory tract microbial imbalance in a healthy young population in Northeastern China/Experiment 2
• Air pollution during the winter period and respiratory tract microbial imbalance in a healthy young population in Northeastern China/Experiment 2/Signature 2
• Air pollution during the winter period and respiratory tract microbial imbalance in a healthy young population in Northeastern China/Experiment 3
• The salivary microbiota as a diagnostic indicator of oral cancer: a descriptive, non-randomized study of cancer-free and oral squamous cell carcinoma subjects
• The salivary microbiota as a diagnostic indicator of oral cancer: a descriptive, non-randomized study of cancer-free and oral squamous cell carcinoma subjects/Experiment 1
• Variations in oral microbiota associated with oral cancer
• Variations in oral microbiota associated with oral cancer/Experiment 1
• Microbiota in the Throat and Risk Factors for Laryngeal Carcinoma
• Microbiota in the Throat and Risk Factors for Laryngeal Carcinoma/Experiment 1
• Microbiota in the Throat and Risk Factors for Laryngeal Carcinoma/Experiment 2
• Structural and functional profiles of the gut microbial community in polycystic ovary syndrome with insulin resistance (IR-PCOS): a pilot study/Experiment 1/Signature 1
• Structural and functional profiles of the gut microbial community in polycystic ovary syndrome with insulin resistance (IR-PCOS): a pilot study/Experiment 1/Signature 2
• Structural and functional profiles of the gut microbial community in polycystic ovary syndrome with insulin resistance (IR-PCOS): a pilot study/Experiment 2/Signature 1
• Structural and functional profiles of the gut microbial community in polycystic ovary syndrome with insulin resistance (IR-PCOS): a pilot study/Experiment 2/Signature 2
• Structural and functional profiles of the gut microbial community in polycystic ovary syndrome with insulin resistance (IR-PCOS): a pilot study/Experiment 3/Signature 2
• The gut microbiome of Mexican children affected by obesity
• The gut microbiome of Mexican children affected by obesity/Experiment 1
• The gut microbiome of Mexican children affected by obesity/Experiment 1/Signature 1
• The gut microbiome of Mexican children affected by obesity/Experiment 1/Signature 2
• Variations in Oral Microbiota Composition Are Associated With a Risk of Throat Cancer
• Variations in Oral Microbiota Composition Are Associated With a Risk of Throat Cancer/Experiment 1
• Variations in Oral Microbiota Composition Are Associated With a Risk of Throat Cancer/Experiment 2
• Breast cancer in postmenopausal women is associated with an altered gut metagenome
• Breast cancer in postmenopausal women is associated with an altered gut metagenome/Experiment 1
• Altered diversity and composition of the gut microbiome in patients with cervical cancer/Experiment 2
• The Microbiome of Prostate Fluid Is Associated With Prostate Cancer/Experiment 1
• The Microbiome of Prostate Fluid Is Associated With Prostate Cancer/Experiment 1/Signature 1
• The Microbiome of Prostate Fluid Is Associated With Prostate Cancer/Experiment 1/Signature 2
• Oral Microbiome Composition Reflects Prospective Risk for Esophageal Cancers
• Oral Microbiome Composition Reflects Prospective Risk for Esophageal Cancers/Experiment 1
• Oral Microbiome Composition Reflects Prospective Risk for Esophageal Cancers/Experiment 2
• Intestinal Microbiota Is Altered in Patients with Gastric Cancer from Shanxi Province, China
• Intestinal Microbiota Is Altered in Patients with Gastric Cancer from Shanxi Province, China/Experiment 1
• Intestinal Microbiota Is Altered in Patients with Gastric Cancer from Shanxi Province, China/Experiment 2
• Oral Microbiota and Risk for Esophageal Squamous Cell Carcinoma in a High-Risk Area of China/Experiment 1
• Oral Microbiota and Risk for Esophageal Squamous Cell Carcinoma in a High-Risk Area of China/Experiment 1/Signature 1
• Oral Microbiota and Risk for Esophageal Squamous Cell Carcinoma in a High-Risk Area of China/Experiment 1/Signature 2
• Oral Microbiota and Risk for Esophageal Squamous Cell Carcinoma in a High-Risk Area of China/Experiment 2
• Oral Microbiota and Risk for Esophageal Squamous Cell Carcinoma in a High-Risk Area of China/Experiment 2/Signature 1
• Oral Microbiota and Risk for Esophageal Squamous Cell Carcinoma in a High-Risk Area of China/Experiment 2/Signature 2
• Salivary Microbial Dysbiosis is Associated with Systemic Inflammatory Markers and Predicted Oral Metabolites in Non-Small Cell Lung Cancer Patients
• Salivary Microbial Dysbiosis is Associated with Systemic Inflammatory Markers and Predicted Oral Metabolites in Non-Small Cell Lung Cancer Patients/Experiment 1/Signature 1
• Salivary Microbial Dysbiosis is Associated with Systemic Inflammatory Markers and Predicted Oral Metabolites in Non-Small Cell Lung Cancer Patients/Experiment 1/Signature 2
• Dysbiosis of the Gut Microbiome is associated with Tumor Biomarkers in Lung Cancer/Experiment 2
• Dysbiosis of the Gut Microbiome is associated with Tumor Biomarkers in Lung Cancer/Experiment 4
• Dysbiosis of the Gut Microbiome is associated with Tumor Biomarkers in Lung Cancer/Experiment 4/Signature 1
• Dysbiosis of the Gut Microbiome is associated with Tumor Biomarkers in Lung Cancer/Experiment 5
• The salivary microbiome as an indicator of carcinogenesis in patients with oropharyngeal squamous cell carcinoma: A pilot study/Experiment 2
• Oral Microbiota Community Dynamics Associated With Oral Squamous Cell Carcinoma Staging/Experiment 1
• Oral Microbiota Community Dynamics Associated With Oral Squamous Cell Carcinoma Staging/Experiment 2
• Oral Microbiota Community Dynamics Associated With Oral Squamous Cell Carcinoma Staging/Experiment 2/Signature 1
• Oral Microbiota Community Dynamics Associated With Oral Squamous Cell Carcinoma Staging/Experiment 2/Signature 2
• Oral Microbiota Community Dynamics Associated With Oral Squamous Cell Carcinoma Staging/Experiment 3
• Oral Microbiota Community Dynamics Associated With Oral Squamous Cell Carcinoma Staging/Experiment 3/Signature 1
• Oral Microbiota Community Dynamics Associated With Oral Squamous Cell Carcinoma Staging/Experiment 3/Signature 2
• Altered oral microbiota in chronic hepatitis B patients with different tongue coatings/Experiment 1
• Altered oral microbiota in chronic hepatitis B patients with different tongue coatings/Experiment 1/Signature 1
• Altered oral microbiota in chronic hepatitis B patients with different tongue coatings/Experiment 2
• Altered oral microbiota in chronic hepatitis B patients with different tongue coatings/Experiment 3
• Microbial biomarkers of common tongue coatings in patients with gastric cancer/Experiment 1
• Difference of lower airway microbiome in bilateral protected specimen brush between lung cancer patients with unilateral lobar masses and control subjects/Experiment 1
• Difference of lower airway microbiome in bilateral protected specimen brush between lung cancer patients with unilateral lobar masses and control subjects/Experiment 2
• Difference of lower airway microbiome in bilateral protected specimen brush between lung cancer patients with unilateral lobar masses and control subjects/Experiment 3
• Difference of lower airway microbiome in bilateral protected specimen brush between lung cancer patients with unilateral lobar masses and control subjects/Experiment 3/Signature 1
• Difference of lower airway microbiome in bilateral protected specimen brush between lung cancer patients with unilateral lobar masses and control subjects/Experiment 4
• Difference of lower airway microbiome in bilateral protected specimen brush between lung cancer patients with unilateral lobar masses and control subjects/Experiment 4/Signature 1
• Difference of lower airway microbiome in bilateral protected specimen brush between lung cancer patients with unilateral lobar masses and control subjects/Experiment 4/Signature 2
• Difference of lower airway microbiome in bilateral protected specimen brush between lung cancer patients with unilateral lobar masses and control subjects/Experiment 5/Signature 1
• Difference of lower airway microbiome in bilateral protected specimen brush between lung cancer patients with unilateral lobar masses and control subjects/Experiment 5/Signature 2
• Difference of lower airway microbiome in bilateral protected specimen brush between lung cancer patients with unilateral lobar masses and control subjects/Experiment 6
• Difference of lower airway microbiome in bilateral protected specimen brush between lung cancer patients with unilateral lobar masses and control subjects/Experiment 6/Signature 1
• Characteristics of the Salivary Microbiota in Patients With Various Digestive Tract Cancers/Experiment 1
• Characteristics of the Salivary Microbiota in Patients With Various Digestive Tract Cancers/Experiment 2
• Characteristics of the Salivary Microbiota in Patients With Various Digestive Tract Cancers/Experiment 3
• Characteristics of the Salivary Microbiota in Patients With Various Digestive Tract Cancers/Experiment 4
• Characteristics of the Salivary Microbiota in Patients With Various Digestive Tract Cancers/Experiment 5
• Microbiomic differences at cancer-prone oral mucosa sites with marijuana usage/Experiment 1
• Microbiomic differences at cancer-prone oral mucosa sites with marijuana usage/Experiment 2
• Microbiomic differences at cancer-prone oral mucosa sites with marijuana usage/Experiment 3
• Microbiomic differences at cancer-prone oral mucosa sites with marijuana usage/Experiment 4
• Mucosa-Associated Microbiota in Gastric Cancer Tissues Compared With Non-cancer Tissues/Experiment 1
• Mucosa-Associated Microbiota in Gastric Cancer Tissues Compared With Non-cancer Tissues/Experiment 1/Signature 1
• Mucosa-Associated Microbiota in Gastric Cancer Tissues Compared With Non-cancer Tissues/Experiment 1/Signature 2
• Mucosa-Associated Microbiota in Gastric Cancer Tissues Compared With Non-cancer Tissues/Experiment 2/Signature 1
• Mucosa-Associated Microbiota in Gastric Cancer Tissues Compared With Non-cancer Tissues/Experiment 2/Signature 2
• Mucosa-Associated Microbiota in Gastric Cancer Tissues Compared With Non-cancer Tissues/Experiment 3/Signature 1
• Mucosa-Associated Microbiota in Gastric Cancer Tissues Compared With Non-cancer Tissues/Experiment 3/Signature 2
• Human oral microbiome and prospective risk for pancreatic cancer: a population-based nested case-control study/Experiment 1
• Human oral microbiome and prospective risk for pancreatic cancer: a population-based nested case-control study/Experiment 2
• Human oral microbiome and prospective risk for pancreatic cancer: a population-based nested case-control study/Experiment 3
• Human oral microbiome and prospective risk for pancreatic cancer: a population-based nested case-control study/Experiment 3/Signature 1
• Intestinal microbiota is altered in patients with colon cancer and modified by probiotic intervention/Experiment 1
• Intestinal microbiota is altered in patients with colon cancer and modified by probiotic intervention/Experiment 2
• Oral Microbiome in Patients with Oesophageal Squamous Cell Carcinoma/Experiment 1
• Oral Microbiome in Patients with Oesophageal Squamous Cell Carcinoma/Experiment 1/Signature 1
• Oral Microbiome in Patients with Oesophageal Squamous Cell Carcinoma/Experiment 1/Signature 2
• Oral Microbiome in Patients with Oesophageal Squamous Cell Carcinoma/Experiment 2
• Oral Microbiome in Patients with Oesophageal Squamous Cell Carcinoma/Experiment 2/Signature 1
• Oral Microbiome in Patients with Oesophageal Squamous Cell Carcinoma/Experiment 2/Signature 2
• A prospective study to examine the association of the urinary and fecal microbiota with prostate cancer diagnosis after transrectal biopsy of the prostate using 16sRNA gene analysis/Experiment 1/Signature 2
• Cigarette smoke promotes colorectal cancer through modulation of gut microbiota and related metabolites/Experiment 2
• Cigarette smoke promotes colorectal cancer through modulation of gut microbiota and related metabolites/Experiment 2/Signature 1
• Cigarette smoke promotes colorectal cancer through modulation of gut microbiota and related metabolites/Experiment 2/Signature 2
• Gut Microbial Dysbiosis Is Associated with Altered Hepatic Functions and Serum Metabolites in Chronic Hepatitis B Patients/Experiment 1
• Differences in gastric mucosal microbiota profiling in patients with chronic gastritis, intestinal metaplasia, and gastric cancer using pyrosequencing methods
• Differences in gastric mucosal microbiota profiling in patients with chronic gastritis, intestinal metaplasia, and gastric cancer using pyrosequencing methods/Experiment 1
• Differences in gastric mucosal microbiota profiling in patients with chronic gastritis, intestinal metaplasia, and gastric cancer using pyrosequencing methods/Experiment 1/Signature 1
• Differences in gastric mucosal microbiota profiling in patients with chronic gastritis, intestinal metaplasia, and gastric cancer using pyrosequencing methods/Experiment 1/Signature 2
• Differences in gastric mucosal microbiota profiling in patients with chronic gastritis, intestinal metaplasia, and gastric cancer using pyrosequencing methods/Experiment 2
• Differences in gastric mucosal microbiota profiling in patients with chronic gastritis, intestinal metaplasia, and gastric cancer using pyrosequencing methods/Experiment 2/Signature 1
• The biodiversity Composition of Microbiome in Ovarian Carcinoma Patients/Experiment 1/Signature 1
• The biodiversity Composition of Microbiome in Ovarian Carcinoma Patients/Experiment 1/Signature 2
• Decreased Diversity of the Oral Microbiota of Patients with Hepatitis B Virus-Induced Chronic Liver Disease: A Pilot Project/Experiment 1
• Decreased Diversity of the Oral Microbiota of Patients with Hepatitis B Virus-Induced Chronic Liver Disease: A Pilot Project/Experiment 2
• Lower airway microbiota and mycobiota in children with severe asthma/Experiment 1
• The differential distribution of bacteria between cancerous and noncancerous ovarian tissues in situ/Experiment 1/Signature 1
• Postmenopause as a key factor in the composition of the Endometrial Cancer Microbiome (ECbiome)/Experiment 1
• Postmenopause as a key factor in the composition of the Endometrial Cancer Microbiome (ECbiome)/Experiment 2
• Postmenopause as a key factor in the composition of the Endometrial Cancer Microbiome (ECbiome)/Experiment 2/Signature 1
• Autism Spectrum Disorder (ASD) with and without Mental Regression is Associated with Changes in the Fecal Microbiota/Experiment 1
• Autism Spectrum Disorder (ASD) with and without Mental Regression is Associated with Changes in the Fecal Microbiota/Experiment 2
• Increased Abundance of Clostridium and Fusobacterium in Gastric Microbiota of Patients with Gastric Cancer in Taiwan/Experiment 1
• Altered fecal microbiota composition associated with food allergy in infants/Experiment 1/Signature 1
• Altered fecal microbiota composition associated with food allergy in infants/Experiment 1/Signature 2
• Gut Microbiota Signatures in Gestational Anemia/Experiment 1
• Gut Microbiota Signatures in Gestational Anemia/Experiment 2
• Gut Microbiota Signatures in Gestational Anemia/Experiment 2/Signature 2
• Association of dietary fibre intake and gut microbiota in adults
• Association of dietary fibre intake and gut microbiota in adults/Experiment 1
• Association of dietary fibre intake and gut microbiota in adults/Experiment 1/Signature 1
• Association of dietary fibre intake and gut microbiota in adults/Experiment 1/Signature 2
• Association of dietary fibre intake and gut microbiota in adults/Experiment 2/Signature 1
• Association of dietary fibre intake and gut microbiota in adults/Experiment 2/Signature 2
• Association of dietary fibre intake and gut microbiota in adults/Experiment 3/Signature 1
• Association of dietary fibre intake and gut microbiota in adults/Experiment 3/Signature 2
• Association of dietary fibre intake and gut microbiota in adults/Experiment 4/Signature 1
• Early-Life Events, Including Mode of Delivery and Type of Feeding, Siblings and Gender, Shape the Developing Gut Microbiota/Experiment 1
• Microarray analysis reveals marked intestinal microbiota aberrancy in infants having eczema compared to healthy children in at-risk for atopic disease/Experiment 1
• Microarray analysis reveals marked intestinal microbiota aberrancy in infants having eczema compared to healthy children in at-risk for atopic disease/Experiment 1/Signature 1
• Microarray analysis reveals marked intestinal microbiota aberrancy in infants having eczema compared to healthy children in at-risk for atopic disease/Experiment 1/Signature 2
• Microarray analysis reveals marked intestinal microbiota aberrancy in infants having eczema compared to healthy children in at-risk for atopic disease/Experiment 2
• Microarray analysis reveals marked intestinal microbiota aberrancy in infants having eczema compared to healthy children in at-risk for atopic disease/Experiment 2/Signature 1
• Microarray analysis reveals marked intestinal microbiota aberrancy in infants having eczema compared to healthy children in at-risk for atopic disease/Experiment 2/Signature 2
• Microarray analysis reveals marked intestinal microbiota aberrancy in infants having eczema compared to healthy children in at-risk for atopic disease/Experiment 3
• Microarray analysis reveals marked intestinal microbiota aberrancy in infants having eczema compared to healthy children in at-risk for atopic disease/Experiment 3/Signature 1
• Microarray analysis reveals marked intestinal microbiota aberrancy in infants having eczema compared to healthy children in at-risk for atopic disease/Experiment 3/Signature 2
• Microarray analysis reveals marked intestinal microbiota aberrancy in infants having eczema compared to healthy children in at-risk for atopic disease/Experiment 4
• Microarray analysis reveals marked intestinal microbiota aberrancy in infants having eczema compared to healthy children in at-risk for atopic disease/Experiment 4/Signature 1
• Microarray analysis reveals marked intestinal microbiota aberrancy in infants having eczema compared to healthy children in at-risk for atopic disease/Experiment 4/Signature 2
• Alteration in gut microbiota associated with hepatitis B and non-hepatitis virus related hepatocellular carcinoma/Experiment 1
• Almond Snacking for 8 wk Increases Alpha-Diversity of the Gastrointestinal Microbiome and Decreases Bacteroides fragilis Abundance Compared with an Isocaloric Snack in College Freshmen/Experiment 1
• Different gastric microbiota compositions in two human populations with high and low gastric cancer risk in Colombia/Experiment 1
• Different gastric microbiota compositions in two human populations with high and low gastric cancer risk in Colombia/Experiment 1/Signature 2
• Alterations in the gut microbiota of patients with acquired immune deficiency syndrome/Experiment 1
• Alterations in the gut microbiota of patients with acquired immune deficiency syndrome/Experiment 2
• Alterations in the gut microbiota of patients with acquired immune deficiency syndrome/Experiment 3
• Alterations in the gut microbiota of patients with acquired immune deficiency syndrome/Experiment 4
• Alterations in the gut microbiota of patients with acquired immune deficiency syndrome/Experiment 5
• Alterations in the gut microbiota of patients with acquired immune deficiency syndrome/Experiment 6
• Low diversity of the gut microbiota in infants with atopic eczema/Experiment 1
• Low diversity of the gut microbiota in infants with atopic eczema/Experiment 1/Signature 1
• Low diversity of the gut microbiota in infants with atopic eczema/Experiment 1/Signature 2
• Low diversity of the gut microbiota in infants with atopic eczema/Experiment 2
• Low diversity of the gut microbiota in infants with atopic eczema/Experiment 2/Signature 1
• Imbalance of Gut Streptococcus, Clostridium, and Akkermansia Determines the Natural Course of Atopic Dermatitis in Infant/Experiment 1/Signature 1
• Imbalance of Gut Streptococcus, Clostridium, and Akkermansia Determines the Natural Course of Atopic Dermatitis in Infant/Experiment 1/Signature 2
• Imbalance of Gut Streptococcus, Clostridium, and Akkermansia Determines the Natural Course of Atopic Dermatitis in Infant/Experiment 2
• Imbalance of Gut Streptococcus, Clostridium, and Akkermansia Determines the Natural Course of Atopic Dermatitis in Infant/Experiment 2/Signature 1
• Imbalance of Gut Streptococcus, Clostridium, and Akkermansia Determines the Natural Course of Atopic Dermatitis in Infant/Experiment 2/Signature 2
• Imbalance of Gut Streptococcus, Clostridium, and Akkermansia Determines the Natural Course of Atopic Dermatitis in Infant/Experiment 3
• Imbalance of Gut Streptococcus, Clostridium, and Akkermansia Determines the Natural Course of Atopic Dermatitis in Infant/Experiment 3/Signature 1
• Imbalance of Gut Streptococcus, Clostridium, and Akkermansia Determines the Natural Course of Atopic Dermatitis in Infant/Experiment 3/Signature 2
• Imbalance of Gut Streptococcus, Clostridium, and Akkermansia Determines the Natural Course of Atopic Dermatitis in Infant/Experiment 4
• Imbalance of Gut Streptococcus, Clostridium, and Akkermansia Determines the Natural Course of Atopic Dermatitis in Infant/Experiment 4/Signature 1
• Imbalance of Gut Streptococcus, Clostridium, and Akkermansia Determines the Natural Course of Atopic Dermatitis in Infant/Experiment 4/Signature 2
• Imbalance of Gut Streptococcus, Clostridium, and Akkermansia Determines the Natural Course of Atopic Dermatitis in Infant/Experiment 5
• Imbalance of Gut Streptococcus, Clostridium, and Akkermansia Determines the Natural Course of Atopic Dermatitis in Infant/Experiment 5/Signature 1
• Imbalance of Gut Streptococcus, Clostridium, and Akkermansia Determines the Natural Course of Atopic Dermatitis in Infant/Experiment 5/Signature 2
• Imbalance of Gut Streptococcus, Clostridium, and Akkermansia Determines the Natural Course of Atopic Dermatitis in Infant/Experiment 6
• Imbalance of Gut Streptococcus, Clostridium, and Akkermansia Determines the Natural Course of Atopic Dermatitis in Infant/Experiment 6/Signature 1
• Imbalance of Gut Streptococcus, Clostridium, and Akkermansia Determines the Natural Course of Atopic Dermatitis in Infant/Experiment 6/Signature 2
• The influence of in vitro pectin fermentation on the human fecal microbiome
• The influence of in vitro pectin fermentation on the human fecal microbiome/Experiment 1
• The influence of in vitro pectin fermentation on the human fecal microbiome/Experiment 1/Signature 1
• The influence of in vitro pectin fermentation on the human fecal microbiome/Experiment 1/Signature 2
• Effects of Commercial Apple Varieties on Human Gut Microbiota Composition and Metabolic Output Using an In Vitro Colonic Model/Experiment 1
• Effects of Commercial Apple Varieties on Human Gut Microbiota Composition and Metabolic Output Using an In Vitro Colonic Model/Experiment 1/Signature 1
• Effects of Commercial Apple Varieties on Human Gut Microbiota Composition and Metabolic Output Using an In Vitro Colonic Model/Experiment 1/Signature 2
• Effects of Commercial Apple Varieties on Human Gut Microbiota Composition and Metabolic Output Using an In Vitro Colonic Model/Experiment 2/Signature 1
• Effects of Commercial Apple Varieties on Human Gut Microbiota Composition and Metabolic Output Using an In Vitro Colonic Model/Experiment 2/Signature 2
• Effects of Commercial Apple Varieties on Human Gut Microbiota Composition and Metabolic Output Using an In Vitro Colonic Model/Experiment 3
• Effects of Commercial Apple Varieties on Human Gut Microbiota Composition and Metabolic Output Using an In Vitro Colonic Model/Experiment 3/Signature 1
• Effects of Commercial Apple Varieties on Human Gut Microbiota Composition and Metabolic Output Using an In Vitro Colonic Model/Experiment 4/Signature 1
• Effects of Commercial Apple Varieties on Human Gut Microbiota Composition and Metabolic Output Using an In Vitro Colonic Model/Experiment 4/Signature 2
• Effects of Commercial Apple Varieties on Human Gut Microbiota Composition and Metabolic Output Using an In Vitro Colonic Model/Experiment 5
• Effects of Commercial Apple Varieties on Human Gut Microbiota Composition and Metabolic Output Using an In Vitro Colonic Model/Experiment 5/Signature 2
• Effects of Commercial Apple Varieties on Human Gut Microbiota Composition and Metabolic Output Using an In Vitro Colonic Model/Experiment 6/Signature 1
• Effects of Commercial Apple Varieties on Human Gut Microbiota Composition and Metabolic Output Using an In Vitro Colonic Model/Experiment 6/Signature 2
• Effects of Commercial Apple Varieties on Human Gut Microbiota Composition and Metabolic Output Using an In Vitro Colonic Model/Experiment 7/Signature 1
• Effects of Commercial Apple Varieties on Human Gut Microbiota Composition and Metabolic Output Using an In Vitro Colonic Model/Experiment 7/Signature 2
• Effects of Commercial Apple Varieties on Human Gut Microbiota Composition and Metabolic Output Using an In Vitro Colonic Model/Experiment 8/Signature 1
• Effects of Commercial Apple Varieties on Human Gut Microbiota Composition and Metabolic Output Using an In Vitro Colonic Model/Experiment 8/Signature 2
• Effects of Commercial Apple Varieties on Human Gut Microbiota Composition and Metabolic Output Using an In Vitro Colonic Model/Experiment 9/Signature 1
• Effects of Commercial Apple Varieties on Human Gut Microbiota Composition and Metabolic Output Using an In Vitro Colonic Model/Experiment 10/Signature 1
• Effects of Commercial Apple Varieties on Human Gut Microbiota Composition and Metabolic Output Using an In Vitro Colonic Model/Experiment 11/Signature 1
• Effects of Commercial Apple Varieties on Human Gut Microbiota Composition and Metabolic Output Using an In Vitro Colonic Model/Experiment 12/Signature 1
• Effects of Commercial Apple Varieties on Human Gut Microbiota Composition and Metabolic Output Using an In Vitro Colonic Model/Experiment 13
• Effects of Commercial Apple Varieties on Human Gut Microbiota Composition and Metabolic Output Using an In Vitro Colonic Model/Experiment 13/Signature 1
• Effects of Commercial Apple Varieties on Human Gut Microbiota Composition and Metabolic Output Using an In Vitro Colonic Model/Experiment 13/Signature 2
• Microbe-host interplay in atopic dermatitis and psoriasis
• Microbe-host interplay in atopic dermatitis and psoriasis/Experiment 1
• Microbe-host interplay in atopic dermatitis and psoriasis/Experiment 1/Signature 1
• Microbe-host interplay in atopic dermatitis and psoriasis/Experiment 1/Signature 2
• Microbe-host interplay in atopic dermatitis and psoriasis/Experiment 2
• Microbe-host interplay in atopic dermatitis and psoriasis/Experiment 2/Signature 1
• Microbe-host interplay in atopic dermatitis and psoriasis/Experiment 2/Signature 2
• Microbe-host interplay in atopic dermatitis and psoriasis/Experiment 3/Signature 1
• Microbe-host interplay in atopic dermatitis and psoriasis/Experiment 4/Signature 1
• Fecal microbiome signatures are different in food-allergic children compared to siblings and healthy children/Experiment 2/Signature 1
• Fecal microbiome signatures are different in food-allergic children compared to siblings and healthy children/Experiment 2/Signature 2
• Intestinal microbiota in patients with chronic hepatitis C with and without cirrhosis compared with healthy controls/Experiment 1
• Intestinal microbiota in patients with chronic hepatitis C with and without cirrhosis compared with healthy controls/Experiment 2
• Intestinal microbiota in patients with chronic hepatitis C with and without cirrhosis compared with healthy controls/Experiment 3
• Intestinal microbiota in patients with chronic hepatitis C with and without cirrhosis compared with healthy controls/Experiment 3/Signature 2
• Gut microbial diversity and genus-level differences identified in cervical cancer patients versus healthy controls
• Gut microbial diversity and genus-level differences identified in cervical cancer patients versus healthy controls/Experiment 1
• Gut microbial diversity and genus-level differences identified in cervical cancer patients versus healthy controls/Experiment 1/Signature 2
• Gut microbial diversity and genus-level differences identified in cervical cancer patients versus healthy controls/Experiment 2
• Gut microbial diversity and genus-level differences identified in cervical cancer patients versus healthy controls/Experiment 3
• Infant gut microbiota and food sensitization: associations in the first year of life
• Infant gut microbiota and food sensitization: associations in the first year of life/Experiment 1
• Infant gut microbiota and food sensitization: associations in the first year of life/Experiment 1/Signature 1
• Infant gut microbiota and food sensitization: associations in the first year of life/Experiment 2
• Infant gut microbiota and food sensitization: associations in the first year of life/Experiment 2/Signature 1
• Infant gut microbiota and food sensitization: associations in the first year of life/Experiment 2/Signature 2
• Iron deficiency anemia-related gut microbiota dysbiosis in infants and young children: A pilot study/Experiment 1
• Iron deficiency anemia-related gut microbiota dysbiosis in infants and young children: A pilot study/Experiment 1/Signature 1
• Iron deficiency anemia-related gut microbiota dysbiosis in infants and young children: A pilot study/Experiment 1/Signature 2
• Comparative analysis of the oral microbiota between iron-deficiency anaemia (IDA) patients and healthy individuals by high-throughput sequencing/Experiment 1/Signature 2
• Comparative analysis of the oral microbiota between iron-deficiency anaemia (IDA) patients and healthy individuals by high-throughput sequencing/Experiment 2
• Comparative analysis of the oral microbiota between iron-deficiency anaemia (IDA) patients and healthy individuals by high-throughput sequencing/Experiment 3
• Association Between Gut Microbiota and Helicobacter pylori-Related Gastric Lesions in a High-Risk Population of Gastric Cancer/Experiment 3/Signature 1
• Association Between Gut Microbiota and Helicobacter pylori-Related Gastric Lesions in a High-Risk Population of Gastric Cancer/Experiment 4/Signature 1
• Association Between Gut Microbiota and Helicobacter pylori-Related Gastric Lesions in a High-Risk Population of Gastric Cancer/Experiment 5/Signature 1
• Association Between Gut Microbiota and Helicobacter pylori-Related Gastric Lesions in a High-Risk Population of Gastric Cancer/Experiment 6/Signature 2
• 16S rRNA gene sequencing reveals altered composition of gut microbiota in individuals with kidney stones/Experiment 1
• Sex-specific impact of asthma during pregnancy on infant gut microbiota/Experiment 1
• Sex-specific impact of asthma during pregnancy on infant gut microbiota/Experiment 1/Signature 1
• Sex-specific impact of asthma during pregnancy on infant gut microbiota/Experiment 1/Signature 2
• Sex-specific impact of asthma during pregnancy on infant gut microbiota/Experiment 2
• Sex-specific impact of asthma during pregnancy on infant gut microbiota/Experiment 2/Signature 1
• Sex-specific impact of asthma during pregnancy on infant gut microbiota/Experiment 2/Signature 2
• Sex-specific impact of asthma during pregnancy on infant gut microbiota/Experiment 4
• Sex-specific impact of asthma during pregnancy on infant gut microbiota/Experiment 4/Signature 1
• Sex-specific impact of asthma during pregnancy on infant gut microbiota/Experiment 5
• Sex-specific impact of asthma during pregnancy on infant gut microbiota/Experiment 5/Signature 1
• Sex-specific impact of asthma during pregnancy on infant gut microbiota/Experiment 5/Signature 2
• Sex-specific impact of asthma during pregnancy on infant gut microbiota/Experiment 6/Signature 1
• Sex-specific impact of asthma during pregnancy on infant gut microbiota/Experiment 7/Signature 1
• Sex-specific impact of asthma during pregnancy on infant gut microbiota/Experiment 7/Signature 2
• Sex-specific impact of asthma during pregnancy on infant gut microbiota/Experiment 8
• Sex-specific impact of asthma during pregnancy on infant gut microbiota/Experiment 8/Signature 1
• Habitual dietary fibre intake influences gut microbiota response to an inulin-type fructan prebiotic: a randomised, double-blind, placebo-controlled, cross-over, human intervention study/Experiment 1
• Habitual dietary fibre intake influences gut microbiota response to an inulin-type fructan prebiotic: a randomised, double-blind, placebo-controlled, cross-over, human intervention study/Experiment 1/Signature 2
• Habitual dietary fibre intake influences gut microbiota response to an inulin-type fructan prebiotic: a randomised, double-blind, placebo-controlled, cross-over, human intervention study/Experiment 2/Signature 1
• Habitual dietary fibre intake influences gut microbiota response to an inulin-type fructan prebiotic: a randomised, double-blind, placebo-controlled, cross-over, human intervention study/Experiment 3
• Habitual dietary fibre intake influences gut microbiota response to an inulin-type fructan prebiotic: a randomised, double-blind, placebo-controlled, cross-over, human intervention study/Experiment 3/Signature 1
• Habitual dietary fibre intake influences gut microbiota response to an inulin-type fructan prebiotic: a randomised, double-blind, placebo-controlled, cross-over, human intervention study/Experiment 3/Signature 2
• Habitual dietary fibre intake influences gut microbiota response to an inulin-type fructan prebiotic: a randomised, double-blind, placebo-controlled, cross-over, human intervention study/Experiment 4/Signature 1
• Habitual dietary fibre intake influences gut microbiota response to an inulin-type fructan prebiotic: a randomised, double-blind, placebo-controlled, cross-over, human intervention study/Experiment 4/Signature 2
• The cervical microbiota in reproductive-age South African women with and without human papillomavirus infection
• The cervical microbiota in reproductive-age South African women with and without human papillomavirus infection/Experiment 1
• The cervical microbiota in reproductive-age South African women with and without human papillomavirus infection/Experiment 2
• Healthy infants harbor intestinal bacteria that protect against food allergy/Experiment 1
• The imbalance of gut microbiota and its correlation with plasma inflammatory cytokines in pemphigus vulgaris patients/Experiment 1
• The imbalance of gut microbiota and its correlation with plasma inflammatory cytokines in pemphigus vulgaris patients/Experiment 1/Signature 2
• Different functional genes of upper airway microbiome associated with natural course of childhood asthma/Experiment 1
• Different functional genes of upper airway microbiome associated with natural course of childhood asthma/Experiment 1/Signature 1
• Different functional genes of upper airway microbiome associated with natural course of childhood asthma/Experiment 1/Signature 2
• Different functional genes of upper airway microbiome associated with natural course of childhood asthma/Experiment 2/Signature 1
• Different functional genes of upper airway microbiome associated with natural course of childhood asthma/Experiment 2/Signature 2
• Relationship between the Cervical Microbiome, HIV Status, and Precancerous Lesions
• Relationship between the Cervical Microbiome, HIV Status, and Precancerous Lesions/Experiment 1
• Relationship between the Cervical Microbiome, HIV Status, and Precancerous Lesions/Experiment 2
• Relationship between the Cervical Microbiome, HIV Status, and Precancerous Lesions/Experiment 3
• Relationship between the Cervical Microbiome, HIV Status, and Precancerous Lesions/Experiment 3/Signature 1
• Alterations of gastric mucosal microbiota across different stomach microhabitats in a cohort of 276 patients with gastric cancer/Experiment 1
• Alterations of gastric mucosal microbiota across different stomach microhabitats in a cohort of 276 patients with gastric cancer/Experiment 2
• Alterations of gastric mucosal microbiota across different stomach microhabitats in a cohort of 276 patients with gastric cancer/Experiment 3
• Alterations of gastric mucosal microbiota across different stomach microhabitats in a cohort of 276 patients with gastric cancer/Experiment 4
• Alterations of gastric mucosal microbiota across different stomach microhabitats in a cohort of 276 patients with gastric cancer/Experiment 5
• Alterations of gastric mucosal microbiota across different stomach microhabitats in a cohort of 276 patients with gastric cancer/Experiment 6
• Alterations of gastric mucosal microbiota across different stomach microhabitats in a cohort of 276 patients with gastric cancer/Experiment 8
• Alterations of gastric mucosal microbiota across different stomach microhabitats in a cohort of 276 patients with gastric cancer/Experiment 9
• Alterations of gastric mucosal microbiota across different stomach microhabitats in a cohort of 276 patients with gastric cancer/Experiment 10
• Alterations of gastric mucosal microbiota across different stomach microhabitats in a cohort of 276 patients with gastric cancer/Experiment 11
• The human gut microbiome as a screening tool for colorectal cancer/Experiment 1
• The human gut microbiome as a screening tool for colorectal cancer/Experiment 1/Signature 1
• The human gut microbiome as a screening tool for colorectal cancer/Experiment 1/Signature 2
• The human gut microbiome as a screening tool for colorectal cancer/Experiment 2/Signature 1
• The human gut microbiome as a screening tool for colorectal cancer/Experiment 2/Signature 2
• The human gut microbiome as a screening tool for colorectal cancer/Experiment 3/Signature 1
• The human gut microbiome as a screening tool for colorectal cancer/Experiment 3/Signature 2
• The human gut microbiome as a screening tool for colorectal cancer/Experiment 4/Signature 1
• The human gut microbiome as a screening tool for colorectal cancer/Experiment 4/Signature 2
• Emollient use alters skin barrier and microbes in infants at risk for developing atopic dermatitis/Experiment 1
• The intestinal microflora in allergic Estonian and Swedish 2-year-old children
• The intestinal microflora in allergic Estonian and Swedish 2-year-old children/Experiment 1/Signature 1
• The intestinal microflora in allergic Estonian and Swedish 2-year-old children/Experiment 1/Signature 2
• The intestinal microflora in allergic Estonian and Swedish 2-year-old children/Experiment 2
• The intestinal microflora in allergic Estonian and Swedish 2-year-old children/Experiment 2/Signature 1
• The intestinal microflora in allergic Estonian and Swedish 2-year-old children/Experiment 2/Signature 2
• Differences in Gut Microbiota Profiles between Autoimmune Pancreatitis and Chronic Pancreatitis/Experiment 1
• Differences in Gut Microbiota Profiles between Autoimmune Pancreatitis and Chronic Pancreatitis/Experiment 1/Signature 1
• Bacterial biogeography of adult airways in atopic asthma
• Bacterial biogeography of adult airways in atopic asthma/Experiment 1
• Bacterial biogeography of adult airways in atopic asthma/Experiment 2
• Bacterial biogeography of adult airways in atopic asthma/Experiment 3
• Bacterial biogeography of adult airways in atopic asthma/Experiment 3/Signature 1
• Bacterial biogeography of adult airways in atopic asthma/Experiment 3/Signature 2
• Bacterial biogeography of adult airways in atopic asthma/Experiment 4
• Bacterial biogeography of adult airways in atopic asthma/Experiment 5
• Bacterial biogeography of adult airways in atopic asthma/Experiment 6
• Bacterial biogeography of adult airways in atopic asthma/Experiment 7
• Bacterial biogeography of adult airways in atopic asthma/Experiment 7/Signature 1
• A comparative study of the gut microbiota in immune-mediated inflammatory diseases-does a common dysbiosis exist?
• A comparative study of the gut microbiota in immune-mediated inflammatory diseases-does a common dysbiosis exist?/Experiment 1
• A comparative study of the gut microbiota in immune-mediated inflammatory diseases-does a common dysbiosis exist?/Experiment 1/Signature 1
• A comparative study of the gut microbiota in immune-mediated inflammatory diseases-does a common dysbiosis exist?/Experiment 2
• A comparative study of the gut microbiota in immune-mediated inflammatory diseases-does a common dysbiosis exist?/Experiment 2/Signature 1
• A comparative study of the gut microbiota in immune-mediated inflammatory diseases-does a common dysbiosis exist?/Experiment 3
• A comparative study of the gut microbiota in immune-mediated inflammatory diseases-does a common dysbiosis exist?/Experiment 3/Signature 1
• A comparative study of the gut microbiota in immune-mediated inflammatory diseases-does a common dysbiosis exist?/Experiment 4
• A comparative study of the gut microbiota in immune-mediated inflammatory diseases-does a common dysbiosis exist?/Experiment 4/Signature 1
• Prevalent high-risk HPV infection and vaginal microbiota in Nigerian women
• Prevalent high-risk HPV infection and vaginal microbiota in Nigerian women/Experiment 1
• Prevalent high-risk HPV infection and vaginal microbiota in Nigerian women/Experiment 1/Signature 1
• Prevalent high-risk HPV infection and vaginal microbiota in Nigerian women/Experiment 1/Signature 2
• Microbial Community of Healthy Thai Vegetarians and Non-Vegetarians, Their Core Gut Microbiota, and Pathogen Risk/Experiment 1/Signature 1
• Microbial Community of Healthy Thai Vegetarians and Non-Vegetarians, Their Core Gut Microbiota, and Pathogen Risk/Experiment 1/Signature 2
• Features of the bronchial bacterial microbiome associated with atopy, asthma, and responsiveness to inhaled corticosteroid treatment/Experiment 1
• Features of the bronchial bacterial microbiome associated with atopy, asthma, and responsiveness to inhaled corticosteroid treatment/Experiment 2
• Features of the bronchial bacterial microbiome associated with atopy, asthma, and responsiveness to inhaled corticosteroid treatment/Experiment 3
• Features of the bronchial bacterial microbiome associated with atopy, asthma, and responsiveness to inhaled corticosteroid treatment/Experiment 4
• Features of the bronchial bacterial microbiome associated with atopy, asthma, and responsiveness to inhaled corticosteroid treatment/Experiment 4/Signature 1
• Features of the bronchial bacterial microbiome associated with atopy, asthma, and responsiveness to inhaled corticosteroid treatment/Experiment 5
• Features of the bronchial bacterial microbiome associated with atopy, asthma, and responsiveness to inhaled corticosteroid treatment/Experiment 6
• Features of the bronchial bacterial microbiome associated with atopy, asthma, and responsiveness to inhaled corticosteroid treatment/Experiment 7
• Features of the bronchial bacterial microbiome associated with atopy, asthma, and responsiveness to inhaled corticosteroid treatment/Experiment 8
• Features of the bronchial bacterial microbiome associated with atopy, asthma, and responsiveness to inhaled corticosteroid treatment/Experiment 9
• Cervical microbiome is altered in cervical intraepithelial neoplasia after loop electrosurgical excision procedure in china
• Cervical microbiome is altered in cervical intraepithelial neoplasia after loop electrosurgical excision procedure in china/Experiment 1
• Cervical microbiome is altered in cervical intraepithelial neoplasia after loop electrosurgical excision procedure in china/Experiment 1/Signature 1
• Characterization of cervico-vaginal microbiota in women developing persistent high-risk Human Papillomavirus infection
• Characterization of cervico-vaginal microbiota in women developing persistent high-risk Human Papillomavirus infection/Experiment 1
• Characterization of cervico-vaginal microbiota in women developing persistent high-risk Human Papillomavirus infection/Experiment 2
• Characterization of cervico-vaginal microbiota in women developing persistent high-risk Human Papillomavirus infection/Experiment 2/Signature 2
• Minimal residual disease negativity in multiple myeloma is associated with intestinal microbiota composition/Experiment 2
• Infectious Complications Are Associated With Alterations in the Gut Microbiome in Pediatric Patients With Acute Lymphoblastic Leukemia/Experiment 1
• Infectious Complications Are Associated With Alterations in the Gut Microbiome in Pediatric Patients With Acute Lymphoblastic Leukemia/Experiment 1/Signature 1
• Infectious Complications Are Associated With Alterations in the Gut Microbiome in Pediatric Patients With Acute Lymphoblastic Leukemia/Experiment 1/Signature 2
• Linking cervicovaginal immune signatures, HPV and microbiota composition in cervical carcinogenesis in non-Hispanic and Hispanic women
• Linking cervicovaginal immune signatures, HPV and microbiota composition in cervical carcinogenesis in non-Hispanic and Hispanic women/Experiment 1
• Linking cervicovaginal immune signatures, HPV and microbiota composition in cervical carcinogenesis in non-Hispanic and Hispanic women/Experiment 2
• Linking cervicovaginal immune signatures, HPV and microbiota composition in cervical carcinogenesis in non-Hispanic and Hispanic women/Experiment 3
• Linking cervicovaginal immune signatures, HPV and microbiota composition in cervical carcinogenesis in non-Hispanic and Hispanic women/Experiment 4
• Linking cervicovaginal immune signatures, HPV and microbiota composition in cervical carcinogenesis in non-Hispanic and Hispanic women/Experiment 5
• Linking cervicovaginal immune signatures, HPV and microbiota composition in cervical carcinogenesis in non-Hispanic and Hispanic women/Experiment 6
• Linking cervicovaginal immune signatures, HPV and microbiota composition in cervical carcinogenesis in non-Hispanic and Hispanic women/Experiment 7
• Linking cervicovaginal immune signatures, HPV and microbiota composition in cervical carcinogenesis in non-Hispanic and Hispanic women/Experiment 7/Signature 2
• Linking cervicovaginal immune signatures, HPV and microbiota composition in cervical carcinogenesis in non-Hispanic and Hispanic women/Experiment 8
• Linking cervicovaginal immune signatures, HPV and microbiota composition in cervical carcinogenesis in non-Hispanic and Hispanic women/Experiment 9
• Linking cervicovaginal immune signatures, HPV and microbiota composition in cervical carcinogenesis in non-Hispanic and Hispanic women/Experiment 10
• Modulation of faecal metagenome in Crohn's disease: Role of microRNAs as biomarkers/Experiment 1
• Nonalcoholic fatty liver disease is associated with dysbiosis independent of body mass index and insulin resistance/Experiment 1/Signature 1
• Nonalcoholic fatty liver disease is associated with dysbiosis independent of body mass index and insulin resistance/Experiment 1/Signature 2
• Observational Cohort Study of Oral Mycobiome and Interkingdom Interactions over the Course of Induction Therapy for Leukemia/Experiment 1
• Observational Cohort Study of Oral Mycobiome and Interkingdom Interactions over the Course of Induction Therapy for Leukemia/Experiment 1/Signature 2
• Observational Cohort Study of Oral Mycobiome and Interkingdom Interactions over the Course of Induction Therapy for Leukemia/Experiment 2
• Observational Cohort Study of Oral Mycobiome and Interkingdom Interactions over the Course of Induction Therapy for Leukemia/Experiment 2/Signature 1
• Observational Cohort Study of Oral Mycobiome and Interkingdom Interactions over the Course of Induction Therapy for Leukemia/Experiment 3
• Observational Cohort Study of Oral Mycobiome and Interkingdom Interactions over the Course of Induction Therapy for Leukemia/Experiment 3/Signature 1
• Cervical intraepithelial neoplasia disease progression is associated with increased vaginal microbiome diversity
• Cervical intraepithelial neoplasia disease progression is associated with increased vaginal microbiome diversity/Experiment 1
• Microbiota changes in a pediatric acute lymphocytic leukemia mouse model/Experiment 1/Signature 1
• Microbiota changes in a pediatric acute lymphocytic leukemia mouse model/Experiment 1/Signature 2
• The vaginal metabolome and microbiota of cervical HPV-positive and HPV-negative women: a cross-sectional analysis
• The vaginal metabolome and microbiota of cervical HPV-positive and HPV-negative women: a cross-sectional analysis/Experiment 1
• Carious status and supragingival plaque microbiota in hemodialysis patients/Experiment 2/Signature 1
• Alterations in the intestinal microbiota of patients with severe and active Graves' orbitopathy: a cross-sectional study
• Alterations in the intestinal microbiota of patients with severe and active Graves' orbitopathy: a cross-sectional study/Experiment 1
• Alterations in the intestinal microbiota of patients with severe and active Graves' orbitopathy: a cross-sectional study/Experiment 1/Signature 1
• Alterations in the intestinal microbiota of patients with severe and active Graves' orbitopathy: a cross-sectional study/Experiment 2
• Alterations in the intestinal microbiota of patients with severe and active Graves' orbitopathy: a cross-sectional study/Experiment 2/Signature 1
• Alterations in the intestinal microbiota of patients with severe and active Graves' orbitopathy: a cross-sectional study/Experiment 2/Signature 2
• Cervicovaginal microbiome and natural history of HPV in a longitudinal study
• Cervicovaginal microbiome and natural history of HPV in a longitudinal study/Experiment 1
• Cervicovaginal microbiome and natural history of HPV in a longitudinal study/Experiment 1/Signature 1
• Cervicovaginal microbiome and natural history of HPV in a longitudinal study/Experiment 2
• Cervicovaginal microbiome and natural history of HPV in a longitudinal study/Experiment 2/Signature 2
• Molecular Alteration Analysis of Human Gut Microbial Composition in Graves' disease Patients/Experiment 1/Signature 1
• Molecular Alteration Analysis of Human Gut Microbial Composition in Graves' disease Patients/Experiment 1/Signature 2
• Evaluation of the Associations Between Cervical Microbiota and HPV Infection, Clearance, and Persistence in Cytologically Normal Women
• Evaluation of the Associations Between Cervical Microbiota and HPV Infection, Clearance, and Persistence in Cytologically Normal Women/Experiment 1
• Evaluation of the Associations Between Cervical Microbiota and HPV Infection, Clearance, and Persistence in Cytologically Normal Women/Experiment 1/Signature 2
• Evaluation of the Associations Between Cervical Microbiota and HPV Infection, Clearance, and Persistence in Cytologically Normal Women/Experiment 2
• Evaluation of the Associations Between Cervical Microbiota and HPV Infection, Clearance, and Persistence in Cytologically Normal Women/Experiment 3
• Evaluation of the Associations Between Cervical Microbiota and HPV Infection, Clearance, and Persistence in Cytologically Normal Women/Experiment 4
• Evaluation of the Associations Between Cervical Microbiota and HPV Infection, Clearance, and Persistence in Cytologically Normal Women/Experiment 5
• Evaluation of the Associations Between Cervical Microbiota and HPV Infection, Clearance, and Persistence in Cytologically Normal Women/Experiment 6
• Evaluation of the Associations Between Cervical Microbiota and HPV Infection, Clearance, and Persistence in Cytologically Normal Women/Experiment 7
• Gut Microbiome Composition Predicts Infection Risk During Chemotherapy in Children With Acute Lymphoblastic Leukemia/Experiment 2
• Gut Microbiome Composition Predicts Infection Risk During Chemotherapy in Children With Acute Lymphoblastic Leukemia/Experiment 3
• Gut Microbiome Composition Predicts Infection Risk During Chemotherapy in Children With Acute Lymphoblastic Leukemia/Experiment 4
• Patients With LR-HPV Infection Have a Distinct Vaginal Microbiota in Comparison With Healthy Controls
• Patients With LR-HPV Infection Have a Distinct Vaginal Microbiota in Comparison With Healthy Controls/Experiment 1
• Patients With LR-HPV Infection Have a Distinct Vaginal Microbiota in Comparison With Healthy Controls/Experiment 1/Signature 1
• Patients With LR-HPV Infection Have a Distinct Vaginal Microbiota in Comparison With Healthy Controls/Experiment 1/Signature 2
• Association between the vaginal microbiome and high-risk human papillomavirus infection in pregnant Chinese women
• Association between the vaginal microbiome and high-risk human papillomavirus infection in pregnant Chinese women/Experiment 1
• Association between the vaginal microbiome and high-risk human papillomavirus infection in pregnant Chinese women/Experiment 2
• Characterization of oral and gut microbiome temporal variability in hospitalized cancer patients/Experiment 2
• Gastrointestinal toxicity during induction treatment for childhood acute lymphoblastic leukemia: The impact of the gut microbiota/Experiment 1
• Gut microbiota is critical for the induction of chemotherapy-induced pain/Experiment 1/Signature 1
• Gut microbiota is critical for the induction of chemotherapy-induced pain/Experiment 1/Signature 2
• Association of the vaginal microbiota with human papillomavirus infection in a Korean twin cohort
• Association of the vaginal microbiota with human papillomavirus infection in a Korean twin cohort/Experiment 1
• Association of the vaginal microbiota with human papillomavirus infection in a Korean twin cohort/Experiment 1/Signature 1
• Association of the vaginal microbiota with human papillomavirus infection in a Korean twin cohort/Experiment 1/Signature 2
• Association of the vaginal microbiota with human papillomavirus infection in a Korean twin cohort/Experiment 2
• Association of the vaginal microbiota with human papillomavirus infection in a Korean twin cohort/Experiment 3
• The nasal microbiome in asthma
• The nasal microbiome in asthma/Experiment 3
• Effects of Gut Microbiota Manipulation by Antibiotics on Host Metabolism in Obese Humans: A Randomized Double-Blind Placebo-Controlled Trial
• Effects of Gut Microbiota Manipulation by Antibiotics on Host Metabolism in Obese Humans: A Randomized Double-Blind Placebo-Controlled Trial/Experiment 1
• Effects of Gut Microbiota Manipulation by Antibiotics on Host Metabolism in Obese Humans: A Randomized Double-Blind Placebo-Controlled Trial/Experiment 1/Signature 1
• Microbiome and diversity indices during blood stem cells transplantation - new perspectives?/Experiment 1
• Protection of the Human Gut Microbiome From Antibiotics/Experiment 1
• Inhalational exposure to particulate matter air pollution alters the composition of the gut microbiome/Experiment 1/Signature 1
• Inhalational exposure to particulate matter air pollution alters the composition of the gut microbiome/Experiment 1/Signature 2
• Inhalational exposure to particulate matter air pollution alters the composition of the gut microbiome/Experiment 2/Signature 1
• Inhalational exposure to particulate matter air pollution alters the composition of the gut microbiome/Experiment 2/Signature 2
• Inhalational exposure to particulate matter air pollution alters the composition of the gut microbiome/Experiment 3/Signature 2
• Inhalational exposure to particulate matter air pollution alters the composition of the gut microbiome/Experiment 4/Signature 1
• Inhalational exposure to particulate matter air pollution alters the composition of the gut microbiome/Experiment 4/Signature 2
• Inhalational exposure to particulate matter air pollution alters the composition of the gut microbiome/Experiment 5/Signature 1
• Inhalational exposure to particulate matter air pollution alters the composition of the gut microbiome/Experiment 5/Signature 2
• Inhalational exposure to particulate matter air pollution alters the composition of the gut microbiome/Experiment 6
• Cervical Microbiota Associated with Higher Grade Cervical Intraepithelial Neoplasia in Women Infected with High-Risk Human Papillomaviruses
• Cervical Microbiota Associated with Higher Grade Cervical Intraepithelial Neoplasia in Women Infected with High-Risk Human Papillomaviruses/Experiment 1
• Cervical Microbiota Associated with Higher Grade Cervical Intraepithelial Neoplasia in Women Infected with High-Risk Human Papillomaviruses/Experiment 2
• Cervical Microbiota Associated with Higher Grade Cervical Intraepithelial Neoplasia in Women Infected with High-Risk Human Papillomaviruses/Experiment 3
• Gut microbiota trajectory in pediatric patients undergoing hematopoietic SCT
• Gut microbiota trajectory in pediatric patients undergoing hematopoietic SCT/Experiment 1
• Gut microbiota trajectory in pediatric patients undergoing hematopoietic SCT/Experiment 1/Signature 1
• Gut microbiota trajectory in pediatric patients undergoing hematopoietic SCT/Experiment 1/Signature 2
• The vaginal microbiota associates with the regression of untreated cervical intraepithelial neoplasia 2 lesions
• The vaginal microbiota associates with the regression of untreated cervical intraepithelial neoplasia 2 lesions/Experiment 1
• The vaginal microbiota associates with the regression of untreated cervical intraepithelial neoplasia 2 lesions/Experiment 2
• The vaginal microbiota associates with the regression of untreated cervical intraepithelial neoplasia 2 lesions/Experiment 3
• The vaginal microbiota associates with the regression of untreated cervical intraepithelial neoplasia 2 lesions/Experiment 4
• Intestinal microbiota development in preterm neonates and effect of perinatal antibiotics/Experiment 1
• Intestinal microbiota development in preterm neonates and effect of perinatal antibiotics/Experiment 1/Signature 1
• Intestinal microbiota development in preterm neonates and effect of perinatal antibiotics/Experiment 1/Signature 2
• Intestinal microbiota development in preterm neonates and effect of perinatal antibiotics/Experiment 2/Signature 1
• Intestinal microbiota development in preterm neonates and effect of perinatal antibiotics/Experiment 3
• Intestinal microbiota development in preterm neonates and effect of perinatal antibiotics/Experiment 3/Signature 1
• Intestinal microbiota development in preterm neonates and effect of perinatal antibiotics/Experiment 3/Signature 2
• Intestinal microbiota development in preterm neonates and effect of perinatal antibiotics/Experiment 4
• Intestinal microbiota development in preterm neonates and effect of perinatal antibiotics/Experiment 4/Signature 1
• Intestinal microbiota development in preterm neonates and effect of perinatal antibiotics/Experiment 5/Signature 1
• Intestinal microbiota development in preterm neonates and effect of perinatal antibiotics/Experiment 6/Signature 1
• Intestinal microbiota development in preterm neonates and effect of perinatal antibiotics/Experiment 7/Signature 1
• Intestinal microbiota development in preterm neonates and effect of perinatal antibiotics/Experiment 8
• Intestinal microbiota development in preterm neonates and effect of perinatal antibiotics/Experiment 8/Signature 1
• Intestinal microbiota development in preterm neonates and effect of perinatal antibiotics/Experiment 9
• Intestinal microbiota development in preterm neonates and effect of perinatal antibiotics/Experiment 9/Signature 1
• Intestinal microbiota development in preterm neonates and effect of perinatal antibiotics/Experiment 10
• Intestinal microbiota development in preterm neonates and effect of perinatal antibiotics/Experiment 11
• The impact of postnatal antibiotics on the preterm intestinal microbiome/Experiment 1/Signature 1
• The impact of postnatal antibiotics on the preterm intestinal microbiome/Experiment 2
• Oral bacterial community dynamics in paediatric patients with malignancies in relation to chemotherapy-related oral mucositis: a prospective study/Experiment 1
• Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors/Experiment 1
• Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors/Experiment 1/Signature 1
• Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors/Experiment 1/Signature 2
• Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors/Experiment 2
• Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors/Experiment 2/Signature 1
• Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors/Experiment 2/Signature 2
• Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors/Experiment 3
• Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors/Experiment 3/Signature 1
• Dynamics of the bacterial gut microbiota in preterm and term infants after intravenous amoxicillin/ceftazidime treatment/Experiment 2
• Dynamics of the bacterial gut microbiota in preterm and term infants after intravenous amoxicillin/ceftazidime treatment/Experiment 2/Signature 1
• Impact of intrapartum and postnatal antibiotics on the gut microbiome and emergence of antimicrobial resistance in infants/Experiment 2
• HPV infection and bacterial microbiota in the placenta, uterine cervix and oral mucosa
• HPV infection and bacterial microbiota in the placenta, uterine cervix and oral mucosa/Experiment 1
• HPV infection and bacterial microbiota in the placenta, uterine cervix and oral mucosa/Experiment 2
• HPV infection and bacterial microbiota in the placenta, uterine cervix and oral mucosa/Experiment 3
• Effects of One-Week Empirical Antibiotic Therapy on the Early Development of Gut Microbiota and Metabolites in Preterm Infants
• Alteration of the gut microbiota associated with childhood obesity by 16S rRNA gene sequencing/Experiment 1
• Alteration of the gut microbiota associated with childhood obesity by 16S rRNA gene sequencing/Experiment 2/Signature 2
• Ambient Ultrafine Particle Ingestion Alters Gut Microbiota in Association with Increased Atherogenic Lipid Metabolites/Experiment 1
• Dysbiosis in Metabolic Genes of the Gut Microbiomes of Patients with an Ileo-anal Pouch Resembles That Observed in Crohn's Disease/Experiment 1/Signature 1
• Dysbiosis in Metabolic Genes of the Gut Microbiomes of Patients with an Ileo-anal Pouch Resembles That Observed in Crohn's Disease/Experiment 1/Signature 2
• Distinct nasal airway bacterial microbiotas differentially relate to exacerbation in pediatric patients with asthma/Experiment 1
• Distinct nasal airway bacterial microbiotas differentially relate to exacerbation in pediatric patients with asthma/Experiment 3
• Distinct nasal airway bacterial microbiotas differentially relate to exacerbation in pediatric patients with asthma/Experiment 5
• Distinct nasal airway bacterial microbiotas differentially relate to exacerbation in pediatric patients with asthma/Experiment 7
• Distinct nasal airway bacterial microbiotas differentially relate to exacerbation in pediatric patients with asthma/Experiment 8
• Gut dysbiosis during antileukemia chemotherapy versus allogeneic hematopoietic cell transplantation/Experiment 1
• Impacts of Dietary Protein and Niacin Deficiency on Reproduction Performance, Body Growth, and Gut Microbiota of Female Hamsters (Tscherskia triton) and Their Offspring
• Impacts of Dietary Protein and Niacin Deficiency on Reproduction Performance, Body Growth, and Gut Microbiota of Female Hamsters (Tscherskia triton) and Their Offspring/Experiment 1
• The gut microbiota is associated with psychiatric symptom severity and treatment outcome among individuals with serious mental illness/Experiment 1
• The gut microbiota is associated with psychiatric symptom severity and treatment outcome among individuals with serious mental illness/Experiment 2
• The gut microbiota is associated with psychiatric symptom severity and treatment outcome among individuals with serious mental illness/Experiment 2/Signature 1
• The gut microbiota is associated with psychiatric symptom severity and treatment outcome among individuals with serious mental illness/Experiment 3
• The gut microbiota is associated with psychiatric symptom severity and treatment outcome among individuals with serious mental illness/Experiment 3/Signature 1
• The gut microbiota is associated with psychiatric symptom severity and treatment outcome among individuals with serious mental illness/Experiment 3/Signature 2
• The gut microbiota is associated with psychiatric symptom severity and treatment outcome among individuals with serious mental illness/Experiment 4/Signature 1
• The gut microbiota is associated with psychiatric symptom severity and treatment outcome among individuals with serious mental illness/Experiment 5/Signature 1
• The gut microbiota is associated with psychiatric symptom severity and treatment outcome among individuals with serious mental illness/Experiment 5/Signature 2
• The gut microbiota is associated with psychiatric symptom severity and treatment outcome among individuals with serious mental illness/Experiment 6/Signature 1
• The gut microbiota is associated with psychiatric symptom severity and treatment outcome among individuals with serious mental illness/Experiment 6/Signature 2
• A study of the correlation between obesity and intestinal flora in school-age children/Experiment 1
• Correlation between body mass index and faecal microbiota from children/Experiment 2
• Cervical microbiota in women with cervical intra-epithelial neoplasia, prior to and after local excisional treatment, a Norwegian cohort study/Experiment 1/Signature 1
• Metatranscriptomic analysis to define the Secrebiome, and 16S rRNA profiling of the gut microbiome in obesity and metabolic syndrome of Mexican children/Experiment 1
• Metatranscriptomic analysis to define the Secrebiome, and 16S rRNA profiling of the gut microbiome in obesity and metabolic syndrome of Mexican children/Experiment 1/Signature 1
• Metatranscriptomic analysis to define the Secrebiome, and 16S rRNA profiling of the gut microbiome in obesity and metabolic syndrome of Mexican children/Experiment 1/Signature 2
• Metatranscriptomic analysis to define the Secrebiome, and 16S rRNA profiling of the gut microbiome in obesity and metabolic syndrome of Mexican children/Experiment 2/Signature 1
• Cervicovaginal Fungi and Bacteria Associated With Cervical Intraepithelial Neoplasia and High-Risk Human Papillomavirus Infections in a Hispanic Population
• Cervicovaginal Fungi and Bacteria Associated With Cervical Intraepithelial Neoplasia and High-Risk Human Papillomavirus Infections in a Hispanic Population/Experiment 1
• Cervicovaginal Fungi and Bacteria Associated With Cervical Intraepithelial Neoplasia and High-Risk Human Papillomavirus Infections in a Hispanic Population/Experiment 2
• Cervicovaginal Fungi and Bacteria Associated With Cervical Intraepithelial Neoplasia and High-Risk Human Papillomavirus Infections in a Hispanic Population/Experiment 3
• Cervicovaginal Fungi and Bacteria Associated With Cervical Intraepithelial Neoplasia and High-Risk Human Papillomavirus Infections in a Hispanic Population/Experiment 4
• The microbiota of the gut in preschool children with normal and excessive body weight/Experiment 1
• The microbiota of the gut in preschool children with normal and excessive body weight/Experiment 1/Signature 1
• The microbiota of the gut in preschool children with normal and excessive body weight/Experiment 1/Signature 2
• Sex-specific effects of PM2.5 maternal exposure on offspring's serum lipoproteins and gut microbiota/Experiment 6/Signature 1
• High-Level PM2.5/PM10 Exposure Is Associated With Alterations in the Human Pharyngeal Microbiota Composition/Experiment 1
• Taxonomic and Functional Differences in Cervical Microbiome Associated with Cervical Cancer Development/Experiment 1
• Taxonomic and Functional Differences in Cervical Microbiome Associated with Cervical Cancer Development/Experiment 1/Signature 1
• Taxonomic and Functional Differences in Cervical Microbiome Associated with Cervical Cancer Development/Experiment 1/Signature 2
• Cigarette smoking and the oral microbiome in a large study of American adults/Experiment 1
• Effects of sex and chronic cigarette smoke exposure on the mouse cecal microbiome/Experiment 1
• Effects of sex and chronic cigarette smoke exposure on the mouse cecal microbiome/Experiment 1/Signature 1
• Effects of sex and chronic cigarette smoke exposure on the mouse cecal microbiome/Experiment 2
• Effects of sex and chronic cigarette smoke exposure on the mouse cecal microbiome/Experiment 2/Signature 1
• Effects of sex and chronic cigarette smoke exposure on the mouse cecal microbiome/Experiment 3
• Effects of sex and chronic cigarette smoke exposure on the mouse cecal microbiome/Experiment 3/Signature 1
• Effects of sex and chronic cigarette smoke exposure on the mouse cecal microbiome/Experiment 4
• Effects of sex and chronic cigarette smoke exposure on the mouse cecal microbiome/Experiment 4/Signature 1
• Effects of sex and chronic cigarette smoke exposure on the mouse cecal microbiome/Experiment 4/Signature 2
• A Metabologenomic Approach Reveals Changes in the Intestinal Environment of Mice Fed on American Diet/Experiment 1
• A Metabologenomic Approach Reveals Changes in the Intestinal Environment of Mice Fed on American Diet/Experiment 1/Signature 1
• Correlation between body mass index and gut concentrations of Lactobacillus reuteri, Bifidobacterium animalis, Methanobrevibacter smithii and Escherichia coli/Experiment 1
• Correlation between body mass index and gut concentrations of Lactobacillus reuteri, Bifidobacterium animalis, Methanobrevibacter smithii and Escherichia coli/Experiment 2
• Correlation between body mass index and gut concentrations of Lactobacillus reuteri, Bifidobacterium animalis, Methanobrevibacter smithii and Escherichia coli/Experiment 3
• Correlation between body mass index and gut concentrations of Lactobacillus reuteri, Bifidobacterium animalis, Methanobrevibacter smithii and Escherichia coli/Experiment 3/Signature 2
• Correlation between body mass index and gut concentrations of Lactobacillus reuteri, Bifidobacterium animalis, Methanobrevibacter smithii and Escherichia coli/Experiment 4/Signature 1
• Correlation between body mass index and gut concentrations of Lactobacillus reuteri, Bifidobacterium animalis, Methanobrevibacter smithii and Escherichia coli/Experiment 5
• Correlation between body mass index and gut concentrations of Lactobacillus reuteri, Bifidobacterium animalis, Methanobrevibacter smithii and Escherichia coli/Experiment 5/Signature 1
• Correlation between body mass index and gut concentrations of Lactobacillus reuteri, Bifidobacterium animalis, Methanobrevibacter smithii and Escherichia coli/Experiment 6
• Correlation between body mass index and gut concentrations of Lactobacillus reuteri, Bifidobacterium animalis, Methanobrevibacter smithii and Escherichia coli/Experiment 6/Signature 1
• Composition and metabolism of fecal microbiota from normal and overweight children are differentially affected by melibiose, raffinose and raffinose-derived fructans/Experiment 1/Signature 1
• Composition and metabolism of fecal microbiota from normal and overweight children are differentially affected by melibiose, raffinose and raffinose-derived fructans/Experiment 1/Signature 2
• Composition and metabolism of fecal microbiota from normal and overweight children are differentially affected by melibiose, raffinose and raffinose-derived fructans/Experiment 2/Signature 1
• Composition and metabolism of fecal microbiota from normal and overweight children are differentially affected by melibiose, raffinose and raffinose-derived fructans/Experiment 2/Signature 2
• Composition and metabolism of fecal microbiota from normal and overweight children are differentially affected by melibiose, raffinose and raffinose-derived fructans/Experiment 3/Signature 1
• Composition and metabolism of fecal microbiota from normal and overweight children are differentially affected by melibiose, raffinose and raffinose-derived fructans/Experiment 3/Signature 2
• Compositional and Functional Differences between Microbiota and Cervical Carcinogenesis as Identified by Shotgun Metagenomic Sequencing/Experiment 1
• Compositional and Functional Differences between Microbiota and Cervical Carcinogenesis as Identified by Shotgun Metagenomic Sequencing/Experiment 2
• Short-term effect of antibiotics on human gut microbiota
• Short-term effect of antibiotics on human gut microbiota/Experiment 1
• Short-term effect of antibiotics on human gut microbiota/Experiment 1/Signature 1
• Short-term effect of antibiotics on human gut microbiota/Experiment 1/Signature 2
• Short-term effect of antibiotics on human gut microbiota/Experiment 2
• Short-term effect of antibiotics on human gut microbiota/Experiment 2/Signature 2
• Electronic Cigarette Aerosol Modulates the Oral Microbiome and Increases Risk of Infection
• Electronic Cigarette Aerosol Modulates the Oral Microbiome and Increases Risk of Infection/Experiment 1
• Electronic Cigarette Aerosol Modulates the Oral Microbiome and Increases Risk of Infection/Experiment 2
• Electronic Cigarette Aerosol Modulates the Oral Microbiome and Increases Risk of Infection/Experiment 3
• Functional and phylogenetic alterations in gut microbiome are linked to graft-versus-host disease severity/Experiment 1
• Functional and phylogenetic alterations in gut microbiome are linked to graft-versus-host disease severity/Experiment 1/Signature 2
• Functional and phylogenetic alterations in gut microbiome are linked to graft-versus-host disease severity/Experiment 2
• Third-party fecal microbiota transplantation following allo-HCT reconstitutes microbiome diversity
• Third-party fecal microbiota transplantation following allo-HCT reconstitutes microbiome diversity/Experiment 1
• Third-party fecal microbiota transplantation following allo-HCT reconstitutes microbiome diversity/Experiment 2
• Third-party fecal microbiota transplantation following allo-HCT reconstitutes microbiome diversity/Experiment 3
• Third-party fecal microbiota transplantation following allo-HCT reconstitutes microbiome diversity/Experiment 4
• Fecal Microbiome, Metabolites, and Stem Cell Transplant Outcomes: A Single-Center Pilot Study
• Fecal Microbiome, Metabolites, and Stem Cell Transplant Outcomes: A Single-Center Pilot Study/Experiment 1
• Fecal Microbiome, Metabolites, and Stem Cell Transplant Outcomes: A Single-Center Pilot Study/Experiment 2
• HPV/Chlamydia trachomatis co-infection: metagenomic analysis of cervical microbiota in asymptomatic women
• HPV/Chlamydia trachomatis co-infection: metagenomic analysis of cervical microbiota in asymptomatic women/Experiment 1
• HPV/Chlamydia trachomatis co-infection: metagenomic analysis of cervical microbiota in asymptomatic women/Experiment 2
• The Gastric Microbiome Is Perturbed in Advanced Gastric Adenocarcinoma Identified Through Shotgun Metagenomics/Experiment 1/Signature 1
• The Gastric Microbiome Is Perturbed in Advanced Gastric Adenocarcinoma Identified Through Shotgun Metagenomics/Experiment 1/Signature 2
• The Gut Microbiome Signatures Discriminate Healthy From Pulmonary Tuberculosis Patients/Experiment 1/Signature 1
• The Gut Microbiome Signatures Discriminate Healthy From Pulmonary Tuberculosis Patients/Experiment 1/Signature 2
• Signatures of Mucosal Microbiome in Oral Squamous Cell Carcinoma Identified Using a Random Forest Model
• Signatures of Mucosal Microbiome in Oral Squamous Cell Carcinoma Identified Using a Random Forest Model/Experiment 1
• Signatures of Mucosal Microbiome in Oral Squamous Cell Carcinoma Identified Using a Random Forest Model/Experiment 1/Signature 1
• Signatures of Mucosal Microbiome in Oral Squamous Cell Carcinoma Identified Using a Random Forest Model/Experiment 1/Signature 2
• Analysis of the diversity of intestinal microbiome and its potential value as a biomarker in patients with schizophrenia: A cohort study/Experiment 1/Signature 1
• Analysis of the diversity of intestinal microbiome and its potential value as a biomarker in patients with schizophrenia: A cohort study/Experiment 1/Signature 2
• Analysis of the diversity of intestinal microbiome and its potential value as a biomarker in patients with schizophrenia: A cohort study/Experiment 2/Signature 1
• Analysis of the diversity of intestinal microbiome and its potential value as a biomarker in patients with schizophrenia: A cohort study/Experiment 2/Signature 2
• Analysis of the diversity of intestinal microbiome and its potential value as a biomarker in patients with schizophrenia: A cohort study/Experiment 3/Signature 1
• Infant airway microbiota and topical immune perturbations in the origins of childhood asthma/Experiment 1
• Intestinal microbiota in pediatric patients with end stage renal disease: a Midwest Pediatric Nephrology Consortium study/Experiment 1
• Cutaneous microbiome effects of fluticasone propionate cream and adjunctive bleach baths in childhood atopic dermatitis/Experiment 1
• Cutaneous microbiome effects of fluticasone propionate cream and adjunctive bleach baths in childhood atopic dermatitis/Experiment 2
• Cutaneous microbiome effects of fluticasone propionate cream and adjunctive bleach baths in childhood atopic dermatitis/Experiment 3
• Alterations in the skin microbiome are associated with disease severity and treatment in the perioral zone of the skin of infants with atopic dermatitis/Experiment 1/Signature 1
• Alterations in the skin microbiome are associated with disease severity and treatment in the perioral zone of the skin of infants with atopic dermatitis/Experiment 1/Signature 2
• Gastro-intestinal and oral microbiome signatures associated with healthy aging/Experiment 1/Signature 1
• Gut microbial-derived butyrate is inversely associated with IgE responses to allergens in childhood asthma/Experiment 1
• Gut microbial-derived butyrate is inversely associated with IgE responses to allergens in childhood asthma/Experiment 1/Signature 1
• Gut microbial-derived butyrate is inversely associated with IgE responses to allergens in childhood asthma/Experiment 1/Signature 2
• Gut microbial-derived butyrate is inversely associated with IgE responses to allergens in childhood asthma/Experiment 2
• Gut microbial-derived butyrate is inversely associated with IgE responses to allergens in childhood asthma/Experiment 2/Signature 1
• Gut microbial-derived butyrate is inversely associated with IgE responses to allergens in childhood asthma/Experiment 2/Signature 2
• Airway Microbial Diversity is Inversely Associated with Mite-Sensitized Rhinitis and Asthma in Early Childhood/Experiment 1
• Airway Microbial Diversity is Inversely Associated with Mite-Sensitized Rhinitis and Asthma in Early Childhood/Experiment 2
• Gut microbiome and innate immune response patterns in IgE-associated eczema/Experiment 1
• Gut microbiome and innate immune response patterns in IgE-associated eczema/Experiment 1/Signature 1
• Gut microbiome and innate immune response patterns in IgE-associated eczema/Experiment 2/Signature 1
• Gut microbiome and innate immune response patterns in IgE-associated eczema/Experiment 3
• Gut microbiome and innate immune response patterns in IgE-associated eczema/Experiment 3/Signature 1
• Gut microbiome and innate immune response patterns in IgE-associated eczema/Experiment 3/Signature 2
• Variations in early gut microbiome are associated with childhood eczema
• Variations in early gut microbiome are associated with childhood eczema/Experiment 1
• Variations in early gut microbiome are associated with childhood eczema/Experiment 2
• Variations in early gut microbiome are associated with childhood eczema/Experiment 3
• Variations in early gut microbiome are associated with childhood eczema/Experiment 4
• Variations in early gut microbiome are associated with childhood eczema/Experiment 5
• Variations in early gut microbiome are associated with childhood eczema/Experiment 6
• Variations in early gut microbiome are associated with childhood eczema/Experiment 7
• Variations in early gut microbiome are associated with childhood eczema/Experiment 7/Signature 1
• Variations in early gut microbiome are associated with childhood eczema/Experiment 8
• Variations in early gut microbiome are associated with childhood eczema/Experiment 9
• Variations in early gut microbiome are associated with childhood eczema/Experiment 10
• Faecalibacterium prausnitzii subspecies-level dysbiosis in the human gut microbiome underlying atopic dermatitis/Experiment 1
• Dysbiosis of the Salivary Microbiome Is Associated With Non-smoking Female Lung Cancer and Correlated With Immunocytochemistry Markers/Experiment 1/Signature 2
• Shifts in Lachnospira and Clostridium sp. in the 3-month stool microbiome are associated with preschool age asthma/Experiment 1/Signature 1
• Shifts in Lachnospira and Clostridium sp. in the 3-month stool microbiome are associated with preschool age asthma/Experiment 1/Signature 2
• Shifts in Lachnospira and Clostridium sp. in the 3-month stool microbiome are associated with preschool age asthma/Experiment 2/Signature 1
• Shifts in Lachnospira and Clostridium sp. in the 3-month stool microbiome are associated with preschool age asthma/Experiment 2/Signature 2
• Lactobacillus rhamnosus GG-supplemented formula expands butyrate-producing bacterial strains in food allergic infants/Experiment 1/Signature 1
• Lactobacillus rhamnosus GG-supplemented formula expands butyrate-producing bacterial strains in food allergic infants/Experiment 1/Signature 2
• Lactobacillus rhamnosus GG-supplemented formula expands butyrate-producing bacterial strains in food allergic infants/Experiment 2/Signature 1
• Lactobacillus rhamnosus GG-supplemented formula expands butyrate-producing bacterial strains in food allergic infants/Experiment 3/Signature 1
• Rectal microbiota among HIV-uninfected, untreated HIV, and treated HIV-infected in Nigeria
• Rectal microbiota among HIV-uninfected, untreated HIV, and treated HIV-infected in Nigeria/Experiment 1/Signature 1
• Rectal microbiota among HIV-uninfected, untreated HIV, and treated HIV-infected in Nigeria/Experiment 1/Signature 2
• Alterations to the Gastrointestinal Microbiome Associated with Methamphetamine Use among Young Men who have Sex with Men/Experiment 1
• Alterations to the Gastrointestinal Microbiome Associated with Methamphetamine Use among Young Men who have Sex with Men/Experiment 2
• Alterations to the Gastrointestinal Microbiome Associated with Methamphetamine Use among Young Men who have Sex with Men/Experiment 3
• Alterations to the Gastrointestinal Microbiome Associated with Methamphetamine Use among Young Men who have Sex with Men/Experiment 4
• Alterations to the Gastrointestinal Microbiome Associated with Methamphetamine Use among Young Men who have Sex with Men/Experiment 4/Signature 2
• Alterations to the Gastrointestinal Microbiome Associated with Methamphetamine Use among Young Men who have Sex with Men/Experiment 5
• The gut microbiome and inflammation in obsessive-compulsive disorder patients compared to age- and sex-matched controls: a pilot study/Experiment 1
• The ketogenic diet influences taxonomic and functional composition of the gut microbiota in children with severe epilepsy/Experiment 1/Signature 1
• The ketogenic diet influences taxonomic and functional composition of the gut microbiota in children with severe epilepsy/Experiment 1/Signature 2
• Oral Microbiome in HIV-Infected Women: Shifts in the Abundance of Pathogenic and Beneficial Bacteria Are Associated with Aging, HIV Load, CD4 Count, and Antiretroviral Therapy
• Oral Microbiome in HIV-Infected Women: Shifts in the Abundance of Pathogenic and Beneficial Bacteria Are Associated with Aging, HIV Load, CD4 Count, and Antiretroviral Therapy/Experiment 1/Signature 1
• Oral Microbiome in HIV-Infected Women: Shifts in the Abundance of Pathogenic and Beneficial Bacteria Are Associated with Aging, HIV Load, CD4 Count, and Antiretroviral Therapy/Experiment 2/Signature 1
• Oral Microbiome in HIV-Infected Women: Shifts in the Abundance of Pathogenic and Beneficial Bacteria Are Associated with Aging, HIV Load, CD4 Count, and Antiretroviral Therapy/Experiment 3/Signature 1
• Oral Microbiome in HIV-Infected Women: Shifts in the Abundance of Pathogenic and Beneficial Bacteria Are Associated with Aging, HIV Load, CD4 Count, and Antiretroviral Therapy/Experiment 4
• Oral Microbiome in HIV-Infected Women: Shifts in the Abundance of Pathogenic and Beneficial Bacteria Are Associated with Aging, HIV Load, CD4 Count, and Antiretroviral Therapy/Experiment 4/Signature 1
• Oral Microbiome in HIV-Infected Women: Shifts in the Abundance of Pathogenic and Beneficial Bacteria Are Associated with Aging, HIV Load, CD4 Count, and Antiretroviral Therapy/Experiment 4/Signature 2
• Cotrimoxazole reduces systemic inflammation in HIV infection by altering the gut microbiome and immune activation/Experiment 1
• Gut microbiota and plasma metabolites associated with diabetes in women with, or at high risk for, HIV infection/Experiment 1
• Impact of probiotic Saccharomyces boulardii on the gut microbiome composition in HIV-treated patients: A double-blind, randomised, placebo-controlled trial/Experiment 1
• Impact of probiotic Saccharomyces boulardii on the gut microbiome composition in HIV-treated patients: A double-blind, randomised, placebo-controlled trial/Experiment 1/Signature 1
• Impact of probiotic Saccharomyces boulardii on the gut microbiome composition in HIV-treated patients: A double-blind, randomised, placebo-controlled trial/Experiment 1/Signature 2
• Impact of probiotic Saccharomyces boulardii on the gut microbiome composition in HIV-treated patients: A double-blind, randomised, placebo-controlled trial/Experiment 2
• Impact of probiotic Saccharomyces boulardii on the gut microbiome composition in HIV-treated patients: A double-blind, randomised, placebo-controlled trial/Experiment 2/Signature 1
• Impact of probiotic Saccharomyces boulardii on the gut microbiome composition in HIV-treated patients: A double-blind, randomised, placebo-controlled trial/Experiment 2/Signature 2
• Reduced Levels of D-dimer and Changes in Gut Microbiota Composition After Probiotic Intervention in HIV-Infected Individuals on Stable ART
• Reduced Levels of D-dimer and Changes in Gut Microbiota Composition After Probiotic Intervention in HIV-Infected Individuals on Stable ART/Experiment 1
• Reduced Levels of D-dimer and Changes in Gut Microbiota Composition After Probiotic Intervention in HIV-Infected Individuals on Stable ART/Experiment 1/Signature 1
• Reduced Levels of D-dimer and Changes in Gut Microbiota Composition After Probiotic Intervention in HIV-Infected Individuals on Stable ART/Experiment 2
• Reduced Levels of D-dimer and Changes in Gut Microbiota Composition After Probiotic Intervention in HIV-Infected Individuals on Stable ART/Experiment 2/Signature 1
• Fecal microbiome signatures of pancreatic cancer patients/Experiment 1
• Fecal microbiome signatures of pancreatic cancer patients/Experiment 4
• Fecal microbiome signatures of pancreatic cancer patients/Experiment 4/Signature 2
• Distinct Features of Gut Microbiota in High-Altitude Tibetan and Middle-Altitude Han Hypertensive Patients
• Distinct Features of Gut Microbiota in High-Altitude Tibetan and Middle-Altitude Han Hypertensive Patients/Experiment 1
• Distinct Features of Gut Microbiota in High-Altitude Tibetan and Middle-Altitude Han Hypertensive Patients/Experiment 2
• Distinct Features of Gut Microbiota in High-Altitude Tibetan and Middle-Altitude Han Hypertensive Patients/Experiment 3
• Distinct Features of Gut Microbiota in High-Altitude Tibetan and Middle-Altitude Han Hypertensive Patients/Experiment 4
• Distinct Features of Gut Microbiota in High-Altitude Tibetan and Middle-Altitude Han Hypertensive Patients/Experiment 5
• Distinct Features of Gut Microbiota in High-Altitude Tibetan and Middle-Altitude Han Hypertensive Patients/Experiment 6
• Alterations of gut microbiome in autoimmune hepatitis/Experiment 1
• Gut microbiota composition reflects disease severity and dysfunctional immune responses in patients with COVID-19
• Gut microbiota composition reflects disease severity and dysfunctional immune responses in patients with COVID-19/Experiment 1
• Gut microbiota composition reflects disease severity and dysfunctional immune responses in patients with COVID-19/Experiment 2
• Gut microbiota composition reflects disease severity and dysfunctional immune responses in patients with COVID-19/Experiment 3
• Gut microbiota composition reflects disease severity and dysfunctional immune responses in patients with COVID-19/Experiment 4
• Alterations in Gastric Microbial Communities Are Associated with Risk of Gastric Cancer in a Korean Population: A Case-Control Study/Experiment 1
• Alterations in Gastric Microbial Communities Are Associated with Risk of Gastric Cancer in a Korean Population: A Case-Control Study/Experiment 1/Signature 2
• Depicting SARS-CoV-2 faecal viral activity in association with gut microbiota composition in patients with COVID-19
• Depicting SARS-CoV-2 faecal viral activity in association with gut microbiota composition in patients with COVID-19/Experiment 1
• Association of high-risk human papillomavirus infection duration and cervical lesions with vaginal microbiota composition/Experiment 1
• Association of high-risk human papillomavirus infection duration and cervical lesions with vaginal microbiota composition/Experiment 1/Signature 1
• Association of high-risk human papillomavirus infection duration and cervical lesions with vaginal microbiota composition/Experiment 2
• Association of high-risk human papillomavirus infection duration and cervical lesions with vaginal microbiota composition/Experiment 3
• Association of high-risk human papillomavirus infection duration and cervical lesions with vaginal microbiota composition/Experiment 4
• Association of high-risk human papillomavirus infection duration and cervical lesions with vaginal microbiota composition/Experiment 5
• Association of high-risk human papillomavirus infection duration and cervical lesions with vaginal microbiota composition/Experiment 6
• Association of high-risk human papillomavirus infection duration and cervical lesions with vaginal microbiota composition/Experiment 7
• Association of high-risk human papillomavirus infection duration and cervical lesions with vaginal microbiota composition/Experiment 8
• Association of high-risk human papillomavirus infection duration and cervical lesions with vaginal microbiota composition/Experiment 9
• Depiction of Vaginal Microbiota in Women With High-Risk Human Papillomavirus Infection
• Depiction of Vaginal Microbiota in Women With High-Risk Human Papillomavirus Infection/Experiment 1
• Human papillomavirus infection and cervical intraepithelial neoplasia progression are associated with increased vaginal microbiome diversity in a Chinese cohort/Experiment 1
• Cervicovaginal microbiota dysbiosis correlates with HPV persistent infection/Experiment 1
• Cervicovaginal microbiota dysbiosis correlates with HPV persistent infection/Experiment 1/Signature 1
• Cervicovaginal microbiota dysbiosis correlates with HPV persistent infection/Experiment 1/Signature 2
• Cervicovaginal microbiota dysbiosis correlates with HPV persistent infection/Experiment 2
• Cervicovaginal microbiota dysbiosis correlates with HPV persistent infection/Experiment 2/Signature 1
• Cervicovaginal microbiota dysbiosis correlates with HPV persistent infection/Experiment 3
• Cervicovaginal microbiota dysbiosis correlates with HPV persistent infection/Experiment 3/Signature 1
• Cervicovaginal microbiota dysbiosis correlates with HPV persistent infection/Experiment 3/Signature 2
• Cervicovaginal microbiota dysbiosis correlates with HPV persistent infection/Experiment 4
• Cervicovaginal microbiota dysbiosis correlates with HPV persistent infection/Experiment 4/Signature 1
• Cervicovaginal microbiota dysbiosis correlates with HPV persistent infection/Experiment 4/Signature 2
• Changes of vaginal microbiota during cervical carcinogenesis in women with human papillomavirus infection/Experiment 1
• The Alterations of Vaginal Microbiome in HPV16 Infection as Identified by Shotgun Metagenomic Sequencing/Experiment 1/Signature 1
• The Alterations of Vaginal Microbiome in HPV16 Infection as Identified by Shotgun Metagenomic Sequencing/Experiment 1/Signature 2
• High-throughput sequencing reveals the incomplete, short-term recovery of infant gut microbiota following parenteral antibiotic treatment with ampicillin and gentamicin
• High-throughput sequencing reveals the incomplete, short-term recovery of infant gut microbiota following parenteral antibiotic treatment with ampicillin and gentamicin/Experiment 1
• High-throughput sequencing reveals the incomplete, short-term recovery of infant gut microbiota following parenteral antibiotic treatment with ampicillin and gentamicin/Experiment 2
• High-throughput sequencing reveals the incomplete, short-term recovery of infant gut microbiota following parenteral antibiotic treatment with ampicillin and gentamicin/Experiment 3
• Characterization and Analysis of the Skin Microbiota in Rosacea: A Case-Control Study/Experiment 1
• Characterization and Analysis of the Skin Microbiota in Rosacea: A Case-Control Study/Experiment 2
• Alterations of the Gut Microbiota in Patients With Coronavirus Disease 2019 or H1N1 Influenza
• Alterations of the Gut Microbiota in Patients With Coronavirus Disease 2019 or H1N1 Influenza/Experiment 1
• Alterations of the Gut Microbiota in Patients With Coronavirus Disease 2019 or H1N1 Influenza/Experiment 2
• Alterations of the Gut Microbiota in Patients With Coronavirus Disease 2019 or H1N1 Influenza/Experiment 3
• Differences in foot skin microbiomes between patients with type 2 diabetes and healthy individuals/Experiment 1
• Differences in foot skin microbiomes between patients with type 2 diabetes and healthy individuals/Experiment 2
• Fecal Microbiota in Patients with Irritable Bowel Syndrome Compared with Healthy Controls Using Real-Time Polymerase Chain Reaction: An Evidence of Dysbiosis/Experiment 1/Signature 1
• Fecal Microbiota in Patients with Irritable Bowel Syndrome Compared with Healthy Controls Using Real-Time Polymerase Chain Reaction: An Evidence of Dysbiosis/Experiment 1/Signature 2
• Fecal Microbiota in Patients with Irritable Bowel Syndrome Compared with Healthy Controls Using Real-Time Polymerase Chain Reaction: An Evidence of Dysbiosis/Experiment 2
• Fecal Microbiota in Patients with Irritable Bowel Syndrome Compared with Healthy Controls Using Real-Time Polymerase Chain Reaction: An Evidence of Dysbiosis/Experiment 2/Signature 1
• Fecal Microbiota in Patients with Irritable Bowel Syndrome Compared with Healthy Controls Using Real-Time Polymerase Chain Reaction: An Evidence of Dysbiosis/Experiment 2/Signature 2
• Fecal Microbiota in Patients with Irritable Bowel Syndrome Compared with Healthy Controls Using Real-Time Polymerase Chain Reaction: An Evidence of Dysbiosis/Experiment 3
• Fecal Microbiota in Patients with Irritable Bowel Syndrome Compared with Healthy Controls Using Real-Time Polymerase Chain Reaction: An Evidence of Dysbiosis/Experiment 3/Signature 1
• Fecal Microbiota in Patients with Irritable Bowel Syndrome Compared with Healthy Controls Using Real-Time Polymerase Chain Reaction: An Evidence of Dysbiosis/Experiment 3/Signature 2
• Fecal Microbiota in Patients with Irritable Bowel Syndrome Compared with Healthy Controls Using Real-Time Polymerase Chain Reaction: An Evidence of Dysbiosis/Experiment 4
• Fecal Microbiota in Patients with Irritable Bowel Syndrome Compared with Healthy Controls Using Real-Time Polymerase Chain Reaction: An Evidence of Dysbiosis/Experiment 5
• Fecal Microbiota in Patients with Irritable Bowel Syndrome Compared with Healthy Controls Using Real-Time Polymerase Chain Reaction: An Evidence of Dysbiosis/Experiment 5/Signature 1
• Fecal Microbiota in Patients with Irritable Bowel Syndrome Compared with Healthy Controls Using Real-Time Polymerase Chain Reaction: An Evidence of Dysbiosis/Experiment 5/Signature 2
• Fecal Microbiota in Patients with Irritable Bowel Syndrome Compared with Healthy Controls Using Real-Time Polymerase Chain Reaction: An Evidence of Dysbiosis/Experiment 6/Signature 1
• Fecal Microbiota in Patients with Irritable Bowel Syndrome Compared with Healthy Controls Using Real-Time Polymerase Chain Reaction: An Evidence of Dysbiosis/Experiment 7/Signature 1
• Differences in the gut microbiome by physical activity and BMI among colorectal cancer patients/Experiment 1
• Differences in the gut microbiome by physical activity and BMI among colorectal cancer patients/Experiment 2
• Differences in the gut microbiome by physical activity and BMI among colorectal cancer patients/Experiment 3
• Differences in the gut microbiome by physical activity and BMI among colorectal cancer patients/Experiment 4
• Differences in the gut microbiome by physical activity and BMI among colorectal cancer patients/Experiment 4/Signature 1
• Differences in the gut microbiome by physical activity and BMI among colorectal cancer patients/Experiment 5
• Differences in the gut microbiome by physical activity and BMI among colorectal cancer patients/Experiment 5/Signature 1
• Differences in the gut microbiome by physical activity and BMI among colorectal cancer patients/Experiment 5/Signature 2
• Differences in the gut microbiome by physical activity and BMI among colorectal cancer patients/Experiment 6
• Differences in the gut microbiome by physical activity and BMI among colorectal cancer patients/Experiment 6/Signature 1
• Differences in the gut microbiome by physical activity and BMI among colorectal cancer patients/Experiment 6/Signature 2
• Differences in the gut microbiome by physical activity and BMI among colorectal cancer patients/Experiment 7
• Differences in the gut microbiome by physical activity and BMI among colorectal cancer patients/Experiment 7/Signature 1
• Differential intestinal and oral microbiota features associated with gestational diabetes and maternal inflammation/Experiment 1
• Differential intestinal and oral microbiota features associated with gestational diabetes and maternal inflammation/Experiment 1/Signature 1
• Differential intestinal and oral microbiota features associated with gestational diabetes and maternal inflammation/Experiment 1/Signature 2
• Modulation of potential respiratory pathogens by pH1N1 viral infection
• Modulation of potential respiratory pathogens by pH1N1 viral infection/Experiment 1
• The active lung microbiota landscape of COVID-19 patients through the metatranscriptome data analysis/Experiment 1
• Respiratory Disease following Viral Lung Infection Alters the Murine Gut Microbiota/Experiment 1
• Respiratory Disease following Viral Lung Infection Alters the Murine Gut Microbiota/Experiment 1/Signature 1
• Respiratory Disease following Viral Lung Infection Alters the Murine Gut Microbiota/Experiment 1/Signature 2
• Respiratory Disease following Viral Lung Infection Alters the Murine Gut Microbiota/Experiment 2
• Respiratory Disease following Viral Lung Infection Alters the Murine Gut Microbiota/Experiment 2/Signature 1
• Respiratory Disease following Viral Lung Infection Alters the Murine Gut Microbiota/Experiment 2/Signature 2
• Respiratory Disease following Viral Lung Infection Alters the Murine Gut Microbiota/Experiment 3
• Respiratory Disease following Viral Lung Infection Alters the Murine Gut Microbiota/Experiment 3/Signature 1
• Respiratory Disease following Viral Lung Infection Alters the Murine Gut Microbiota/Experiment 3/Signature 2
• Characterization of the Oral Microbiome of Medicated Type-2 Diabetes Patients
• Characterization of the Oral Microbiome of Medicated Type-2 Diabetes Patients/Experiment 1
• Characterization of the Oral Microbiome of Medicated Type-2 Diabetes Patients/Experiment 1/Signature 1
• Characterization of the Oral Microbiome of Medicated Type-2 Diabetes Patients/Experiment 1/Signature 2
• The Association Between Gestational Diabetes and Microbiota in Placenta and Cord Blood/Experiment 1/Signature 1
• The Association Between Gestational Diabetes and Microbiota in Placenta and Cord Blood/Experiment 1/Signature 2
• The gut microbiome of COVID-19 recovered patients returns to uninfected status in a minority-dominated United States cohort
• The gut microbiome of COVID-19 recovered patients returns to uninfected status in a minority-dominated United States cohort/Experiment 1
• The gut microbiome of COVID-19 recovered patients returns to uninfected status in a minority-dominated United States cohort/Experiment 2
• The gut microbiome of COVID-19 recovered patients returns to uninfected status in a minority-dominated United States cohort/Experiment 3
• The gut microbiome of COVID-19 recovered patients returns to uninfected status in a minority-dominated United States cohort/Experiment 4
• Tumour-associated and non-tumour-associated microbiota in colorectal cancer/Experiment 1
• Tumour-associated and non-tumour-associated microbiota in colorectal cancer/Experiment 1/Signature 2
• Tumour-associated and non-tumour-associated microbiota in colorectal cancer/Experiment 3/Signature 1
• Tumour-associated and non-tumour-associated microbiota in colorectal cancer/Experiment 3/Signature 2
• Subgingival Microbiota during Healthy Pregnancy and Pregnancy Gingivitis
• Subgingival Microbiota during Healthy Pregnancy and Pregnancy Gingivitis/Experiment 1
• Subgingival Microbiota during Healthy Pregnancy and Pregnancy Gingivitis/Experiment 2
• The Alteration in Composition and Function of Gut Microbiome in Patients with Type 2 Diabetes
• The Alteration in Composition and Function of Gut Microbiome in Patients with Type 2 Diabetes/Experiment 1
• The Alteration in Composition and Function of Gut Microbiome in Patients with Type 2 Diabetes/Experiment 1/Signature 1
• The Alteration in Composition and Function of Gut Microbiome in Patients with Type 2 Diabetes/Experiment 1/Signature 2
• Alteration of salivary microbiome in periodontitis with or without type-2 diabetes mellitus and metformin treatment/Experiment 1
• Alteration of salivary microbiome in periodontitis with or without type-2 diabetes mellitus and metformin treatment/Experiment 2
• Alteration of salivary microbiome in periodontitis with or without type-2 diabetes mellitus and metformin treatment/Experiment 3
• Alteration of salivary microbiome in periodontitis with or without type-2 diabetes mellitus and metformin treatment/Experiment 4
• Alteration of salivary microbiome in periodontitis with or without type-2 diabetes mellitus and metformin treatment/Experiment 5
• Evaluation of superinfection, antimicrobial usage, and airway microbiome with metagenomic sequencing in COVID-19 patients: A cohort study in Shanghai
• Evaluation of superinfection, antimicrobial usage, and airway microbiome with metagenomic sequencing in COVID-19 patients: A cohort study in Shanghai/Experiment 1
• Evaluation of superinfection, antimicrobial usage, and airway microbiome with metagenomic sequencing in COVID-19 patients: A cohort study in Shanghai/Experiment 2
• Nasopharyngeal Microbiota in SARS-CoV-2 Positive and Negative Patients
• Nasopharyngeal Microbiota in SARS-CoV-2 Positive and Negative Patients/Experiment 1
• Nasopharyngeal Microbiota in SARS-CoV-2 Positive and Negative Patients/Experiment 1/Signature 1
• Six-month follow-up of gut microbiota richness in patients with COVID-19/Experiment 1
• Alterations in the human oral and gut microbiomes and lipidomics in COVID-19
• Alterations in the human oral and gut microbiomes and lipidomics in COVID-19/Experiment 1
• Characteristics of the intestinal flora in patients with peripheral neuropathy associated with type 2 diabetes/Experiment 1
• Compositional profile of mucosal bacteriome of smokers and smokeless tobacco users/Experiment 1/Signature 1
• Compositional profile of mucosal bacteriome of smokers and smokeless tobacco users/Experiment 3
• Gut microbiome associations with breast cancer risk factors and tumor characteristics: a pilot study/Experiment 1
• Gut microbiome associations with breast cancer risk factors and tumor characteristics: a pilot study/Experiment 1/Signature 2
• Gut microbiome associations with breast cancer risk factors and tumor characteristics: a pilot study/Experiment 2
• Gut microbiome associations with breast cancer risk factors and tumor characteristics: a pilot study/Experiment 3
• Gut microbiome associations with breast cancer risk factors and tumor characteristics: a pilot study/Experiment 5
• Gut microbiome associations with breast cancer risk factors and tumor characteristics: a pilot study/Experiment 6
• Gut microbiome associations with breast cancer risk factors and tumor characteristics: a pilot study/Experiment 7
• Gut microbiome associations with breast cancer risk factors and tumor characteristics: a pilot study/Experiment 9
• Gut microbiome associations with breast cancer risk factors and tumor characteristics: a pilot study/Experiment 10
• The Endobiota Study: Comparison of Vaginal, Cervical and Gut Microbiota Between Women with Stage 3/4 Endometriosis and Healthy Controls/Experiment 1/Signature 1
• The Endobiota Study: Comparison of Vaginal, Cervical and Gut Microbiota Between Women with Stage 3/4 Endometriosis and Healthy Controls/Experiment 1/Signature 2
• Association between the nasopharyngeal microbiome and metabolome in patients with COVID-19
• Association between the nasopharyngeal microbiome and metabolome in patients with COVID-19/Experiment 1
• Meta-analysis of fecal metagenomes reveals global microbial signatures that are specific for colorectal cancer
• Meta-analysis of fecal metagenomes reveals global microbial signatures that are specific for colorectal cancer/Experiment 1
• Metagenomic analysis of colorectal cancer datasets identifies cross-cohort microbial diagnostic signatures and a link with choline degradation
• 16S rRNA gene amplicon sequencing of gut microbiota in gestational diabetes mellitus and their correlation with disease risk factors/Experiment 1
• Nasopharyngeal Microbiome Signature in COVID-19 Positive Patients: Can We Definitively Get a Role to Fusobacterium periodonticum?/Experiment 1/Signature 1
• Diversity and genomic determinants of the microbiomes associated with COVID-19 and non-COVID respiratory diseases
• Diversity and genomic determinants of the microbiomes associated with COVID-19 and non-COVID respiratory diseases/Experiment 1
• Diversity and genomic determinants of the microbiomes associated with COVID-19 and non-COVID respiratory diseases/Experiment 1/Signature 1
• Gut Microbiota May Not Be Fully Restored in Recovered COVID-19 Patients After 3-Month Recovery/Experiment 1
• Gut Microbiota May Not Be Fully Restored in Recovered COVID-19 Patients After 3-Month Recovery/Experiment 1/Signature 2
• Nasopharyngeal Microbial Communities of Patients Infected With SARS-CoV-2 That Developed COVID-19
• Nasopharyngeal Microbial Communities of Patients Infected With SARS-CoV-2 That Developed COVID-19/Experiment 1
• Nasopharyngeal Microbial Communities of Patients Infected With SARS-CoV-2 That Developed COVID-19/Experiment 2
• Nasopharyngeal Microbial Communities of Patients Infected With SARS-CoV-2 That Developed COVID-19/Experiment 3
• Microbiome Profile of Deep Endometriosis Patients: Comparison of Vaginal Fluid, Endometrium and Lesion/Experiment 3/Signature 2
• Integrated gut virome and bacteriome dynamics in COVID-19 patients/Experiment 1
• Characterization of respiratory microbial dysbiosis in hospitalized COVID-19 patients
• Characterization of respiratory microbial dysbiosis in hospitalized COVID-19 patients/Experiment 1
• Characterization of respiratory microbial dysbiosis in hospitalized COVID-19 patients/Experiment 2
• Alterations in Gut Microbiota of Patients With COVID-19 During Time of Hospitalization
• Alterations in Gut Microbiota of Patients With COVID-19 During Time of Hospitalization/Experiment 1
• Alterations in Gut Microbiota of Patients With COVID-19 During Time of Hospitalization/Experiment 2
• Alterations in Gut Microbiota of Patients With COVID-19 During Time of Hospitalization/Experiment 3
• Enriched Opportunistic Pathogens Revealed by Metagenomic Sequencing Hint Potential Linkages between Pharyngeal Microbiota and COVID-19
• Enriched Opportunistic Pathogens Revealed by Metagenomic Sequencing Hint Potential Linkages between Pharyngeal Microbiota and COVID-19/Experiment 1
• Enriched Opportunistic Pathogens Revealed by Metagenomic Sequencing Hint Potential Linkages between Pharyngeal Microbiota and COVID-19/Experiment 2
• Enriched Opportunistic Pathogens Revealed by Metagenomic Sequencing Hint Potential Linkages between Pharyngeal Microbiota and COVID-19/Experiment 3
• Gut Microbiota Dysbiosis Correlates with Abnormal Immune Response in Moderate COVID-19 Patients with Fever
• Gut Microbiota Dysbiosis Correlates with Abnormal Immune Response in Moderate COVID-19 Patients with Fever/Experiment 1
• Gut Microbiota Dysbiosis Correlates with Abnormal Immune Response in Moderate COVID-19 Patients with Fever/Experiment 2
• Gut Dysbiosis and IL-21 Response in Patients with Severe COVID-19
• Gut Dysbiosis and IL-21 Response in Patients with Severe COVID-19/Experiment 1
• Gut Dysbiosis and IL-21 Response in Patients with Severe COVID-19/Experiment 1/Signature 1
• Gut Dysbiosis and IL-21 Response in Patients with Severe COVID-19/Experiment 1/Signature 2
• Gut Dysbiosis and IL-21 Response in Patients with Severe COVID-19/Experiment 2
• Gut Dysbiosis and IL-21 Response in Patients with Severe COVID-19/Experiment 2/Signature 1
• Gut Dysbiosis and IL-21 Response in Patients with Severe COVID-19/Experiment 3
• 16S rRNA gene sequencing of rectal swab in patients affected by COVID-19
• 16S rRNA gene sequencing of rectal swab in patients affected by COVID-19/Experiment 1
• 16S rRNA gene sequencing of rectal swab in patients affected by COVID-19/Experiment 2
• 16S rRNA gene sequencing of rectal swab in patients affected by COVID-19/Experiment 3
• Gastrointestinal microbiome signatures of pediatric patients with irritable bowel syndrome/Experiment 1
• Alterations in the gut bacterial microbiome in people with type 2 diabetes mellitus and diabetic retinopathy/Experiment 1
• The impact of NBUVB on microbial community profiling in the lesional skin of vitiligo subjects/Experiment 1
• The impact of NBUVB on microbial community profiling in the lesional skin of vitiligo subjects/Experiment 1/Signature 1
• The impact of NBUVB on microbial community profiling in the lesional skin of vitiligo subjects/Experiment 1/Signature 2
• The impact of NBUVB on microbial community profiling in the lesional skin of vitiligo subjects/Experiment 2/Signature 1
• The impact of NBUVB on microbial community profiling in the lesional skin of vitiligo subjects/Experiment 2/Signature 2
• The impact of NBUVB on microbial community profiling in the lesional skin of vitiligo subjects/Experiment 3/Signature 1
• The impact of NBUVB on microbial community profiling in the lesional skin of vitiligo subjects/Experiment 3/Signature 2
• Characteristics of the gut microbiome in patients with prediabetes and type 2 diabetes/Experiment 1
• Analysis of the intestinal microbiota in COVID-19 patients and its correlation with the inflammatory factor IL-18
• Analysis of the intestinal microbiota in COVID-19 patients and its correlation with the inflammatory factor IL-18/Experiment 1
• Analysis of the intestinal microbiota in COVID-19 patients and its correlation with the inflammatory factor IL-18/Experiment 1/Signature 1
• Analysis of the intestinal microbiota in COVID-19 patients and its correlation with the inflammatory factor IL-18/Experiment 2
• Analysis of the intestinal microbiota in COVID-19 patients and its correlation with the inflammatory factor IL-18/Experiment 2/Signature 2
• Gut microbiota profiles of treatment-naïve adult acute myeloid leukemia patients with neutropenic fever during intensive chemotherapy/Experiment 1
• Gut microbiota profiles of treatment-naïve adult acute myeloid leukemia patients with neutropenic fever during intensive chemotherapy/Experiment 1/Signature 1
• Gut microbiota profiles of treatment-naïve adult acute myeloid leukemia patients with neutropenic fever during intensive chemotherapy/Experiment 1/Signature 2
• Gut microbiota profiles of treatment-naïve adult acute myeloid leukemia patients with neutropenic fever during intensive chemotherapy/Experiment 3
• Gut microbiota profiles of treatment-naïve adult acute myeloid leukemia patients with neutropenic fever during intensive chemotherapy/Experiment 3/Signature 1
• Gut microbiota profiles of treatment-naïve adult acute myeloid leukemia patients with neutropenic fever during intensive chemotherapy/Experiment 3/Signature 2
• SARS-CoV-2 infection and viral load are associated with the upper respiratory tract microbiome/Experiment 1/Signature 1
• SARS-CoV-2 infection and viral load are associated with the upper respiratory tract microbiome/Experiment 1/Signature 2
• SARS-CoV-2 infection and viral load are associated with the upper respiratory tract microbiome/Experiment 2/Signature 1
• Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome
• Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome/Experiment 1
• Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome/Experiment 2
• Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome/Experiment 3
• Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome/Experiment 4
• The lower respiratory tract microbiome of critically ill patients with COVID-19/Experiment 1/Signature 1
• The lower respiratory tract microbiome of critically ill patients with COVID-19/Experiment 1/Signature 2
• IBS-associated phylogenetic unbalances of the intestinal microbiota are not reverted by probiotic supplementation
• IBS-associated phylogenetic unbalances of the intestinal microbiota are not reverted by probiotic supplementation/Experiment 1/Signature 2
• Effects of amoxicillin treatment on the salivary microbiota in children with acute otitis media/Experiment 1
• Comparative analysis of racial differences in breast tumor microbiome
• Comparative analysis of racial differences in breast tumor microbiome/Experiment 1
• Comparative analysis of racial differences in breast tumor microbiome/Experiment 2
• Comparative analysis of racial differences in breast tumor microbiome/Experiment 3
• Comparative analysis of racial differences in breast tumor microbiome/Experiment 4
• Comparative analysis of racial differences in breast tumor microbiome/Experiment 5
• Comparative analysis of racial differences in breast tumor microbiome/Experiment 6
• Comparative analysis of racial differences in breast tumor microbiome/Experiment 6/Signature 2
• Lower Bifidobacteria counts in both duodenal mucosa-associated and fecal microbiota in irritable bowel syndrome patients
• Lower Bifidobacteria counts in both duodenal mucosa-associated and fecal microbiota in irritable bowel syndrome patients/Experiment 1
• Lower Bifidobacteria counts in both duodenal mucosa-associated and fecal microbiota in irritable bowel syndrome patients/Experiment 1/Signature 2
• Lower Bifidobacteria counts in both duodenal mucosa-associated and fecal microbiota in irritable bowel syndrome patients/Experiment 2
• Lower Bifidobacteria counts in both duodenal mucosa-associated and fecal microbiota in irritable bowel syndrome patients/Experiment 3
• Lower Bifidobacteria counts in both duodenal mucosa-associated and fecal microbiota in irritable bowel syndrome patients/Experiment 4
• The Role of Antibiotics in Gut Microbiota Modulation: The Eubiotic Effects of Rifaximin
• The Role of Antibiotics in Gut Microbiota Modulation: The Eubiotic Effects of Rifaximin/Experiment 1
• The Role of Antibiotics in Gut Microbiota Modulation: The Eubiotic Effects of Rifaximin/Experiment 2
• Effects of smoking on the lower respiratory tract microbiome in mice
• Effects of smoking on the lower respiratory tract microbiome in mice/Experiment 2/Signature 1
• Effects of smoking on the lower respiratory tract microbiome in mice/Experiment 2/Signature 2
• Oral microbial dysbiosis linked to worsened periodontal condition in rheumatoid arthritis patients
• Oral microbial dysbiosis linked to worsened periodontal condition in rheumatoid arthritis patients/Experiment 1
• Altered oral and gut microbiota and its association with SARS-CoV-2 viral load in COVID-19 patients during hospitalization
• Altered oral and gut microbiota and its association with SARS-CoV-2 viral load in COVID-19 patients during hospitalization/Experiment 1
• Altered oral and gut microbiota and its association with SARS-CoV-2 viral load in COVID-19 patients during hospitalization/Experiment 2
• Altered oral and gut microbiota and its association with SARS-CoV-2 viral load in COVID-19 patients during hospitalization/Experiment 3
• Altered oral and gut microbiota and its association with SARS-CoV-2 viral load in COVID-19 patients during hospitalization/Experiment 4
• Altered oral and gut microbiota and its association with SARS-CoV-2 viral load in COVID-19 patients during hospitalization/Experiment 5
• Acute SARS-CoV-2 infection is associated with an expansion of bacteria pathogens in the nose including Pseudomonas Aeruginosa/Experiment 5/Signature 2
• Acute SARS-CoV-2 infection is associated with an expansion of bacteria pathogens in the nose including Pseudomonas Aeruginosa/Experiment 6/Signature 1
• Acute SARS-CoV-2 infection is associated with an expansion of bacteria pathogens in the nose including Pseudomonas Aeruginosa/Experiment 7/Signature 2
• Nasopharyngeal Microbiome Community Composition and Structure Is Associated with Severity of COVID-19 Disease and Breathing Treatment/Experiment 2
• Molecular detection of microbial colonization in cervical mucus of women with and without endometriosis/Experiment 1
• Endometriosis induces gut microbiota alterations in mice
• Endometriosis induces gut microbiota alterations in mice/Experiment 1
• Endometriosis induces gut microbiota alterations in mice/Experiment 2
• Endometriosis induces gut microbiota alterations in mice/Experiment 2/Signature 1
• Endometriosis induces gut microbiota alterations in mice/Experiment 2/Signature 2
• Molecular detection of intrauterine microbial colonization in women with endometriosis/Experiment 1
• Gut microbiota imbalance and its correlations with hormone and inflammatory factors in patients with stage 3/4 endometriosis/Experiment 1
• Gut microbiota imbalance and its correlations with hormone and inflammatory factors in patients with stage 3/4 endometriosis/Experiment 1/Signature 1
• Gut microbiota imbalance and its correlations with hormone and inflammatory factors in patients with stage 3/4 endometriosis/Experiment 1/Signature 2
• Antibiotic therapy with metronidazole reduces endometriosis disease progression in mice: a potential role for gut microbiota/Experiment 1
• The Vaginal Microbiome as a Tool to Predict rASRM Stage of Disease in Endometriosis: a Pilot Study/Experiment 2/Signature 2
• Altered Composition of Microbiota in Women with Ovarian Endometrioma: Microbiome Analyses of Extracellular Vesicles in the Peritoneal Fluid/Experiment 1
• Microbiota composition and distribution along the female reproductive tract of women with endometriosis/Experiment 1
• Microbiota composition and distribution along the female reproductive tract of women with endometriosis/Experiment 1/Signature 1
• Microbiota composition and distribution along the female reproductive tract of women with endometriosis/Experiment 1/Signature 2
• Correlation of fecal metabolomics and gut microbiota in mice with endometriosis/Experiment 1
• Associations Between Endometriosis and Gut Microbiota/Experiment 1
• Associations Between Endometriosis and Gut Microbiota/Experiment 1/Signature 1
• Effect of endometriosis on the fecal bacteriota composition of mice during the acute phase of lesion formation/Experiment 1
• Variations in oral microbiome profiles in rheumatoid arthritis and osteoarthritis with potential biomarkers for arthritis screening
• Variations in oral microbiome profiles in rheumatoid arthritis and osteoarthritis with potential biomarkers for arthritis screening/Experiment 1
• Variations in oral microbiome profiles in rheumatoid arthritis and osteoarthritis with potential biomarkers for arthritis screening/Experiment 2
• Cigarette smoking and oral microbiota in low-income and African-American populations/Experiment 1
• Cigarette smoking and oral microbiota in low-income and African-American populations/Experiment 2
• Cigarette smoking and oral microbiota in low-income and African-American populations/Experiment 3
• Oral Microbiota Perturbations Are Linked to High Risk for Rheumatoid Arthritis/Experiment 1/Signature 1
• Oral Microbiota Perturbations Are Linked to High Risk for Rheumatoid Arthritis/Experiment 1/Signature 2
• Oral Microbiota Perturbations Are Linked to High Risk for Rheumatoid Arthritis/Experiment 2/Signature 1
• Oral Microbiota Perturbations Are Linked to High Risk for Rheumatoid Arthritis/Experiment 2/Signature 2
• Oral Microbiota Perturbations Are Linked to High Risk for Rheumatoid Arthritis/Experiment 3/Signature 1
• Oral Microbiota Perturbations Are Linked to High Risk for Rheumatoid Arthritis/Experiment 3/Signature 2
• An expansion of rare lineage intestinal microbes characterizes rheumatoid arthritis/Experiment 1/Signature 1
• An expansion of rare lineage intestinal microbes characterizes rheumatoid arthritis/Experiment 1/Signature 2
• Exercise Alters Gut Microbiota Composition and Function in Lean and Obese Humans/Experiment 1
• Exercise Alters Gut Microbiota Composition and Function in Lean and Obese Humans/Experiment 2
• Exercise Alters Gut Microbiota Composition and Function in Lean and Obese Humans/Experiment 2/Signature 1
• Unraveling gut microbiota in Parkinson's disease and atypical parkinsonism
• Unraveling gut microbiota in Parkinson's disease and atypical parkinsonism/Experiment 1
• Unraveling gut microbiota in Parkinson's disease and atypical parkinsonism/Experiment 2/Signature 2
• Collateral damage from oral ciprofloxacin versus nitrofurantoin in outpatients with urinary tract infections: a culture-free analysis of gut microbiota/Experiment 1
• Collateral damage from oral ciprofloxacin versus nitrofurantoin in outpatients with urinary tract infections: a culture-free analysis of gut microbiota/Experiment 2
• Collateral damage from oral ciprofloxacin versus nitrofurantoin in outpatients with urinary tract infections: a culture-free analysis of gut microbiota/Experiment 6
• Collateral damage from oral ciprofloxacin versus nitrofurantoin in outpatients with urinary tract infections: a culture-free analysis of gut microbiota/Experiment 7
• Salivary Microbiome and Cigarette Smoking: A First of Its Kind Investigation in Jordan/Experiment 1
• Metagenome-wide association of gut microbiome features for schizophrenia/Experiment 1
• Metagenome-wide association of gut microbiome features for schizophrenia/Experiment 2
• Metagenome-wide association of gut microbiome features for schizophrenia/Experiment 4
• Metagenome-wide association of gut microbiome features for schizophrenia/Experiment 4/Signature 1
• The Follicular Skin Microbiome in Patients With Hidradenitis Suppurativa and Healthy Controls/Experiment 1/Signature 1
• The Follicular Skin Microbiome in Patients With Hidradenitis Suppurativa and Healthy Controls/Experiment 2/Signature 2
• Changes in gut microbiota and plasma inflammatory factors across the stages of colorectal tumorigenesis: a case-control study/Experiment 1
• Changes in gut microbiota and plasma inflammatory factors across the stages of colorectal tumorigenesis: a case-control study/Experiment 1/Signature 1
• Changes in gut microbiota and plasma inflammatory factors across the stages of colorectal tumorigenesis: a case-control study/Experiment 1/Signature 2
• Dynamics of Gut Microbiota Recovery after Antibiotic Exposure in Young and Old Mice (A Pilot Study)/Experiment 1
• Dynamics of Gut Microbiota Recovery after Antibiotic Exposure in Young and Old Mice (A Pilot Study)/Experiment 2
• Dynamics of Gut Microbiota Recovery after Antibiotic Exposure in Young and Old Mice (A Pilot Study)/Experiment 3
• Dynamics of Gut Microbiota Recovery after Antibiotic Exposure in Young and Old Mice (A Pilot Study)/Experiment 4
• Nasopharyngeal microbiome reveals the prevalence of opportunistic pathogens in SARS-CoV-2 infected individuals and their association with host types/Experiment 1/Signature 1
• Nasopharyngeal microbiome reveals the prevalence of opportunistic pathogens in SARS-CoV-2 infected individuals and their association with host types/Experiment 1/Signature 2
• Linking the gut microbiota to persistent symptoms in survivors of COVID-19 after discharge
• Linking the gut microbiota to persistent symptoms in survivors of COVID-19 after discharge/Experiment 1
• Linking the gut microbiota to persistent symptoms in survivors of COVID-19 after discharge/Experiment 1/Signature 1
• Linking the gut microbiota to persistent symptoms in survivors of COVID-19 after discharge/Experiment 1/Signature 2
• Analysis of the Conjunctival Microbiome in Patients with Atopic Keratoconjunctivitis and Healthy Individuals
• Fiber-Mediated Nourishment of Gut Microbiota Protects against Diet-Induced Obesity by Restoring IL-22-Mediated Colonic Health/Experiment 1/Signature 1
• Fiber-Mediated Nourishment of Gut Microbiota Protects against Diet-Induced Obesity by Restoring IL-22-Mediated Colonic Health/Experiment 1/Signature 2
• Fiber-Mediated Nourishment of Gut Microbiota Protects against Diet-Induced Obesity by Restoring IL-22-Mediated Colonic Health/Experiment 2
• Fiber-Mediated Nourishment of Gut Microbiota Protects against Diet-Induced Obesity by Restoring IL-22-Mediated Colonic Health/Experiment 2/Signature 1
• Fiber-Mediated Nourishment of Gut Microbiota Protects against Diet-Induced Obesity by Restoring IL-22-Mediated Colonic Health/Experiment 2/Signature 2
• Ecological succession in the vaginal microbiota during pregnancy and birth/Experiment 1
• The association between vaginal bacterial composition and miscarriage: a nested case-control study
• The association between vaginal bacterial composition and miscarriage: a nested case-control study/Experiment 1
• The association between vaginal bacterial composition and miscarriage: a nested case-control study/Experiment 2
• The association between vaginal bacterial composition and miscarriage: a nested case-control study/Experiment 3
• Self-Balance of Intestinal Flora in Spouses of Patients With Rheumatoid Arthritis/Experiment 1
• Self-Balance of Intestinal Flora in Spouses of Patients With Rheumatoid Arthritis/Experiment 1/Signature 1
• Self-Balance of Intestinal Flora in Spouses of Patients With Rheumatoid Arthritis/Experiment 1/Signature 2
• The closed eye harbours a unique microbiome in dry eye disease/Experiment 1/Signature 1
• The closed eye harbours a unique microbiome in dry eye disease/Experiment 1/Signature 2
• Role of dietary fiber in the recovery of the human gut microbiome and its metabolome
• Role of dietary fiber in the recovery of the human gut microbiome and its metabolome/Experiment 1
• The oral microbiome of early stage Parkinson's disease and its relationship with functional measures of motor and non-motor function/Experiment 1
• Body site-typical microbiome signatures for adults
• Body site-typical microbiome signatures for adults/Experiment 1
• Body site-typical microbiome signatures for adults/Experiment 2
• Body site-typical microbiome signatures for adults/Experiment 3
• Body site-typical microbiome signatures for adults/Experiment 4
• Body site-typical microbiome signatures for adults/Experiment 5
• Body site-typical microbiome signatures for adults/Experiment 6
• Body site-typical microbiome signatures for adults/Experiment 7
• Body site-typical microbiome signatures for adults/Experiment 8
• Body site-typical microbiome signatures for adults/Experiment 9
• Body site-typical microbiome signatures for adults/Experiment 10
• Body site-typical microbiome signatures for adults/Experiment 10/Signature 1
• Body site-typical microbiome signatures for adults/Experiment 11
• The conjunctival microbiome in health and trachomatous disease: a case control study/Experiment 1/Signature 1
• The conjunctival microbiome in health and trachomatous disease: a case control study/Experiment 1/Signature 2
• The conjunctival microbiome in health and trachomatous disease: a case control study/Experiment 2
• The conjunctival microbiome in health and trachomatous disease: a case control study/Experiment 2/Signature 1
• The conjunctival microbiome in health and trachomatous disease: a case control study/Experiment 3
• The conjunctival microbiome in health and trachomatous disease: a case control study/Experiment 3/Signature 1
• The conjunctival microbiome in health and trachomatous disease: a case control study/Experiment 3/Signature 2
• The conjunctival microbiome in health and trachomatous disease: a case control study/Experiment 4/Signature 1
• The conjunctival microbiome in health and trachomatous disease: a case control study/Experiment 4/Signature 2
• The conjunctival microbiome in health and trachomatous disease: a case control study/Experiment 6
• The conjunctival microbiome in health and trachomatous disease: a case control study/Experiment 6/Signature 1
• The conjunctival microbiome in health and trachomatous disease: a case control study/Experiment 6/Signature 2
• Influence of Intrapartum Antibiotic Prophylaxis for Group B Streptococcus on Gut Microbiota in the First Month of Life/Experiment 1
• Gut Microbiome of Healthy and Arthritic Dogs
• Gut Microbiome of Healthy and Arthritic Dogs/Experiment 1
• Decreased dietary fiber intake and structural alteration of gut microbiota in patients with advanced colorectal adenoma
• Decreased dietary fiber intake and structural alteration of gut microbiota in patients with advanced colorectal adenoma/Experiment 1/Signature 1
• Analysis of the Gut Microflora in Patients With Parkinson's Disease/Experiment 2
• Analysis of the Gut Microflora in Patients With Parkinson's Disease/Experiment 3
• Alterations of the Predominant Fecal Microbiota and Disruption of the Gut Mucosal Barrier in Patients with Early-Stage Colorectal Cancer
• Alterations of the Predominant Fecal Microbiota and Disruption of the Gut Mucosal Barrier in Patients with Early-Stage Colorectal Cancer/Experiment 1
• Gut Microbial Composition and Function Are Altered in Patients with Early Rheumatoid Arthritis/Experiment 1
• Association of Gut Microbiome and Vitamin D Deficiency in Knee Osteoarthritis Patients: A Pilot Study
• Association of Gut Microbiome and Vitamin D Deficiency in Knee Osteoarthritis Patients: A Pilot Study/Experiment 1
• Association of Gut Microbiome and Vitamin D Deficiency in Knee Osteoarthritis Patients: A Pilot Study/Experiment 2
• Expansion of intestinal Prevotella copri correlates with enhanced susceptibility to arthritis/Experiment 1/Signature 1
• Expansion of intestinal Prevotella copri correlates with enhanced susceptibility to arthritis/Experiment 1/Signature 2
• Study of the Relationship between Microbiome and Colorectal Cancer Susceptibility Using 16SrRNA Sequencing
• Study of the Relationship between Microbiome and Colorectal Cancer Susceptibility Using 16SrRNA Sequencing/Experiment 1
• Intestinal microbiome analysis demonstrates azithromycin post-treatment effects improve when combined with lactulose/Experiment 1
• Intestinal microbiome analysis demonstrates azithromycin post-treatment effects improve when combined with lactulose/Experiment 1/Signature 1
• Intestinal microbiome analysis demonstrates azithromycin post-treatment effects improve when combined with lactulose/Experiment 1/Signature 2
• Intestinal microbiome analysis demonstrates azithromycin post-treatment effects improve when combined with lactulose/Experiment 2
• Intestinal microbiome analysis demonstrates azithromycin post-treatment effects improve when combined with lactulose/Experiment 2/Signature 1
• Intestinal microbiome analysis demonstrates azithromycin post-treatment effects improve when combined with lactulose/Experiment 2/Signature 2
• Intestinal microbiome analysis demonstrates azithromycin post-treatment effects improve when combined with lactulose/Experiment 3
• Intestinal microbiome analysis demonstrates azithromycin post-treatment effects improve when combined with lactulose/Experiment 3/Signature 1
• Intestinal microbiome analysis demonstrates azithromycin post-treatment effects improve when combined with lactulose/Experiment 3/Signature 2
• Intestinal microbiome analysis demonstrates azithromycin post-treatment effects improve when combined with lactulose/Experiment 4
• Intestinal microbiome analysis demonstrates azithromycin post-treatment effects improve when combined with lactulose/Experiment 4/Signature 1
• Intestinal microbiome analysis demonstrates azithromycin post-treatment effects improve when combined with lactulose/Experiment 4/Signature 2
• Intestinal microbiome analysis demonstrates azithromycin post-treatment effects improve when combined with lactulose/Experiment 5
• Intestinal microbiome analysis demonstrates azithromycin post-treatment effects improve when combined with lactulose/Experiment 5/Signature 1
• Intestinal microbiome analysis demonstrates azithromycin post-treatment effects improve when combined with lactulose/Experiment 5/Signature 2
• Intestinal microbiome analysis demonstrates azithromycin post-treatment effects improve when combined with lactulose/Experiment 6
• Intestinal microbiome analysis demonstrates azithromycin post-treatment effects improve when combined with lactulose/Experiment 6/Signature 1
• Intestinal microbiome analysis demonstrates azithromycin post-treatment effects improve when combined with lactulose/Experiment 7
• Intestinal microbiome analysis demonstrates azithromycin post-treatment effects improve when combined with lactulose/Experiment 7/Signature 1
• Intestinal microbiome analysis demonstrates azithromycin post-treatment effects improve when combined with lactulose/Experiment 7/Signature 2
• Intestinal microbiome analysis demonstrates azithromycin post-treatment effects improve when combined with lactulose/Experiment 8
• Antibiotics at birth and later antibiotic courses: effects on gut microbiota
• Antibiotics at birth and later antibiotic courses: effects on gut microbiota/Experiment 1
• Antibiotics at birth and later antibiotic courses: effects on gut microbiota/Experiment 1/Signature 1
• Antibiotics at birth and later antibiotic courses: effects on gut microbiota/Experiment 1/Signature 2
• Human gut microbiome and risk for colorectal cancer/Experiment 1
• Human gut microbiome and risk for colorectal cancer/Experiment 1/Signature 1
• Sex effects in the association between airway microbiome and asthma/Experiment 1
• Sex effects in the association between airway microbiome and asthma/Experiment 1/Signature 1
• Sex effects in the association between airway microbiome and asthma/Experiment 2
• Metagenomic analysis of the impact of nitrofurantoin treatment on the human faecal microbiota/Experiment 1/Signature 1
• Metagenomic analysis of the impact of nitrofurantoin treatment on the human faecal microbiota/Experiment 2/Signature 1
• Metagenomic analysis of the impact of nitrofurantoin treatment on the human faecal microbiota/Experiment 3/Signature 1
• Alterations in Oral Microbiota in HIV Are Related to Decreased Pulmonary Function/Experiment 1
• Alterations in Oral Microbiota in HIV Are Related to Decreased Pulmonary Function/Experiment 2
• Alterations in Oral Microbiota in HIV Are Related to Decreased Pulmonary Function/Experiment 3
• Alterations in Oral Microbiota in HIV Are Related to Decreased Pulmonary Function/Experiment 3/Signature 1
• Alterations in Oral Microbiota in HIV Are Related to Decreased Pulmonary Function/Experiment 3/Signature 2
• Altered composition of the gut microbiome in patients with drug-resistant epilepsy
• Altered composition of the gut microbiome in patients with drug-resistant epilepsy/Experiment 1
• Altered composition of the gut microbiome in patients with drug-resistant epilepsy/Experiment 2
• Integrative Analysis of Fecal Metagenomics and Metabolomics in Colorectal Cancer/Experiment 1
• Integrative Analysis of Fecal Metagenomics and Metabolomics in Colorectal Cancer/Experiment 2
• Oral and Gut Microbial Diversity and Immune Regulation in Patients with HIV on Antiretroviral Therapy/Experiment 1
• Oral and Gut Microbial Diversity and Immune Regulation in Patients with HIV on Antiretroviral Therapy/Experiment 1/Signature 1
• Oral and Gut Microbial Diversity and Immune Regulation in Patients with HIV on Antiretroviral Therapy/Experiment 1/Signature 2
• Fecal Microbiota Characteristics of Patients with Colorectal Adenoma Detected by Screening: A Population-based Study/Experiment 1
• Preliminary Comparison of Oral and Intestinal Human Microbiota in Patients with Colorectal Cancer: A Pilot Study/Experiment 1/Signature 1
• Preliminary Comparison of Oral and Intestinal Human Microbiota in Patients with Colorectal Cancer: A Pilot Study/Experiment 2/Signature 1
• The Association Between Smoking and Gut Microbiome in Bangladesh/Experiment 1/Signature 1
• The Association Between Smoking and Gut Microbiome in Bangladesh/Experiment 2/Signature 1
• Colorectal Cancer Stage-Specific Fecal Bacterial Community Fingerprinting of the Taiwanese Population and Underpinning of Potential Taxonomic Biomarkers/Experiment 1
• Colorectal Cancer Stage-Specific Fecal Bacterial Community Fingerprinting of the Taiwanese Population and Underpinning of Potential Taxonomic Biomarkers/Experiment 3
• Evolution of the gut microbiome following acute HIV-1 infection/Experiment 1
• Gut Microbiome Changes Associated With HIV Infection and Sexual Orientation/Experiment 1
• Gut Microbiome Changes Associated With HIV Infection and Sexual Orientation/Experiment 1/Signature 1
• Gut Microbiome Changes Associated With HIV Infection and Sexual Orientation/Experiment 1/Signature 2
• Gut Microbiome Changes Associated With HIV Infection and Sexual Orientation/Experiment 2
• Gut Microbiome Changes Associated With HIV Infection and Sexual Orientation/Experiment 2/Signature 2
• Unique Gut Microbiome in HIV Patients on Antiretroviral Therapy (ART) Suggests Association with Chronic Inflammation/Experiment 1
• Correlation Between Fecal Metabolomics and Gut Microbiota in Obesity and Polycystic Ovary Syndrome/Experiment 1/Signature 1
• Correlation Between Fecal Metabolomics and Gut Microbiota in Obesity and Polycystic Ovary Syndrome/Experiment 1/Signature 2
• Oral microbiome in HIV-associated periodontitis/Experiment 1
• Potential of fecal microbiota for early-stage detection of colorectal cancer/Experiment 1
• Potential of fecal microbiota for early-stage detection of colorectal cancer/Experiment 3
• Human gut microbiota is associated with HIV-reactive immunoglobulin at baseline and following HIV vaccination
• Human gut microbiota is associated with HIV-reactive immunoglobulin at baseline and following HIV vaccination/Experiment 1
• Penile Anaerobic Dysbiosis as a Risk Factor for HIV Infection/Experiment 1
• Changes in Bacteroides and the microbiota in patients with obstructed colorectal cancer: retrospective cohort study
• Alteration of the fecal microbiota in Chinese patients with Parkinson's disease/Experiment 1
• Gut metagenomics-derived genes as potential biomarkers of Parkinson's disease/Experiment 2
• Molecular analysis of the luminal- and mucosal-associated intestinal microbiota in diarrhea-predominant irritable bowel syndrome/Experiment 1/Signature 1
• Metagenomic Analysis of Common Intestinal Diseases Reveals Relationships among Microbial Signatures and Powers Multidisease Diagnostic Models/Experiment 1
• Metagenomic Analysis of Common Intestinal Diseases Reveals Relationships among Microbial Signatures and Powers Multidisease Diagnostic Models/Experiment 1/Signature 1
• Metagenomic Analysis of Common Intestinal Diseases Reveals Relationships among Microbial Signatures and Powers Multidisease Diagnostic Models/Experiment 1/Signature 2
• Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens/Experiment 1
• Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens/Experiment 2
• Altered gut microbiota and inflammatory cytokine responses in patients with Parkinson's disease
• Altered Gut Microbiome in Parkinson's Disease and the Influence of Lipopolysaccharide in a Human α-Synuclein Over-Expressing Mouse Model/Experiment 1
• Parkinson's disease-associated alterations of the gut microbiome predict disease-relevant changes in metabolic functions
• Parkinson's disease-associated alterations of the gut microbiome predict disease-relevant changes in metabolic functions/Experiment 1
• Parkinson's disease-associated alterations of the gut microbiome predict disease-relevant changes in metabolic functions/Experiment 1/Signature 1
• Parkinson's disease-associated alterations of the gut microbiome predict disease-relevant changes in metabolic functions/Experiment 1/Signature 2
• Body site-typical microbiome signatures for children
• Body site-typical microbiome signatures for children/Experiment 1
• Alteration of fecal tryptophan metabolism correlates with shifted microbiota and may be involved in pathogenesis of colorectal cancer/Experiment 1
• Alteration of fecal tryptophan metabolism correlates with shifted microbiota and may be involved in pathogenesis of colorectal cancer/Experiment 1/Signature 1
• Alteration of fecal tryptophan metabolism correlates with shifted microbiota and may be involved in pathogenesis of colorectal cancer/Experiment 1/Signature 2
• Functional dysbiosis within the gut microbiota of patients with constipated-irritable bowel syndrome/Experiment 1
• Functional dysbiosis within the gut microbiota of patients with constipated-irritable bowel syndrome/Experiment 1/Signature 3
• Colorectal Cancer and the Human Gut Microbiome: Reproducibility with Whole-Genome Shotgun Sequencing/Experiment 1
• Comparison of Microbiota in Patients Treated by Surgery or Chemotherapy by 16S rRNA Sequencing Reveals Potential Biomarkers for Colorectal Cancer Therapy
• Comparison of Microbiota in Patients Treated by Surgery or Chemotherapy by 16S rRNA Sequencing Reveals Potential Biomarkers for Colorectal Cancer Therapy/Experiment 1
• Characteristics of fecal gut microbiota in patients with colorectal cancer at different stages and different sites
• Characteristics of fecal gut microbiota in patients with colorectal cancer at different stages and different sites/Experiment 1
• Maturation of the infant microbiome community structure and function across multiple body sites and in relation to mode of delivery/Experiment 1/Signature 1
• Maturation of the infant microbiome community structure and function across multiple body sites and in relation to mode of delivery/Experiment 1/Signature 2
• Maturation of the infant microbiome community structure and function across multiple body sites and in relation to mode of delivery/Experiment 2
• Maturation of the infant microbiome community structure and function across multiple body sites and in relation to mode of delivery/Experiment 2/Signature 2
• Dysbiosis, gut barrier dysfunction and inflammation in dementia: a pilot study
• Dysbiosis, gut barrier dysfunction and inflammation in dementia: a pilot study/Experiment 1
• Dysbiosis, gut barrier dysfunction and inflammation in dementia: a pilot study/Experiment 2
• Dysbiosis, gut barrier dysfunction and inflammation in dementia: a pilot study/Experiment 2/Signature 1
• Dysbiosis, gut barrier dysfunction and inflammation in dementia: a pilot study/Experiment 2/Signature 2
• Dysbiosis, gut barrier dysfunction and inflammation in dementia: a pilot study/Experiment 3
• Dysbiosis, gut barrier dysfunction and inflammation in dementia: a pilot study/Experiment 4
• Delivery mode shapes the acquisition and structure of the initial microbiota across multiple body habitats in newborns
• Microbiota profile is different for early and invasive colorectal cancer and is consistent throughout the colon/Experiment 1
• Randomised clinical study: oral aspirin 325 mg daily vs placebo alters gut microbial composition and bacterial taxa associated with colorectal cancer risk/Experiment 1
• Randomised clinical study: oral aspirin 325 mg daily vs placebo alters gut microbial composition and bacterial taxa associated with colorectal cancer risk/Experiment 1/Signature 2
• Randomised clinical study: oral aspirin 325 mg daily vs placebo alters gut microbial composition and bacterial taxa associated with colorectal cancer risk/Experiment 2
• Berberine may rescue Fusobacterium nucleatum-induced colorectal tumorigenesis by modulating the tumor microenvironment/Experiment 1
• Fusobacterium nucleatum Promotes Chemoresistance to Colorectal Cancer by Modulating Autophagy/Experiment 1
• Gut bacteria identified in colorectal cancer patients promote tumourigenesis via butyrate secretion/Experiment 4
• Family SES Is Associated with the Gut Microbiome in Infants and Children/Experiment 1/Signature 1
• Family SES Is Associated with the Gut Microbiome in Infants and Children/Experiment 1/Signature 2
• Fusobacterium nucleatum and T Cells in Colorectal Carcinoma/Experiment 1
• Gut microbiome development along the colorectal adenoma-carcinoma sequence/Experiment 1
• Gut microbiome development along the colorectal adenoma-carcinoma sequence/Experiment 2
• Gut microbiome development along the colorectal adenoma-carcinoma sequence/Experiment 3
• Joint effects of pregnancy, sociocultural, and environmental factors on early life gut microbiome structure and diversity/Experiment 1/Signature 1
• Joint effects of pregnancy, sociocultural, and environmental factors on early life gut microbiome structure and diversity/Experiment 1/Signature 2
• Microbiota disbiosis is associated with colorectal cancer/Experiment 3
• Sociodemographic variation in the oral microbiome/Experiment 6
• Effect of electronic cigarette and tobacco smoking on the human saliva microbial community/Experiment 1
• Effect of electronic cigarette and tobacco smoking on the human saliva microbial community/Experiment 1/Signature 1
• Effect of electronic cigarette and tobacco smoking on the human saliva microbial community/Experiment 2
• Effect of electronic cigarette and tobacco smoking on the human saliva microbial community/Experiment 3
• Effect of electronic cigarette and tobacco smoking on the human saliva microbial community/Experiment 3/Signature 1
• Effect of electronic cigarette and tobacco smoking on the human saliva microbial community/Experiment 3/Signature 2
• Effect of electronic cigarette and tobacco smoking on the human saliva microbial community/Experiment 5
• Association of Bitter Taste Receptor T2R38 Polymorphisms, Oral Microbiota, and Rheumatoid Arthritis/Experiment 2
• Association of Bitter Taste Receptor T2R38 Polymorphisms, Oral Microbiota, and Rheumatoid Arthritis/Experiment 2/Signature 1
• Association of Bitter Taste Receptor T2R38 Polymorphisms, Oral Microbiota, and Rheumatoid Arthritis/Experiment 2/Signature 2
• Association of Bitter Taste Receptor T2R38 Polymorphisms, Oral Microbiota, and Rheumatoid Arthritis/Experiment 3
• Association of Bitter Taste Receptor T2R38 Polymorphisms, Oral Microbiota, and Rheumatoid Arthritis/Experiment 3/Signature 1
• Association of Bitter Taste Receptor T2R38 Polymorphisms, Oral Microbiota, and Rheumatoid Arthritis/Experiment 3/Signature 2
• Association of Bitter Taste Receptor T2R38 Polymorphisms, Oral Microbiota, and Rheumatoid Arthritis/Experiment 4/Signature 1
• Association of Bitter Taste Receptor T2R38 Polymorphisms, Oral Microbiota, and Rheumatoid Arthritis/Experiment 4/Signature 2
• Differences in the Oral Microbiome in Patients With Early Rheumatoid Arthritis and Individuals at Risk of Rheumatoid Arthritis Compared to Healthy Individuals/Experiment 1
• Effect of ethnicity and socioeconomic variation to the gut microbiota composition among pre-adolescent in Malaysia/Experiment 1
• Effect of ethnicity and socioeconomic variation to the gut microbiota composition among pre-adolescent in Malaysia/Experiment 3
• Dysbiosis of human gut microbiome in young-onset colorectal cancer/Experiment 1
• Dysbiosis of human gut microbiome in young-onset colorectal cancer/Experiment 1/Signature 1
• Dysbiosis of human gut microbiome in young-onset colorectal cancer/Experiment 2
• Gut mucosal microbiome across stages of colorectal carcinogenesis/Experiment 1
• Gut mucosal microbiome across stages of colorectal carcinogenesis/Experiment 4
• Improved feeding tolerance and growth are linked to increased gut microbial community diversity in very-low-birth-weight infants fed mother's own milk compared with donor breast milk/Experiment 1/Signature 1
• Improved feeding tolerance and growth are linked to increased gut microbial community diversity in very-low-birth-weight infants fed mother's own milk compared with donor breast milk/Experiment 1/Signature 2
• Associations Between Race, Perceived Psychological Stress, and the Gut Microbiota in a Sample of Generally Healthy Black and White Women: A Pilot Study on the Role of Race and Perceived Psychological Stress/Experiment 1
• Ethnic variability associating gut and oral microbiome with obesity in children/Experiment 1
• Ethnic variability associating gut and oral microbiome with obesity in children/Experiment 2/Signature 1
• Ethnic variability associating gut and oral microbiome with obesity in children/Experiment 2/Signature 2
• Ethnic variability associating gut and oral microbiome with obesity in children/Experiment 3
• Ethnic variability associating gut and oral microbiome with obesity in children/Experiment 3/Signature 1
• Ethnic variability associating gut and oral microbiome with obesity in children/Experiment 3/Signature 2
• Ethnic variability associating gut and oral microbiome with obesity in children/Experiment 4/Signature 1
• Ethnic variability associating gut and oral microbiome with obesity in children/Experiment 5
• Ethnic variability associating gut and oral microbiome with obesity in children/Experiment 5/Signature 1
• Ethnic variability associating gut and oral microbiome with obesity in children/Experiment 6/Signature 1
• The Bacterial Gut Microbiota of Schoolchildren from High and Low Socioeconomic Status: A Study in an Urban Area of Makassar, Indonesia/Experiment 1/Signature 1
• The Bacterial Gut Microbiota of Schoolchildren from High and Low Socioeconomic Status: A Study in an Urban Area of Makassar, Indonesia/Experiment 1/Signature 2
• Metagenomic analyses of the gut microbiota associated with colorectal adenoma/Experiment 1
• Metagenomic analyses of the gut microbiota associated with colorectal adenoma/Experiment 2
• The oral microbiota in colorectal cancer is distinctive and predictive
• The oral microbiota in colorectal cancer is distinctive and predictive/Experiment 1/Signature 1
• The oral microbiota in colorectal cancer is distinctive and predictive/Experiment 1/Signature 2
• The oral microbiota in colorectal cancer is distinctive and predictive/Experiment 2
• The oral microbiota in colorectal cancer is distinctive and predictive/Experiment 2/Signature 1
• The oral microbiota in colorectal cancer is distinctive and predictive/Experiment 3
• The oral microbiota in colorectal cancer is distinctive and predictive/Experiment 3/Signature 1
• Gut microbiota diversity across ethnicities in the United States/Experiment 1
• Gut microbiota diversity across ethnicities in the United States/Experiment 2/Signature 1
• Gut microbiota diversity across ethnicities in the United States/Experiment 2/Signature 2
• Gut microbiota diversity across ethnicities in the United States/Experiment 3
• Gut microbiota diversity across ethnicities in the United States/Experiment 3/Signature 1
• Gut microbiota diversity across ethnicities in the United States/Experiment 3/Signature 2
• Gut microbiota diversity across ethnicities in the United States/Experiment 4
• Gut microbiota diversity across ethnicities in the United States/Experiment 4/Signature 1
• Gut microbiota diversity across ethnicities in the United States/Experiment 4/Signature 2
• Gut microbiota diversity across ethnicities in the United States/Experiment 5
• Gut microbiota diversity across ethnicities in the United States/Experiment 5/Signature 1
• Gut microbiota diversity across ethnicities in the United States/Experiment 5/Signature 2
• Gut microbiota diversity across ethnicities in the United States/Experiment 6
• Salivary microbiome profiles of oral cancer patients analyzed before and after treatment/Experiment 2/Signature 1
• Regorafenib plus toripalimab in patients with metastatic colorectal cancer: a phase Ib/II clinical trial and gut microbiome analysis/Experiment 1/Signature 1
• Regorafenib plus toripalimab in patients with metastatic colorectal cancer: a phase Ib/II clinical trial and gut microbiome analysis/Experiment 1/Signature 2
• Gut microbiota: impacts on gastrointestinal cancer immunotherapy/Experiment 1/Signature 1
• Predominance of Escherichia-Shigella in Gut Microbiome and Its Potential Correlation with Elevated Level of Plasma Tumor Necrosis Factor Alpha in Patients with Tuberculous Meningitis/Experiment 1/Signature 2
• Predominance of Escherichia-Shigella in Gut Microbiome and Its Potential Correlation with Elevated Level of Plasma Tumor Necrosis Factor Alpha in Patients with Tuberculous Meningitis/Experiment 2/Signature 2
• Ethnicity influences the gut microbiota of individuals sharing a geographical location: a cross-sectional study from a middle-income country/Experiment 1
• Ethnicity influences the gut microbiota of individuals sharing a geographical location: a cross-sectional study from a middle-income country/Experiment 2
• Ethnicity influences the gut microbiota of individuals sharing a geographical location: a cross-sectional study from a middle-income country/Experiment 3
• Ethnicity influences the gut microbiota of individuals sharing a geographical location: a cross-sectional study from a middle-income country/Experiment 4
• Ethnicity influences the gut microbiota of individuals sharing a geographical location: a cross-sectional study from a middle-income country/Experiment 5
• Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab/Experiment 1
• Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab/Experiment 1/Signature 1
• Distinct gut microbiota in southeastern African and northern European infants/Experiment 1
• Impact of diet in shaping gut microbiota revealed by a comparative study in children from Europe and rural Africa/Experiment 1/Signature 1
• Impact of diet in shaping gut microbiota revealed by a comparative study in children from Europe and rural Africa/Experiment 1/Signature 2
• Impact of diet in shaping gut microbiota revealed by a comparative study in children from Europe and rural Africa/Experiment 2
• Impact of diet in shaping gut microbiota revealed by a comparative study in children from Europe and rural Africa/Experiment 2/Signature 1
• Impact of diet in shaping gut microbiota revealed by a comparative study in children from Europe and rural Africa/Experiment 3
• Impact of diet in shaping gut microbiota revealed by a comparative study in children from Europe and rural Africa/Experiment 3/Signature 1
• Impact of diet in shaping gut microbiota revealed by a comparative study in children from Europe and rural Africa/Experiment 3/Signature 2
• Distinct distal gut microbiome diversity and composition in healthy children from Bangladesh and the United States/Experiment 1
• Environmental exposures and child and maternal gut microbiota in rural Malawi/Experiment 1
• The gut microbiota of Colombians differs from that of Americans, Europeans and Asians/Experiment 1/Signature 1
• The gut microbiota of Colombians differs from that of Americans, Europeans and Asians/Experiment 1/Signature 2
• The gut microbiota of Colombians differs from that of Americans, Europeans and Asians/Experiment 2/Signature 2
• The gut microbiota of Colombians differs from that of Americans, Europeans and Asians/Experiment 3/Signature 2
• The gut microbiota of Colombians differs from that of Americans, Europeans and Asians/Experiment 4/Signature 1
• The gut microbiota of Colombians differs from that of Americans, Europeans and Asians/Experiment 4/Signature 2
• The Associations between Diet and Socioeconomic Disparities and the Intestinal Microbiome in Preadolescence/Experiment 1/Signature 1
• The Associations between Diet and Socioeconomic Disparities and the Intestinal Microbiome in Preadolescence/Experiment 1/Signature 2
• The Diversity of Gut Microbiome is Associated With Favorable Responses to Anti-Programmed Death 1 Immunotherapy in Chinese Patients With NSCLC/Experiment 1
• The Diversity of Gut Microbiome is Associated With Favorable Responses to Anti-Programmed Death 1 Immunotherapy in Chinese Patients With NSCLC/Experiment 1/Signature 1
• The Diversity of Gut Microbiome is Associated With Favorable Responses to Anti-Programmed Death 1 Immunotherapy in Chinese Patients With NSCLC/Experiment 1/Signature 2
• Types of tobacco consumption and the oral microbiome in the United Arab Emirates Healthy Future (UAEHFS) Pilot Study
• Types of tobacco consumption and the oral microbiome in the United Arab Emirates Healthy Future (UAEHFS) Pilot Study/Experiment 1
• Types of tobacco consumption and the oral microbiome in the United Arab Emirates Healthy Future (UAEHFS) Pilot Study/Experiment 1/Signature 1
• Types of tobacco consumption and the oral microbiome in the United Arab Emirates Healthy Future (UAEHFS) Pilot Study/Experiment 2
• Types of tobacco consumption and the oral microbiome in the United Arab Emirates Healthy Future (UAEHFS) Pilot Study/Experiment 2/Signature 1
• Types of tobacco consumption and the oral microbiome in the United Arab Emirates Healthy Future (UAEHFS) Pilot Study/Experiment 2/Signature 2
• Types of tobacco consumption and the oral microbiome in the United Arab Emirates Healthy Future (UAEHFS) Pilot Study/Experiment 3
• Types of tobacco consumption and the oral microbiome in the United Arab Emirates Healthy Future (UAEHFS) Pilot Study/Experiment 3/Signature 2
• Types of tobacco consumption and the oral microbiome in the United Arab Emirates Healthy Future (UAEHFS) Pilot Study/Experiment 4
• Types of tobacco consumption and the oral microbiome in the United Arab Emirates Healthy Future (UAEHFS) Pilot Study/Experiment 4/Signature 1
• Types of tobacco consumption and the oral microbiome in the United Arab Emirates Healthy Future (UAEHFS) Pilot Study/Experiment 4/Signature 2
• The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients/Experiment 1
• The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients/Experiment 2
• The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients/Experiment 3
• Gut Microbiota Profiling in Patients With HER2-Negative Metastatic Breast Cancer Receiving Metronomic Chemotherapy of Capecitabine Compared to Those Under Conventional Dosage/Experiment 1
• Gut Microbiota Profiling in Patients With HER2-Negative Metastatic Breast Cancer Receiving Metronomic Chemotherapy of Capecitabine Compared to Those Under Conventional Dosage/Experiment 1/Signature 1
• Gut Microbiota Profiling in Patients With HER2-Negative Metastatic Breast Cancer Receiving Metronomic Chemotherapy of Capecitabine Compared to Those Under Conventional Dosage/Experiment 1/Signature 2
• Duodenal and rectal mucosal microbiota related to small intestinal bacterial overgrowth in diarrhea-predominant irritable bowel syndrome/Experiment 1
• Duodenal and rectal mucosal microbiota related to small intestinal bacterial overgrowth in diarrhea-predominant irritable bowel syndrome/Experiment 1/Signature 1
• Duodenal and rectal mucosal microbiota related to small intestinal bacterial overgrowth in diarrhea-predominant irritable bowel syndrome/Experiment 1/Signature 2
• Duodenal and rectal mucosal microbiota related to small intestinal bacterial overgrowth in diarrhea-predominant irritable bowel syndrome/Experiment 3
• Duodenal and rectal mucosal microbiota related to small intestinal bacterial overgrowth in diarrhea-predominant irritable bowel syndrome/Experiment 3/Signature 1
• Duodenal and rectal mucosal microbiota related to small intestinal bacterial overgrowth in diarrhea-predominant irritable bowel syndrome/Experiment 3/Signature 2
• Duodenal and rectal mucosal microbiota related to small intestinal bacterial overgrowth in diarrhea-predominant irritable bowel syndrome/Experiment 4
• Duodenal and rectal mucosal microbiota related to small intestinal bacterial overgrowth in diarrhea-predominant irritable bowel syndrome/Experiment 4/Signature 1
• Duodenal and rectal mucosal microbiota related to small intestinal bacterial overgrowth in diarrhea-predominant irritable bowel syndrome/Experiment 5/Signature 1
• Altered Fecal Small RNA Profiles in Colorectal Cancer Reflect Gut Microbiome Composition in Stool Samples/Experiment 1
• Altered Fecal Small RNA Profiles in Colorectal Cancer Reflect Gut Microbiome Composition in Stool Samples/Experiment 1/Signature 1
• Altered Fecal Small RNA Profiles in Colorectal Cancer Reflect Gut Microbiome Composition in Stool Samples/Experiment 1/Signature 2
• Altered Fecal Small RNA Profiles in Colorectal Cancer Reflect Gut Microbiome Composition in Stool Samples/Experiment 2
• Altered Fecal Small RNA Profiles in Colorectal Cancer Reflect Gut Microbiome Composition in Stool Samples/Experiment 2/Signature 1
• Altered Fecal Small RNA Profiles in Colorectal Cancer Reflect Gut Microbiome Composition in Stool Samples/Experiment 3
• Altered Fecal Small RNA Profiles in Colorectal Cancer Reflect Gut Microbiome Composition in Stool Samples/Experiment 3/Signature 1
• Altered Fecal Small RNA Profiles in Colorectal Cancer Reflect Gut Microbiome Composition in Stool Samples/Experiment 3/Signature 2
• A comprehensive analysis of the microbiota composition and host driver gene mutations in colorectal cancer/Experiment 1
• A comprehensive analysis of the microbiota composition and host driver gene mutations in colorectal cancer/Experiment 2
• A comprehensive analysis of the microbiota composition and host driver gene mutations in colorectal cancer/Experiment 2/Signature 1
• Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients/Experiment 2
• Metagenomic Shotgun Sequencing and Unbiased Metabolomic Profiling Identify Specific Human Gut Microbiota and Metabolites Associated with Immune Checkpoint Therapy Efficacy in Melanoma Patients/Experiment 1/Signature 1
• Metagenomic Shotgun Sequencing and Unbiased Metabolomic Profiling Identify Specific Human Gut Microbiota and Metabolites Associated with Immune Checkpoint Therapy Efficacy in Melanoma Patients/Experiment 1/Signature 2
• The role of the gut microbiome on the efficacy of immune checkpoint inhibitors in Japanese responder patients with advanced non-small cell lung cancer
• The role of the gut microbiome on the efficacy of immune checkpoint inhibitors in Japanese responder patients with advanced non-small cell lung cancer/Experiment 1
• Gut microbial species and metabolic pathways associated with response to treatment with immune checkpoint inhibitors in metastatic melanoma/Experiment 1
• Effects of prebiotics on immunologic indicators and intestinal microbiota structure in perioperative colorectal cancer patients/Experiment 1
• Effects of prebiotics on immunologic indicators and intestinal microbiota structure in perioperative colorectal cancer patients/Experiment 2
• Effects of prebiotics on immunologic indicators and intestinal microbiota structure in perioperative colorectal cancer patients/Experiment 3
• Gut microbiome affects the response to anti-PD-1 immunotherapy in patients with hepatocellular carcinoma/Experiment 1
• Gut microbiome affects the response to anti-PD-1 immunotherapy in patients with hepatocellular carcinoma/Experiment 1/Signature 2
• Gegen Qinlian decoction enhances the effect of PD-1 blockade in colorectal cancer with microsatellite stability by remodelling the gut microbiota and the tumour microenvironment/Experiment 1
• Gegen Qinlian decoction enhances the effect of PD-1 blockade in colorectal cancer with microsatellite stability by remodelling the gut microbiota and the tumour microenvironment/Experiment 1/Signature 1
• Gegen Qinlian decoction enhances the effect of PD-1 blockade in colorectal cancer with microsatellite stability by remodelling the gut microbiota and the tumour microenvironment/Experiment 1/Signature 2
• Gegen Qinlian decoction enhances the effect of PD-1 blockade in colorectal cancer with microsatellite stability by remodelling the gut microbiota and the tumour microenvironment/Experiment 2
• Gegen Qinlian decoction enhances the effect of PD-1 blockade in colorectal cancer with microsatellite stability by remodelling the gut microbiota and the tumour microenvironment/Experiment 3
• Gegen Qinlian decoction enhances the effect of PD-1 blockade in colorectal cancer with microsatellite stability by remodelling the gut microbiota and the tumour microenvironment/Experiment 4
• Gegen Qinlian decoction enhances the effect of PD-1 blockade in colorectal cancer with microsatellite stability by remodelling the gut microbiota and the tumour microenvironment/Experiment 5
• Gegen Qinlian decoction enhances the effect of PD-1 blockade in colorectal cancer with microsatellite stability by remodelling the gut microbiota and the tumour microenvironment/Experiment 6
• Gegen Qinlian decoction enhances the effect of PD-1 blockade in colorectal cancer with microsatellite stability by remodelling the gut microbiota and the tumour microenvironment/Experiment 6/Signature 2
• Gut Microbiome Influences the Efficacy of PD-1 Antibody Immunotherapy on MSS-Type Colorectal Cancer via Metabolic Pathway/Experiment 1
• Gut Microbiome Influences the Efficacy of PD-1 Antibody Immunotherapy on MSS-Type Colorectal Cancer via Metabolic Pathway/Experiment 3/Signature 1
• Probiotics modify human intestinal mucosa-associated microbiota in patients with colorectal cancer
• Probiotics modify human intestinal mucosa-associated microbiota in patients with colorectal cancer/Experiment 1/Signature 1
• Probiotics modify human intestinal mucosa-associated microbiota in patients with colorectal cancer/Experiment 1/Signature 2
• Probiotics modify human intestinal mucosa-associated microbiota in patients with colorectal cancer/Experiment 2/Signature 1
• Probiotics modify human intestinal mucosa-associated microbiota in patients with colorectal cancer/Experiment 3/Signature 1
• Probiotics modify human intestinal mucosa-associated microbiota in patients with colorectal cancer/Experiment 3/Signature 2
• Fecal microbial dysbiosis in Chinese patients with inflammatory bowel disease/Experiment 1
• Fecal microbial dysbiosis in Chinese patients with inflammatory bowel disease/Experiment 2
• Fecal microbial dysbiosis in Chinese patients with inflammatory bowel disease/Experiment 3
• 16S rRNA and metagenomic shotgun sequencing data revealed consistent patterns of gut microbiome signature in pediatric ulcerative colitis
• Subgingival microbiome of rheumatoid arthritis patients in relation to their disease status and periodontal health/Experiment 1/Signature 1
• Subgingival microbiome of rheumatoid arthritis patients in relation to their disease status and periodontal health/Experiment 1/Signature 2
• Subgingival microbiome of rheumatoid arthritis patients in relation to their disease status and periodontal health/Experiment 2/Signature 1
• Subgingival microbiome of rheumatoid arthritis patients in relation to their disease status and periodontal health/Experiment 3/Signature 1
• Subgingival microbiome of rheumatoid arthritis patients in relation to their disease status and periodontal health/Experiment 3/Signature 2
• Subgingival microbiome of rheumatoid arthritis patients in relation to their disease status and periodontal health/Experiment 4/Signature 1
• Subgingival microbiome of rheumatoid arthritis patients in relation to their disease status and periodontal health/Experiment 4/Signature 2
• Subgingival microbiome of rheumatoid arthritis patients in relation to their disease status and periodontal health/Experiment 5
• Subgingival microbiome of rheumatoid arthritis patients in relation to their disease status and periodontal health/Experiment 5/Signature 1
• Subgingival microbiome of rheumatoid arthritis patients in relation to their disease status and periodontal health/Experiment 5/Signature 2
• Subgingival microbiome of deep and shallow periodontal sites in patients with rheumatoid arthritis: a pilot study/Experiment 1/Signature 1
• Subgingival microbiome of deep and shallow periodontal sites in patients with rheumatoid arthritis: a pilot study/Experiment 1/Signature 2
• The subgingival microbiome in patients with established rheumatoid arthritis/Experiment 1
• The subgingival microbiome in patients with established rheumatoid arthritis/Experiment 1/Signature 1
• Oral status in patients with early rheumatoid arthritis: a prospective, case-control study/Experiment 1
• Oral status in patients with early rheumatoid arthritis: a prospective, case-control study/Experiment 1/Signature 1
• Oral status in patients with early rheumatoid arthritis: a prospective, case-control study/Experiment 1/Signature 2
• Periodontal disease and the oral microbiota in new-onset rheumatoid arthritis/Experiment 1/Signature 1
• Periodontal disease and the oral microbiota in new-onset rheumatoid arthritis/Experiment 1/Signature 2
• Periodontal disease and the oral microbiota in new-onset rheumatoid arthritis/Experiment 2/Signature 1
• Periodontal disease and the oral microbiota in new-onset rheumatoid arthritis/Experiment 2/Signature 2
• Periodontal disease and the oral microbiota in new-onset rheumatoid arthritis/Experiment 3/Signature 1
• Oral Microbiota Identifies Patients in Early Onset Rheumatoid Arthritis
• Oral Microbiota Identifies Patients in Early Onset Rheumatoid Arthritis/Experiment 1
• Oral Microbiota Identifies Patients in Early Onset Rheumatoid Arthritis/Experiment 1/Signature 1
• Oral Microbiota Identifies Patients in Early Onset Rheumatoid Arthritis/Experiment 1/Signature 2
• Salivary microbiota and inflammation-related proteins in patients with psoriasis/Experiment 1
• Oral health and plaque microbial profile in juvenile idiopathic arthritis/Experiment 1
• Respiratory Tract Dysbiosis Is Associated with Worse Outcomes in Mechanically Ventilated Patients/Experiment 1/Signature 1
• Respiratory Tract Dysbiosis Is Associated with Worse Outcomes in Mechanically Ventilated Patients/Experiment 2/Signature 1
• Respiratory Tract Dysbiosis Is Associated with Worse Outcomes in Mechanically Ventilated Patients/Experiment 2/Signature 2
• Respiratory Tract Dysbiosis Is Associated with Worse Outcomes in Mechanically Ventilated Patients/Experiment 3
• Respiratory Tract Dysbiosis Is Associated with Worse Outcomes in Mechanically Ventilated Patients/Experiment 3/Signature 1
• Respiratory Tract Dysbiosis Is Associated with Worse Outcomes in Mechanically Ventilated Patients/Experiment 4
• Respiratory Tract Dysbiosis Is Associated with Worse Outcomes in Mechanically Ventilated Patients/Experiment 5
• Respiratory Tract Dysbiosis Is Associated with Worse Outcomes in Mechanically Ventilated Patients/Experiment 6
• Respiratory Tract Dysbiosis Is Associated with Worse Outcomes in Mechanically Ventilated Patients/Experiment 6/Signature 1
• Respiratory Tract Dysbiosis Is Associated with Worse Outcomes in Mechanically Ventilated Patients/Experiment 6/Signature 2
• Respiratory Tract Dysbiosis Is Associated with Worse Outcomes in Mechanically Ventilated Patients/Experiment 7
• Respiratory Tract Dysbiosis Is Associated with Worse Outcomes in Mechanically Ventilated Patients/Experiment 7/Signature 1
• Respiratory Tract Dysbiosis Is Associated with Worse Outcomes in Mechanically Ventilated Patients/Experiment 7/Signature 2
• Respiratory Tract Dysbiosis Is Associated with Worse Outcomes in Mechanically Ventilated Patients/Experiment 8
• Respiratory Tract Dysbiosis Is Associated with Worse Outcomes in Mechanically Ventilated Patients/Experiment 8/Signature 1
• Respiratory Tract Dysbiosis Is Associated with Worse Outcomes in Mechanically Ventilated Patients/Experiment 9
• Respiratory Tract Dysbiosis Is Associated with Worse Outcomes in Mechanically Ventilated Patients/Experiment 9/Signature 1
• Respiratory Tract Dysbiosis Is Associated with Worse Outcomes in Mechanically Ventilated Patients/Experiment 10/Signature 1
• Respiratory Tract Dysbiosis Is Associated with Worse Outcomes in Mechanically Ventilated Patients/Experiment 11
• Respiratory Tract Dysbiosis Is Associated with Worse Outcomes in Mechanically Ventilated Patients/Experiment 12
• Gut microbiota in patients with Parkinson's disease in southern China/Experiment 1/Signature 2
• Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression/Experiment 1
• Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression/Experiment 1/Signature 1
• Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression/Experiment 1/Signature 2
• Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression/Experiment 2
• Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression/Experiment 2/Signature 1
• Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression/Experiment 2/Signature 2
• Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression/Experiment 3
• Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression/Experiment 3/Signature 1
• Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression/Experiment 3/Signature 2
• Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression/Experiment 4
• Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression/Experiment 4/Signature 1
• Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression/Experiment 4/Signature 2
• Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression/Experiment 5
• Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression/Experiment 5/Signature 1
• Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression/Experiment 5/Signature 2
• Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression/Experiment 6
• Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression/Experiment 6/Signature 1
• Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression/Experiment 6/Signature 2
• The nasal and gut microbiome in Parkinson's disease and idiopathic rapid eye movement sleep behavior disorder/Experiment 1/Signature 2
• Diversity of vaginal microbiome and metabolome during genital infections/Experiment 1
• Evolution of the Gut Microbiome in HIV-Exposed Uninfected and Unexposed Infants during the First Year of Life
• Evolution of the Gut Microbiome in HIV-Exposed Uninfected and Unexposed Infants during the First Year of Life/Experiment 1
• Evolution of the Gut Microbiome in HIV-Exposed Uninfected and Unexposed Infants during the First Year of Life/Experiment 2
• Evolution of the Gut Microbiome in HIV-Exposed Uninfected and Unexposed Infants during the First Year of Life/Experiment 3
• Evolution of the Gut Microbiome in HIV-Exposed Uninfected and Unexposed Infants during the First Year of Life/Experiment 4
• Evolution of the Gut Microbiome in HIV-Exposed Uninfected and Unexposed Infants during the First Year of Life/Experiment 5
• Evolution of the Gut Microbiome in HIV-Exposed Uninfected and Unexposed Infants during the First Year of Life/Experiment 5/Signature 1
• Evolution of the Gut Microbiome in HIV-Exposed Uninfected and Unexposed Infants during the First Year of Life/Experiment 5/Signature 2
• Evolution of the Gut Microbiome in HIV-Exposed Uninfected and Unexposed Infants during the First Year of Life/Experiment 6/Signature 1
• Evolution of the Gut Microbiome in HIV-Exposed Uninfected and Unexposed Infants during the First Year of Life/Experiment 6/Signature 2
• Evolution of the Gut Microbiome in HIV-Exposed Uninfected and Unexposed Infants during the First Year of Life/Experiment 7/Signature 1
• Evolution of the Gut Microbiome in HIV-Exposed Uninfected and Unexposed Infants during the First Year of Life/Experiment 7/Signature 2
• Evolution of the Gut Microbiome in HIV-Exposed Uninfected and Unexposed Infants during the First Year of Life/Experiment 8/Signature 1
• Evolution of the Gut Microbiome in HIV-Exposed Uninfected and Unexposed Infants during the First Year of Life/Experiment 8/Signature 2
• The impact of intestinal microbiota on weight loss in Parkinson's disease patients: a pilot study/Experiment 1/Signature 1
• The impact of intestinal microbiota on weight loss in Parkinson's disease patients: a pilot study/Experiment 1/Signature 2
• The impact of intestinal microbiota on weight loss in Parkinson's disease patients: a pilot study/Experiment 2/Signature 1
• The impact of intestinal microbiota on weight loss in Parkinson's disease patients: a pilot study/Experiment 3/Signature 1
• The impact of intestinal microbiota on weight loss in Parkinson's disease patients: a pilot study/Experiment 3/Signature 2
• The impact of intestinal microbiota on weight loss in Parkinson's disease patients: a pilot study/Experiment 4/Signature 1
• The impact of intestinal microbiota on weight loss in Parkinson's disease patients: a pilot study/Experiment 4/Signature 2
• The impact of intestinal microbiota on weight loss in Parkinson's disease patients: a pilot study/Experiment 5/Signature 1
• The impact of intestinal microbiota on weight loss in Parkinson's disease patients: a pilot study/Experiment 5/Signature 2
• Whole metagenome profiling reveals skin microbiome-dependent susceptibility to atopic dermatitis flare/Experiment 1/Signature 1
• Whole metagenome profiling reveals skin microbiome-dependent susceptibility to atopic dermatitis flare/Experiment 1/Signature 2
• Whole metagenome profiling reveals skin microbiome-dependent susceptibility to atopic dermatitis flare/Experiment 2/Signature 1
• Whole metagenome profiling reveals skin microbiome-dependent susceptibility to atopic dermatitis flare/Experiment 3/Signature 1
• Whole metagenome profiling reveals skin microbiome-dependent susceptibility to atopic dermatitis flare/Experiment 3/Signature 2
• Whole metagenome profiling reveals skin microbiome-dependent susceptibility to atopic dermatitis flare/Experiment 4/Signature 1
• Whole metagenome profiling reveals skin microbiome-dependent susceptibility to atopic dermatitis flare/Experiment 4/Signature 2
• Age and the aging process significantly alter the small bowel microbiome/Experiment 2/Signature 2
• Age and the aging process significantly alter the small bowel microbiome/Experiment 3/Signature 2
• Tobacco exposure associated with oral microbiota oxygen utilization in the New York City Health and Nutrition Examination Study/Experiment 1/Signature 1
• Tobacco exposure associated with oral microbiota oxygen utilization in the New York City Health and Nutrition Examination Study/Experiment 1/Signature 2
• Tobacco exposure associated with oral microbiota oxygen utilization in the New York City Health and Nutrition Examination Study/Experiment 2/Signature 1
• Tobacco exposure associated with oral microbiota oxygen utilization in the New York City Health and Nutrition Examination Study/Experiment 2/Signature 2
• Gut microbiota dysbiosis and diarrhea in kidney transplant recipients/Experiment 1/Signature 1
• Gut microbiota dysbiosis and diarrhea in kidney transplant recipients/Experiment 2/Signature 1
• Gut microbiota dysbiosis and diarrhea in kidney transplant recipients/Experiment 2/Signature 2
• The gut microbiota and metabolite profiles are altered in patients with spinal cord injury/Experiment 1
• The gut microbiota and metabolite profiles are altered in patients with spinal cord injury/Experiment 1/Signature 1
• Fecal microbiome alterations in treatment-naive de novo Parkinson's disease/Experiment 1
• Fecal microbiome alterations in treatment-naive de novo Parkinson's disease/Experiment 1/Signature 1
• Fecal microbiome alterations in treatment-naive de novo Parkinson's disease/Experiment 1/Signature 2
• Gut microbiome composition in the Hispanic Community Health Study/Study of Latinos is shaped by geographic relocation, environmental factors, and obesity/Experiment 1
• Gut microbiome composition in the Hispanic Community Health Study/Study of Latinos is shaped by geographic relocation, environmental factors, and obesity/Experiment 2
• Gut microbiome composition in the Hispanic Community Health Study/Study of Latinos is shaped by geographic relocation, environmental factors, and obesity/Experiment 2/Signature 1
• Gut microbiome composition in the Hispanic Community Health Study/Study of Latinos is shaped by geographic relocation, environmental factors, and obesity/Experiment 4
• Gut microbiome composition in the Hispanic Community Health Study/Study of Latinos is shaped by geographic relocation, environmental factors, and obesity/Experiment 6
• Biliary Microbiota in Choledocholithiasis and Correlation With Duodenal Microbiota
• Biliary Microbiota in Choledocholithiasis and Correlation With Duodenal Microbiota/Experiment 1
• The treatment-naive microbiome in new-onset Crohn's disease/Experiment 1
• The treatment-naive microbiome in new-onset Crohn's disease/Experiment 2
• The treatment-naive microbiome in new-onset Crohn's disease/Experiment 3
• Structural and Functional Dysbiosis of Fecal Microbiota in Chinese Patients With Alzheimer's Disease/Experiment 1/Signature 1
• Structural and Functional Dysbiosis of Fecal Microbiota in Chinese Patients With Alzheimer's Disease/Experiment 1/Signature 2
• Comparison of the respiratory microbiome in healthy nonsmokers and smokers/Experiment 2
• Comparison of the respiratory microbiome in healthy nonsmokers and smokers/Experiment 2/Signature 1
• Comparison of the respiratory microbiome in healthy nonsmokers and smokers/Experiment 2/Signature 2
• Comparison of the respiratory microbiome in healthy nonsmokers and smokers/Experiment 3
• Comparison of the respiratory microbiome in healthy nonsmokers and smokers/Experiment 3/Signature 1
• Comparison of the respiratory microbiome in healthy nonsmokers and smokers/Experiment 3/Signature 2
• Comparison of the respiratory microbiome in healthy nonsmokers and smokers/Experiment 4
• Comparison of the respiratory microbiome in healthy nonsmokers and smokers/Experiment 4/Signature 1
• Comparison of the respiratory microbiome in healthy nonsmokers and smokers/Experiment 4/Signature 2
• Widespread protein lysine acetylation in gut microbiome and its alterations in patients with Crohn's disease/Experiment 1
• Widespread protein lysine acetylation in gut microbiome and its alterations in patients with Crohn's disease/Experiment 1/Signature 2
• Role of a probiotic strain in the modulation of gut microbiota and cytokines in inflammatory bowel disease/Experiment 1
• Role of a probiotic strain in the modulation of gut microbiota and cytokines in inflammatory bowel disease/Experiment 1/Signature 1
• Role of a probiotic strain in the modulation of gut microbiota and cytokines in inflammatory bowel disease/Experiment 1/Signature 2
• An analysis of the characteristics of the intestinal flora in patients with Parkinson's disease complicated with constipation/Experiment 1
• Cross-Sectional Study on the Gut Microbiome of Parkinson's Disease Patients in Central China/Experiment 1/Signature 1
• Cross-Sectional Study on the Gut Microbiome of Parkinson's Disease Patients in Central China/Experiment 1/Signature 2
• Parkinson's Disease and the Gut Microbiome in Rural California/Experiment 1/Signature 1
• Structural changes in gut microbiome after Ramadan fasting: a pilot study/Experiment 1
• Metagenomics of Parkinson's disease implicates the gut microbiome in multiple disease mechanisms/Experiment 1/Signature 1
• Metagenomics of Parkinson's disease implicates the gut microbiome in multiple disease mechanisms/Experiment 1/Signature 2
• Altered Gut Microbiome in Patients With Dermatomyositis/Experiment 1
• Altered Gut Microbiome in Patients With Dermatomyositis/Experiment 2
• Altered Gut Microbiome in Patients With Dermatomyositis/Experiment 3/Signature 1
• Salivary microbiome in children with Down syndrome: a case-control study/Experiment 1/Signature 1
• Salivary microbiome in children with Down syndrome: a case-control study/Experiment 1/Signature 2
• Salivary microbiome in children with Down syndrome: a case-control study/Experiment 2/Signature 1
• Salivary microbiome in children with Down syndrome: a case-control study/Experiment 2/Signature 2
• Profiling the Salivary microbiome of the Qatari population/Experiment 1/Signature 1
• Profiling the Salivary microbiome of the Qatari population/Experiment 1/Signature 2
• Profiling the Salivary microbiome of the Qatari population/Experiment 2/Signature 1
• Profiling the Salivary microbiome of the Qatari population/Experiment 2/Signature 2
• Profiling the Salivary microbiome of the Qatari population/Experiment 3/Signature 2
• Profiling the Salivary microbiome of the Qatari population/Experiment 5/Signature 1
• Profiling the Salivary microbiome of the Qatari population/Experiment 5/Signature 2
• Profiling the Salivary microbiome of the Qatari population/Experiment 8
• Cigarette Smoking Modulation of Saliva Microbial Composition and Cytokine Levels/Experiment 1/Signature 1
• Cigarette Smoking Modulation of Saliva Microbial Composition and Cytokine Levels/Experiment 1/Signature 2
• Alcohol and tobacco consumption affects bacterial richness in oral cavity mucosa biofilms/Experiment 2/Signature 1
• Alcohol and tobacco consumption affects bacterial richness in oral cavity mucosa biofilms/Experiment 2/Signature 2
• Changes of saliva microbiota in nasopharyngeal carcinoma patients under chemoradiation therapy/Experiment 1/Signature 1
• Changes of saliva microbiota in nasopharyngeal carcinoma patients under chemoradiation therapy/Experiment 1/Signature 2
• Changes of saliva microbiota in nasopharyngeal carcinoma patients under chemoradiation therapy/Experiment 2/Signature 1
• Changes of saliva microbiota in nasopharyngeal carcinoma patients under chemoradiation therapy/Experiment 2/Signature 2
• Postoperative Probiotics Administration Attenuates Gastrointestinal Complications and Gut Microbiota Dysbiosis Caused by Chemotherapy in Colorectal Cancer Patients/Experiment 1/Signature 1
• Postoperative Probiotics Administration Attenuates Gastrointestinal Complications and Gut Microbiota Dysbiosis Caused by Chemotherapy in Colorectal Cancer Patients/Experiment 1/Signature 2
• Postoperative Probiotics Administration Attenuates Gastrointestinal Complications and Gut Microbiota Dysbiosis Caused by Chemotherapy in Colorectal Cancer Patients/Experiment 2/Signature 1
• Postoperative Probiotics Administration Attenuates Gastrointestinal Complications and Gut Microbiota Dysbiosis Caused by Chemotherapy in Colorectal Cancer Patients/Experiment 2/Signature 2
• Postoperative Probiotics Administration Attenuates Gastrointestinal Complications and Gut Microbiota Dysbiosis Caused by Chemotherapy in Colorectal Cancer Patients/Experiment 3
• Postoperative Probiotics Administration Attenuates Gastrointestinal Complications and Gut Microbiota Dysbiosis Caused by Chemotherapy in Colorectal Cancer Patients/Experiment 3/Signature 2
• Comparative portrayal of ocular surface microbe with and without dry eye/Experiment 2/Signature 2
• The Influence of Age and Sex on Ocular Surface Microbiota in Healthy Adults/Experiment 1
• The Influence of Age and Sex on Ocular Surface Microbiota in Healthy Adults/Experiment 1/Signature 1
• The Influence of Age and Sex on Ocular Surface Microbiota in Healthy Adults/Experiment 1/Signature 2
• The Influence of Age and Sex on Ocular Surface Microbiota in Healthy Adults/Experiment 2
• The Influence of Age and Sex on Ocular Surface Microbiota in Healthy Adults/Experiment 2/Signature 1
• The Influence of Age and Sex on Ocular Surface Microbiota in Healthy Adults/Experiment 2/Signature 2
• Vaginal microbiome of women with adenomyosis: A case-control study/Experiment 1/Signature 1
• Stratification of the Gut Microbiota Composition Landscape across the Alzheimer's Disease Continuum in a Turkish Cohort
• Stratification of the Gut Microbiota Composition Landscape across the Alzheimer's Disease Continuum in a Turkish Cohort/Experiment 1/Signature 1
• Stratification of the Gut Microbiota Composition Landscape across the Alzheimer's Disease Continuum in a Turkish Cohort/Experiment 1/Signature 2
• Stratification of the Gut Microbiota Composition Landscape across the Alzheimer's Disease Continuum in a Turkish Cohort/Experiment 2/Signature 1
• Stratification of the Gut Microbiota Composition Landscape across the Alzheimer's Disease Continuum in a Turkish Cohort/Experiment 2/Signature 2
• Depicting the landscape of gut microbial-metabolic interaction and microbial-host immune heterogeneity in deficient and proficient DNA mismatch repair colorectal cancers/Experiment 1/Signature 1
• Depicting the landscape of gut microbial-metabolic interaction and microbial-host immune heterogeneity in deficient and proficient DNA mismatch repair colorectal cancers/Experiment 1/Signature 2
• Depicting the landscape of gut microbial-metabolic interaction and microbial-host immune heterogeneity in deficient and proficient DNA mismatch repair colorectal cancers/Experiment 2/Signature 1
• Depicting the landscape of gut microbial-metabolic interaction and microbial-host immune heterogeneity in deficient and proficient DNA mismatch repair colorectal cancers/Experiment 3/Signature 1
• Depicting the landscape of gut microbial-metabolic interaction and microbial-host immune heterogeneity in deficient and proficient DNA mismatch repair colorectal cancers/Experiment 3/Signature 2
• Development of the oral resistome during the first decade of life
• Development of the oral resistome during the first decade of life/Experiment 1/Signature 1
• Development of the oral resistome during the first decade of life/Experiment 2/Signature 1
• Development of the oral resistome during the first decade of life/Experiment 2/Signature 2
• Development of the oral resistome during the first decade of life/Experiment 3/Signature 1
• Geographic Difference Shaped Human Ocular Surface Metagenome of Young Han Chinese From Beijing, Wenzhou, and Guangzhou Cities/Experiment 1/Signature 1
• Geographic Difference Shaped Human Ocular Surface Metagenome of Young Han Chinese From Beijing, Wenzhou, and Guangzhou Cities/Experiment 1/Signature 2
• Differential Responses to Dietary Protein and Carbohydrate Ratio on Gut Microbiome in Obese vs. Lean Cats/Experiment 1
• Differential Responses to Dietary Protein and Carbohydrate Ratio on Gut Microbiome in Obese vs. Lean Cats/Experiment 2/Signature 1
• Differential Responses to Dietary Protein and Carbohydrate Ratio on Gut Microbiome in Obese vs. Lean Cats/Experiment 3/Signature 1
• Differential Responses to Dietary Protein and Carbohydrate Ratio on Gut Microbiome in Obese vs. Lean Cats/Experiment 3/Signature 2
• Differential Responses to Dietary Protein and Carbohydrate Ratio on Gut Microbiome in Obese vs. Lean Cats/Experiment 4/Signature 1
• Differential Responses to Dietary Protein and Carbohydrate Ratio on Gut Microbiome in Obese vs. Lean Cats/Experiment 4/Signature 2
• Dynamic gut microbiome across life history of the malaria mosquito Anopheles gambiae in Kenya/Experiment 1
• Dynamic gut microbiome across life history of the malaria mosquito Anopheles gambiae in Kenya/Experiment 1/Signature 1
• Dynamic gut microbiome across life history of the malaria mosquito Anopheles gambiae in Kenya/Experiment 1/Signature 2
• Dynamic gut microbiome across life history of the malaria mosquito Anopheles gambiae in Kenya/Experiment 2
• Dynamic gut microbiome across life history of the malaria mosquito Anopheles gambiae in Kenya/Experiment 2/Signature 1
• Dynamic gut microbiome across life history of the malaria mosquito Anopheles gambiae in Kenya/Experiment 2/Signature 2
• Gut microbiome signatures reflect different subtypes of irritable bowel syndrome/Experiment 1
• Gut microbiome signatures reflect different subtypes of irritable bowel syndrome/Experiment 1/Signature 1
• Gut microbiome signatures reflect different subtypes of irritable bowel syndrome/Experiment 1/Signature 2
• Gut microbiome signatures reflect different subtypes of irritable bowel syndrome/Experiment 2
• Gut microbiome signatures reflect different subtypes of irritable bowel syndrome/Experiment 2/Signature 1
• Gut microbiome signatures reflect different subtypes of irritable bowel syndrome/Experiment 2/Signature 2
• Gut microbiome signatures reflect different subtypes of irritable bowel syndrome/Experiment 3
• Gut microbiome signatures reflect different subtypes of irritable bowel syndrome/Experiment 3/Signature 1
• Gut microbiome signatures reflect different subtypes of irritable bowel syndrome/Experiment 3/Signature 2
• Gut microbiome signatures reflect different subtypes of irritable bowel syndrome/Experiment 4
• Gut microbiome signatures reflect different subtypes of irritable bowel syndrome/Experiment 4/Signature 1
• Gut microbiome signatures reflect different subtypes of irritable bowel syndrome/Experiment 4/Signature 2
• Gut microbiome signatures reflect different subtypes of irritable bowel syndrome/Experiment 5
• Gut microbiome signatures reflect different subtypes of irritable bowel syndrome/Experiment 5/Signature 1
• Gut microbiome signatures reflect different subtypes of irritable bowel syndrome/Experiment 5/Signature 2
• Gut microbiome signatures reflect different subtypes of irritable bowel syndrome/Experiment 6
• Gut microbiome signatures reflect different subtypes of irritable bowel syndrome/Experiment 6/Signature 1
• Gut microbiome signatures reflect different subtypes of irritable bowel syndrome/Experiment 6/Signature 2
• Gut microbiome signatures reflect different subtypes of irritable bowel syndrome/Experiment 7
• Gut microbiome signatures reflect different subtypes of irritable bowel syndrome/Experiment 7/Signature 1
• Gut microbiome signatures reflect different subtypes of irritable bowel syndrome/Experiment 7/Signature 2
• Breast cancer patients from the Midwest region of the United States have reduced levels of short-chain fatty acid-producing gut bacteria/Experiment 1/Signature 1
• Breast cancer patients from the Midwest region of the United States have reduced levels of short-chain fatty acid-producing gut bacteria/Experiment 1/Signature 2
• Urinary Microbiome and Psychological Factors in Women with Overactive Bladder/Experiment 1/Signature 1
• Urinary Microbiome and Psychological Factors in Women with Overactive Bladder/Experiment 1/Signature 2
• Urinary Microbiome and Psychological Factors in Women with Overactive Bladder/Experiment 2
• Urinary Microbiome and Psychological Factors in Women with Overactive Bladder/Experiment 2/Signature 1
• Urinary Microbiome and Psychological Factors in Women with Overactive Bladder/Experiment 2/Signature 2
• Urinary Microbiome and Psychological Factors in Women with Overactive Bladder/Experiment 3/Signature 1
• A Comparison of Tumor-Associated and Non-Tumor-Associated Gastric Microbiota in Gastric Cancer Patients/Experiment 1/Signature 2
• A Comparison of Tumor-Associated and Non-Tumor-Associated Gastric Microbiota in Gastric Cancer Patients/Experiment 2
• Gastrointestinal symptoms of long COVID-19 related to the ectopic colonization of specific bacteria that move between the upper and lower alimentary tract and alterations in serum metabolites/Experiment 1/Signature 1
• Gastrointestinal symptoms of long COVID-19 related to the ectopic colonization of specific bacteria that move between the upper and lower alimentary tract and alterations in serum metabolites/Experiment 2/Signature 1
• Assessment of microbiota in the gut and upper respiratory tract associated with SARS-CoV-2 infection
• Assessment of microbiota in the gut and upper respiratory tract associated with SARS-CoV-2 infection/Experiment 1/Signature 1
• Assessment of microbiota in the gut and upper respiratory tract associated with SARS-CoV-2 infection/Experiment 1/Signature 2
• Assessment of microbiota in the gut and upper respiratory tract associated with SARS-CoV-2 infection/Experiment 2/Signature 1
• Assessment of microbiota in the gut and upper respiratory tract associated with SARS-CoV-2 infection/Experiment 2/Signature 2
• Assessment of microbiota in the gut and upper respiratory tract associated with SARS-CoV-2 infection/Experiment 3
• Assessment of microbiota in the gut and upper respiratory tract associated with SARS-CoV-2 infection/Experiment 3/Signature 1
• Assessment of microbiota in the gut and upper respiratory tract associated with SARS-CoV-2 infection/Experiment 3/Signature 2
• Metagenomic assessment of gut microbial communities and risk of severe COVID-19/Experiment 1
• Metagenomic assessment of gut microbial communities and risk of severe COVID-19/Experiment 1/Signature 1
• Metagenomic assessment of gut microbial communities and risk of severe COVID-19/Experiment 1/Signature 2
• Compositional changes in fecal microbiota associated with clinical phenotypes and prognosis in Korean patients with inflammatory bowel disease/Experiment 1
• Compositional changes in fecal microbiota associated with clinical phenotypes and prognosis in Korean patients with inflammatory bowel disease/Experiment 1/Signature 1
• Compositional changes in fecal microbiota associated with clinical phenotypes and prognosis in Korean patients with inflammatory bowel disease/Experiment 1/Signature 2
• Compositional changes in fecal microbiota associated with clinical phenotypes and prognosis in Korean patients with inflammatory bowel disease/Experiment 2/Signature 1
• Compositional changes in fecal microbiota associated with clinical phenotypes and prognosis in Korean patients with inflammatory bowel disease/Experiment 2/Signature 2
• Compositional changes in fecal microbiota associated with clinical phenotypes and prognosis in Korean patients with inflammatory bowel disease/Experiment 3/Signature 1
• Compositional changes in fecal microbiota associated with clinical phenotypes and prognosis in Korean patients with inflammatory bowel disease/Experiment 3/Signature 2
• Compositional changes in fecal microbiota associated with clinical phenotypes and prognosis in Korean patients with inflammatory bowel disease/Experiment 4
• Compositional changes in fecal microbiota associated with clinical phenotypes and prognosis in Korean patients with inflammatory bowel disease/Experiment 4/Signature 1
• Compositional changes in fecal microbiota associated with clinical phenotypes and prognosis in Korean patients with inflammatory bowel disease/Experiment 4/Signature 2
• Compositional changes in fecal microbiota associated with clinical phenotypes and prognosis in Korean patients with inflammatory bowel disease/Experiment 5
• Compositional changes in fecal microbiota associated with clinical phenotypes and prognosis in Korean patients with inflammatory bowel disease/Experiment 5/Signature 1
• Compositional changes in fecal microbiota associated with clinical phenotypes and prognosis in Korean patients with inflammatory bowel disease/Experiment 5/Signature 2
• Compositional changes in fecal microbiota associated with clinical phenotypes and prognosis in Korean patients with inflammatory bowel disease/Experiment 6
• Compositional changes in fecal microbiota associated with clinical phenotypes and prognosis in Korean patients with inflammatory bowel disease/Experiment 6/Signature 1
• Compositional changes in fecal microbiota associated with clinical phenotypes and prognosis in Korean patients with inflammatory bowel disease/Experiment 6/Signature 2
• Compositional changes in fecal microbiota associated with clinical phenotypes and prognosis in Korean patients with inflammatory bowel disease/Experiment 7/Signature 1
• Compositional changes in fecal microbiota associated with clinical phenotypes and prognosis in Korean patients with inflammatory bowel disease/Experiment 7/Signature 2
• Exploring the gut microbiota in patients with pre-diabetes and treatment naïve diabetes type 2 - a pilot study/Experiment 1/Signature 1
• Exploring the gut microbiota in patients with pre-diabetes and treatment naïve diabetes type 2 - a pilot study/Experiment 1/Signature 2
• Exploring the gut microbiota in patients with pre-diabetes and treatment naïve diabetes type 2 - a pilot study/Experiment 2/Signature 1
• Exploring the gut microbiota in patients with pre-diabetes and treatment naïve diabetes type 2 - a pilot study/Experiment 2/Signature 2
• Exploring the gut microbiota in patients with pre-diabetes and treatment naïve diabetes type 2 - a pilot study/Experiment 3/Signature 1
• Exploring the gut microbiota in patients with pre-diabetes and treatment naïve diabetes type 2 - a pilot study/Experiment 3/Signature 2
• Exploring the gut microbiota in patients with pre-diabetes and treatment naïve diabetes type 2 - a pilot study/Experiment 4/Signature 1
• Exploring the gut microbiota in patients with pre-diabetes and treatment naïve diabetes type 2 - a pilot study/Experiment 4/Signature 2
• Differential Dynamics of the Ruminal Microbiome of Jersey Cows in a Heat Stress Environment/Experiment 1
• Differential Dynamics of the Ruminal Microbiome of Jersey Cows in a Heat Stress Environment/Experiment 1/Signature 1
• Differential Dynamics of the Ruminal Microbiome of Jersey Cows in a Heat Stress Environment/Experiment 1/Signature 2
• Differential Dynamics of the Ruminal Microbiome of Jersey Cows in a Heat Stress Environment/Experiment 2
• Differential Dynamics of the Ruminal Microbiome of Jersey Cows in a Heat Stress Environment/Experiment 2/Signature 1
• Differential Dynamics of the Ruminal Microbiome of Jersey Cows in a Heat Stress Environment/Experiment 2/Signature 2
• Composition and Functional Potential of the Human Mammary Microbiota Prior to and Following Breast Tumor Diagnosis
• Composition and Functional Potential of the Human Mammary Microbiota Prior to and Following Breast Tumor Diagnosis/Experiment 1
• Composition and Functional Potential of the Human Mammary Microbiota Prior to and Following Breast Tumor Diagnosis/Experiment 1/Signature 1
• Composition and Functional Potential of the Human Mammary Microbiota Prior to and Following Breast Tumor Diagnosis/Experiment 1/Signature 2
• Composition and Functional Potential of the Human Mammary Microbiota Prior to and Following Breast Tumor Diagnosis/Experiment 2
• Composition and Functional Potential of the Human Mammary Microbiota Prior to and Following Breast Tumor Diagnosis/Experiment 2/Signature 1
• Composition and Functional Potential of the Human Mammary Microbiota Prior to and Following Breast Tumor Diagnosis/Experiment 2/Signature 2
• Composition and Functional Potential of the Human Mammary Microbiota Prior to and Following Breast Tumor Diagnosis/Experiment 3
• Composition and Functional Potential of the Human Mammary Microbiota Prior to and Following Breast Tumor Diagnosis/Experiment 3/Signature 1
• Composition and Functional Potential of the Human Mammary Microbiota Prior to and Following Breast Tumor Diagnosis/Experiment 3/Signature 2
• Targeted Analysis of the Gut Microbiome for Diagnosis, Prognosis and Treatment Individualization in Pediatric Inflammatory Bowel Disease/Experiment 1
• Targeted Analysis of the Gut Microbiome for Diagnosis, Prognosis and Treatment Individualization in Pediatric Inflammatory Bowel Disease/Experiment 2
• Targeted Analysis of the Gut Microbiome for Diagnosis, Prognosis and Treatment Individualization in Pediatric Inflammatory Bowel Disease/Experiment 3
• Targeted Analysis of the Gut Microbiome for Diagnosis, Prognosis and Treatment Individualization in Pediatric Inflammatory Bowel Disease/Experiment 3/Signature 2
• Targeted Analysis of the Gut Microbiome for Diagnosis, Prognosis and Treatment Individualization in Pediatric Inflammatory Bowel Disease/Experiment 4
• Targeted Analysis of the Gut Microbiome for Diagnosis, Prognosis and Treatment Individualization in Pediatric Inflammatory Bowel Disease/Experiment 5
• Targeted Analysis of the Gut Microbiome for Diagnosis, Prognosis and Treatment Individualization in Pediatric Inflammatory Bowel Disease/Experiment 6
• Targeted Analysis of the Gut Microbiome for Diagnosis, Prognosis and Treatment Individualization in Pediatric Inflammatory Bowel Disease/Experiment 6/Signature 1
• Shotgun sequencing of the vaginal microbiome reveals both a species and functional potential signature of preterm birth/Experiment 1
• Shotgun sequencing of the vaginal microbiome reveals both a species and functional potential signature of preterm birth/Experiment 1/Signature 1
• Shotgun sequencing of the vaginal microbiome reveals both a species and functional potential signature of preterm birth/Experiment 1/Signature 2
• Shotgun sequencing of the vaginal microbiome reveals both a species and functional potential signature of preterm birth/Experiment 2
• Shotgun sequencing of the vaginal microbiome reveals both a species and functional potential signature of preterm birth/Experiment 2/Signature 1
• Shotgun sequencing of the vaginal microbiome reveals both a species and functional potential signature of preterm birth/Experiment 2/Signature 2
• Shotgun sequencing of the vaginal microbiome reveals both a species and functional potential signature of preterm birth/Experiment 3
• Shotgun sequencing of the vaginal microbiome reveals both a species and functional potential signature of preterm birth/Experiment 3/Signature 1
• Shotgun sequencing of the vaginal microbiome reveals both a species and functional potential signature of preterm birth/Experiment 3/Signature 2
• Characterizing both bacteria and fungi improves understanding of the Arabidopsis root microbiome/Experiment 1/Signature 1
• Characterizing both bacteria and fungi improves understanding of the Arabidopsis root microbiome/Experiment 1/Signature 2
• Cerebral small vessel disease burden is associated with decreased abundance of gut Barnesiella intestinihominis bacterium in the Framingham Heart Study/Experiment 1/Signature 1
• Cerebral small vessel disease burden is associated with decreased abundance of gut Barnesiella intestinihominis bacterium in the Framingham Heart Study/Experiment 1/Signature 2
• Cerebral small vessel disease burden is associated with decreased abundance of gut Barnesiella intestinihominis bacterium in the Framingham Heart Study/Experiment 2
• Cerebral small vessel disease burden is associated with decreased abundance of gut Barnesiella intestinihominis bacterium in the Framingham Heart Study/Experiment 2/Signature 1
• Cerebral small vessel disease burden is associated with decreased abundance of gut Barnesiella intestinihominis bacterium in the Framingham Heart Study/Experiment 2/Signature 2
• Cerebral small vessel disease burden is associated with decreased abundance of gut Barnesiella intestinihominis bacterium in the Framingham Heart Study/Experiment 3
• Cerebral small vessel disease burden is associated with decreased abundance of gut Barnesiella intestinihominis bacterium in the Framingham Heart Study/Experiment 3/Signature 1
• Cerebral small vessel disease burden is associated with decreased abundance of gut Barnesiella intestinihominis bacterium in the Framingham Heart Study/Experiment 3/Signature 2
• Gut microbiota display alternative profiles in patients with early-onset colorectal cancer/Experiment 1
• Gut microbiota display alternative profiles in patients with early-onset colorectal cancer/Experiment 1/Signature 1
• The upper respiratory tract microbiota of healthy adults is affected by Streptococcus pneumoniae carriage, smoking habits, and contact with children
• The upper respiratory tract microbiota of healthy adults is affected by Streptococcus pneumoniae carriage, smoking habits, and contact with children/Experiment 1/Signature 1
• The upper respiratory tract microbiota of healthy adults is affected by Streptococcus pneumoniae carriage, smoking habits, and contact with children/Experiment 1/Signature 2
• The upper respiratory tract microbiota of healthy adults is affected by Streptococcus pneumoniae carriage, smoking habits, and contact with children/Experiment 2/Signature 1
• The upper respiratory tract microbiota of healthy adults is affected by Streptococcus pneumoniae carriage, smoking habits, and contact with children/Experiment 2/Signature 2
• The upper respiratory tract microbiota of healthy adults is affected by Streptococcus pneumoniae carriage, smoking habits, and contact with children/Experiment 3/Signature 1
• The upper respiratory tract microbiota of healthy adults is affected by Streptococcus pneumoniae carriage, smoking habits, and contact with children/Experiment 3/Signature 2
• The upper respiratory tract microbiota of healthy adults is affected by Streptococcus pneumoniae carriage, smoking habits, and contact with children/Experiment 4/Signature 1
• The upper respiratory tract microbiota of healthy adults is affected by Streptococcus pneumoniae carriage, smoking habits, and contact with children/Experiment 4/Signature 2
• The upper respiratory tract microbiota of healthy adults is affected by Streptococcus pneumoniae carriage, smoking habits, and contact with children/Experiment 5
• The upper respiratory tract microbiota of healthy adults is affected by Streptococcus pneumoniae carriage, smoking habits, and contact with children/Experiment 5/Signature 1
• The upper respiratory tract microbiota of healthy adults is affected by Streptococcus pneumoniae carriage, smoking habits, and contact with children/Experiment 5/Signature 2
• The upper respiratory tract microbiota of healthy adults is affected by Streptococcus pneumoniae carriage, smoking habits, and contact with children/Experiment 6
• The upper respiratory tract microbiota of healthy adults is affected by Streptococcus pneumoniae carriage, smoking habits, and contact with children/Experiment 6/Signature 1
• The upper respiratory tract microbiota of healthy adults is affected by Streptococcus pneumoniae carriage, smoking habits, and contact with children/Experiment 6/Signature 2
• The small bowel microbiome changes significantly with age and aspects of the ageing process/Experiment 1
• The small bowel microbiome changes significantly with age and aspects of the ageing process/Experiment 1/Signature 1
• The small bowel microbiome changes significantly with age and aspects of the ageing process/Experiment 1/Signature 2
• The small bowel microbiome changes significantly with age and aspects of the ageing process/Experiment 2
• The small bowel microbiome changes significantly with age and aspects of the ageing process/Experiment 2/Signature 1
• Lower respiratory tract microbiome composition and community interactions in smokers/Experiment 1/Signature 1
• Lower respiratory tract microbiome composition and community interactions in smokers/Experiment 1/Signature 2
• Lower respiratory tract microbiome composition and community interactions in smokers/Experiment 2/Signature 1
• Lower respiratory tract microbiome composition and community interactions in smokers/Experiment 2/Signature 2
• Lower respiratory tract microbiome composition and community interactions in smokers/Experiment 3/Signature 1
• Lower respiratory tract microbiome composition and community interactions in smokers/Experiment 3/Signature 2
• Lower respiratory tract microbiome composition and community interactions in smokers/Experiment 4
• Lower respiratory tract microbiome composition and community interactions in smokers/Experiment 4/Signature 1
• Lower respiratory tract microbiome composition and community interactions in smokers/Experiment 5/Signature 1
• Lower respiratory tract microbiome composition and community interactions in smokers/Experiment 6/Signature 1
• Lower respiratory tract microbiome composition and community interactions in smokers/Experiment 7/Signature 1
• Sputum Microbiome and Chronic Obstructive Pulmonary Disease in a Rural Ugandan Cohort of Well-Controlled HIV Infection/Experiment 1/Signature 1
• Sputum Microbiome and Chronic Obstructive Pulmonary Disease in a Rural Ugandan Cohort of Well-Controlled HIV Infection/Experiment 1/Signature 2
• Sputum Microbiome and Chronic Obstructive Pulmonary Disease in a Rural Ugandan Cohort of Well-Controlled HIV Infection/Experiment 2
• Sputum Microbiome and Chronic Obstructive Pulmonary Disease in a Rural Ugandan Cohort of Well-Controlled HIV Infection/Experiment 2/Signature 1
• Sputum Microbiome and Chronic Obstructive Pulmonary Disease in a Rural Ugandan Cohort of Well-Controlled HIV Infection/Experiment 2/Signature 2
• A comparison of the infant gut microbiome before versus after the start of the covid-19 pandemic/Experiment 2/Signature 1
• A comparison of the infant gut microbiome before versus after the start of the covid-19 pandemic/Experiment 2/Signature 2
• The impact of cancer cachexia on gut microbiota composition and short-chain fatty acid metabolism in a murine model/Experiment 1/Signature 1
• The impact of cancer cachexia on gut microbiota composition and short-chain fatty acid metabolism in a murine model/Experiment 1/Signature 2
• Microbiome diversity in African American, European American, and Egyptian colorectal cancer patients/Experiment 1
• Microbiome diversity in African American, European American, and Egyptian colorectal cancer patients/Experiment 1/Signature 1
• Microbiome diversity in African American, European American, and Egyptian colorectal cancer patients/Experiment 1/Signature 2
• Microbiome diversity in African American, European American, and Egyptian colorectal cancer patients/Experiment 2
• Microbiome diversity in African American, European American, and Egyptian colorectal cancer patients/Experiment 2/Signature 1
• Microbiome diversity in African American, European American, and Egyptian colorectal cancer patients/Experiment 2/Signature 2
• Microbiome diversity in African American, European American, and Egyptian colorectal cancer patients/Experiment 3
• Microbiome diversity in African American, European American, and Egyptian colorectal cancer patients/Experiment 3/Signature 1
• Microbiome diversity in African American, European American, and Egyptian colorectal cancer patients/Experiment 3/Signature 2
• Microbiome diversity in African American, European American, and Egyptian colorectal cancer patients/Experiment 4
• Microbiome diversity in African American, European American, and Egyptian colorectal cancer patients/Experiment 4/Signature 1
• Microbiome diversity in African American, European American, and Egyptian colorectal cancer patients/Experiment 5
• Microbiome diversity in African American, European American, and Egyptian colorectal cancer patients/Experiment 5/Signature 1
• Microbiome diversity in African American, European American, and Egyptian colorectal cancer patients/Experiment 6
• Microbiome diversity in African American, European American, and Egyptian colorectal cancer patients/Experiment 6/Signature 1
• Microbiome diversity in African American, European American, and Egyptian colorectal cancer patients/Experiment 7
• Microbiome diversity in African American, European American, and Egyptian colorectal cancer patients/Experiment 7/Signature 1
• Gut microbiota-derived metabolites mediate the neuroprotective effect of melatonin in cognitive impairment induced by sleep deprivation/Experiment 1/Signature 1
• Gut microbiota-derived metabolites mediate the neuroprotective effect of melatonin in cognitive impairment induced by sleep deprivation/Experiment 2
• Gut microbiota-derived metabolites mediate the neuroprotective effect of melatonin in cognitive impairment induced by sleep deprivation/Experiment 2/Signature 1
• Gut microbiota-derived metabolites mediate the neuroprotective effect of melatonin in cognitive impairment induced by sleep deprivation/Experiment 2/Signature 2
• Gut microbiota-derived metabolites mediate the neuroprotective effect of melatonin in cognitive impairment induced by sleep deprivation/Experiment 3
• Gut microbiota-derived metabolites mediate the neuroprotective effect of melatonin in cognitive impairment induced by sleep deprivation/Experiment 3/Signature 1
• The gut-microbiota-brain axis in a Spanish population in the aftermath of the COVID-19 pandemic: microbiota composition linked to anxiety, trauma, and depression profiles/Experiment 1
• The gut-microbiota-brain axis in a Spanish population in the aftermath of the COVID-19 pandemic: microbiota composition linked to anxiety, trauma, and depression profiles/Experiment 1/Signature 1
• The gut-microbiota-brain axis in a Spanish population in the aftermath of the COVID-19 pandemic: microbiota composition linked to anxiety, trauma, and depression profiles/Experiment 2
• The gut-microbiota-brain axis in a Spanish population in the aftermath of the COVID-19 pandemic: microbiota composition linked to anxiety, trauma, and depression profiles/Experiment 2/Signature 1
• The gut-microbiota-brain axis in a Spanish population in the aftermath of the COVID-19 pandemic: microbiota composition linked to anxiety, trauma, and depression profiles/Experiment 3
• The gut-microbiota-brain axis in a Spanish population in the aftermath of the COVID-19 pandemic: microbiota composition linked to anxiety, trauma, and depression profiles/Experiment 3/Signature 1
• The gut-microbiota-brain axis in a Spanish population in the aftermath of the COVID-19 pandemic: microbiota composition linked to anxiety, trauma, and depression profiles/Experiment 3/Signature 2
• The gut-microbiota-brain axis in a Spanish population in the aftermath of the COVID-19 pandemic: microbiota composition linked to anxiety, trauma, and depression profiles/Experiment 4/Signature 1
• The gut-microbiota-brain axis in a Spanish population in the aftermath of the COVID-19 pandemic: microbiota composition linked to anxiety, trauma, and depression profiles/Experiment 4/Signature 2
• Gut Microbial Signatures Can Discriminate Unipolar from Bipolar Depression/Experiment 3
• Enrichment of human nasopharyngeal bacteriome with bacteria from dust after short-term exposure to indoor environment: a pilot study/Experiment 1
• Enrichment of human nasopharyngeal bacteriome with bacteria from dust after short-term exposure to indoor environment: a pilot study/Experiment 1/Signature 1
• Dysbiosis and Implication of the Gut Microbiota in Diabetic Retinopathy/Experiment 1
• Dysbiosis and Implication of the Gut Microbiota in Diabetic Retinopathy/Experiment 2
• Dysbiosis and Implication of the Gut Microbiota in Diabetic Retinopathy/Experiment 3
• Alterations in the vaginal microbiota of patients with preterm premature rupture of membranes
• Alterations in the vaginal microbiota of patients with preterm premature rupture of membranes/Experiment 1/Signature 1
• Alterations in the vaginal microbiota of patients with preterm premature rupture of membranes/Experiment 1/Signature 2
• The gut microbiota profile in psoriasis: a Brazilian case-control study/Experiment 1/Signature 1
• The gut microbiota profile in psoriasis: a Brazilian case-control study/Experiment 1/Signature 2
• Recurrent urinary tract infection and estrogen shape the taxonomic ecology and function of the postmenopausal urogenital microbiome/Experiment 1
• Recurrent urinary tract infection and estrogen shape the taxonomic ecology and function of the postmenopausal urogenital microbiome/Experiment 1/Signature 1
• Recurrent urinary tract infection and estrogen shape the taxonomic ecology and function of the postmenopausal urogenital microbiome/Experiment 1/Signature 2
• Recurrent urinary tract infection and estrogen shape the taxonomic ecology and function of the postmenopausal urogenital microbiome/Experiment 2
• Recurrent urinary tract infection and estrogen shape the taxonomic ecology and function of the postmenopausal urogenital microbiome/Experiment 2/Signature 1
• Recurrent urinary tract infection and estrogen shape the taxonomic ecology and function of the postmenopausal urogenital microbiome/Experiment 2/Signature 2
• Recurrent urinary tract infection and estrogen shape the taxonomic ecology and function of the postmenopausal urogenital microbiome/Experiment 3
• The aging mouse microbiome has obesogenic characteristics/Experiment 2
• Gastrointestinal tract involvement in systemic sclerosis: The roles of diet and the microbiome
• Gastrointestinal tract involvement in systemic sclerosis: The roles of diet and the microbiome/Experiment 1
• Gastrointestinal tract involvement in systemic sclerosis: The roles of diet and the microbiome/Experiment 1/Signature 1
• Gastrointestinal tract involvement in systemic sclerosis: The roles of diet and the microbiome/Experiment 1/Signature 2
• Gastrointestinal tract involvement in systemic sclerosis: The roles of diet and the microbiome/Experiment 2
• Gastrointestinal tract involvement in systemic sclerosis: The roles of diet and the microbiome/Experiment 2/Signature 1
• Gastrointestinal tract involvement in systemic sclerosis: The roles of diet and the microbiome/Experiment 2/Signature 2
• Gastrointestinal tract involvement in systemic sclerosis: The roles of diet and the microbiome/Experiment 3
• Gastrointestinal tract involvement in systemic sclerosis: The roles of diet and the microbiome/Experiment 3/Signature 1
• Gastrointestinal tract involvement in systemic sclerosis: The roles of diet and the microbiome/Experiment 3/Signature 2
• Gastrointestinal tract involvement in systemic sclerosis: The roles of diet and the microbiome/Experiment 4/Signature 1
• Gastrointestinal tract involvement in systemic sclerosis: The roles of diet and the microbiome/Experiment 4/Signature 2
• Longitudinal disease-associated gut microbiome differences in infants with food protein-induced allergic proctocolitis/Experiment 1
• Longitudinal disease-associated gut microbiome differences in infants with food protein-induced allergic proctocolitis/Experiment 1/Signature 1
• Longitudinal disease-associated gut microbiome differences in infants with food protein-induced allergic proctocolitis/Experiment 1/Signature 2
• Changes in gut microbiota composition and diversity associated with post-cholecystectomy diarrhea/Experiment 1/Signature 1
• Changes in gut microbiota composition and diversity associated with post-cholecystectomy diarrhea/Experiment 2
• Changes in gut microbiota composition and diversity associated with post-cholecystectomy diarrhea/Experiment 2/Signature 1
• Changes in gut microbiota composition and diversity associated with post-cholecystectomy diarrhea/Experiment 2/Signature 2
• Delayed gut microbiota maturation in the first year of life is a hallmark of pediatric allergic disease/Experiment 1/Signature 1
• Delayed gut microbiota maturation in the first year of life is a hallmark of pediatric allergic disease/Experiment 1/Signature 2
• Alterations in the oral microbiome in HIV-infected participants after antiretroviral therapy administration are influenced by immune status/Experiment 1
• Alterations in the oral microbiome in HIV-infected participants after antiretroviral therapy administration are influenced by immune status/Experiment 2
• Alterations in the oral microbiome in HIV-infected participants after antiretroviral therapy administration are influenced by immune status/Experiment 2/Signature 1
• Alterations in the oral microbiome in HIV-infected participants after antiretroviral therapy administration are influenced by immune status/Experiment 2/Signature 2
• Alterations in the oral microbiome in HIV-infected participants after antiretroviral therapy administration are influenced by immune status/Experiment 3
• Alterations in the oral microbiome in HIV-infected participants after antiretroviral therapy administration are influenced by immune status/Experiment 3/Signature 1
• Alterations in the oral microbiome in HIV-infected participants after antiretroviral therapy administration are influenced by immune status/Experiment 4
• Alterations in the oral microbiome in HIV-infected participants after antiretroviral therapy administration are influenced by immune status/Experiment 4/Signature 1
• Antibiotic treatment using amoxicillin-clavulanic acid impairs gut mycobiota development through modification of the bacterial ecosystem
• Antibiotic treatment using amoxicillin-clavulanic acid impairs gut mycobiota development through modification of the bacterial ecosystem/Experiment 1/Signature 2
• Antibiotic treatment using amoxicillin-clavulanic acid impairs gut mycobiota development through modification of the bacterial ecosystem/Experiment 2/Signature 2
• Ambient temperature alters body size and gut microbiota of Xenopus tropicalis/Experiment 1/Signature 1
• Ambient temperature alters body size and gut microbiota of Xenopus tropicalis/Experiment 1/Signature 2
• Sputum bacterial load and bacterial composition correlate with lung function and are altered by long-term azithromycin treatment in children with HIV-associated chronic lung disease
• Sputum bacterial load and bacterial composition correlate with lung function and are altered by long-term azithromycin treatment in children with HIV-associated chronic lung disease/Experiment 1/Signature 1
• Sputum bacterial load and bacterial composition correlate with lung function and are altered by long-term azithromycin treatment in children with HIV-associated chronic lung disease/Experiment 2/Signature 1
• Sputum bacterial load and bacterial composition correlate with lung function and are altered by long-term azithromycin treatment in children with HIV-associated chronic lung disease/Experiment 3/Signature 1
• Sputum bacterial load and bacterial composition correlate with lung function and are altered by long-term azithromycin treatment in children with HIV-associated chronic lung disease/Experiment 4/Signature 1
• Sputum bacterial load and bacterial composition correlate with lung function and are altered by long-term azithromycin treatment in children with HIV-associated chronic lung disease/Experiment 5
• Sputum bacterial load and bacterial composition correlate with lung function and are altered by long-term azithromycin treatment in children with HIV-associated chronic lung disease/Experiment 5/Signature 1
• Changes in salivary microbiota due to gastric cancer resection and its relation to gastric fluid microbiota/Experiment 2
• Rare phylotypes in stone, stool, and urine microbiomes are associated with urinary stone disease/Experiment 1/Signature 1
• Rare phylotypes in stone, stool, and urine microbiomes are associated with urinary stone disease/Experiment 2/Signature 1
• Long-term follow-up of colorectal cancer screening attendees identifies differences in Phascolarctobacterium spp. using 16S rRNA and metagenome sequencing
• Long-term follow-up of colorectal cancer screening attendees identifies differences in Phascolarctobacterium spp. using 16S rRNA and metagenome sequencing/Experiment 1
• Long-term follow-up of colorectal cancer screening attendees identifies differences in Phascolarctobacterium spp. using 16S rRNA and metagenome sequencing/Experiment 1/Signature 1
• Long-term follow-up of colorectal cancer screening attendees identifies differences in Phascolarctobacterium spp. using 16S rRNA and metagenome sequencing/Experiment 1/Signature 2
• Long-term follow-up of colorectal cancer screening attendees identifies differences in Phascolarctobacterium spp. using 16S rRNA and metagenome sequencing/Experiment 2
• Long-term follow-up of colorectal cancer screening attendees identifies differences in Phascolarctobacterium spp. using 16S rRNA and metagenome sequencing/Experiment 2/Signature 1
• Long-term follow-up of colorectal cancer screening attendees identifies differences in Phascolarctobacterium spp. using 16S rRNA and metagenome sequencing/Experiment 3
• Long-term follow-up of colorectal cancer screening attendees identifies differences in Phascolarctobacterium spp. using 16S rRNA and metagenome sequencing/Experiment 3/Signature 1
• Long-term follow-up of colorectal cancer screening attendees identifies differences in Phascolarctobacterium spp. using 16S rRNA and metagenome sequencing/Experiment 4/Signature 1
• Long-term follow-up of colorectal cancer screening attendees identifies differences in Phascolarctobacterium spp. using 16S rRNA and metagenome sequencing/Experiment 4/Signature 2
• Long-term follow-up of colorectal cancer screening attendees identifies differences in Phascolarctobacterium spp. using 16S rRNA and metagenome sequencing/Experiment 5
• Long-term follow-up of colorectal cancer screening attendees identifies differences in Phascolarctobacterium spp. using 16S rRNA and metagenome sequencing/Experiment 5/Signature 1
• Long-term follow-up of colorectal cancer screening attendees identifies differences in Phascolarctobacterium spp. using 16S rRNA and metagenome sequencing/Experiment 5/Signature 2
• Long-term follow-up of colorectal cancer screening attendees identifies differences in Phascolarctobacterium spp. using 16S rRNA and metagenome sequencing/Experiment 6
• Long-term follow-up of colorectal cancer screening attendees identifies differences in Phascolarctobacterium spp. using 16S rRNA and metagenome sequencing/Experiment 6/Signature 1
• Long-term follow-up of colorectal cancer screening attendees identifies differences in Phascolarctobacterium spp. using 16S rRNA and metagenome sequencing/Experiment 7
• Long-term follow-up of colorectal cancer screening attendees identifies differences in Phascolarctobacterium spp. using 16S rRNA and metagenome sequencing/Experiment 7/Signature 1
• Long-term follow-up of colorectal cancer screening attendees identifies differences in Phascolarctobacterium spp. using 16S rRNA and metagenome sequencing/Experiment 7/Signature 2
• Gallbladder microbiota composition is associated with pancreaticobiliary and gallbladder cancer prognosis/Experiment 1/Signature 1
• Gallbladder microbiota composition is associated with pancreaticobiliary and gallbladder cancer prognosis/Experiment 2/Signature 1
• Gallbladder microbiota composition is associated with pancreaticobiliary and gallbladder cancer prognosis/Experiment 2/Signature 2
• Gallbladder microbiota composition is associated with pancreaticobiliary and gallbladder cancer prognosis/Experiment 3/Signature 1
• Gallbladder microbiota composition is associated with pancreaticobiliary and gallbladder cancer prognosis/Experiment 4/Signature 1
• Gallbladder microbiota composition is associated with pancreaticobiliary and gallbladder cancer prognosis/Experiment 4/Signature 2
• Gallbladder microbiota composition is associated with pancreaticobiliary and gallbladder cancer prognosis/Experiment 5/Signature 1
• Gallbladder microbiota composition is associated with pancreaticobiliary and gallbladder cancer prognosis/Experiment 5/Signature 2
• Uncover a microbiota signature of upper respiratory tract in patients with SARS-CoV-2 + 
• Uncover a microbiota signature of upper respiratory tract in patients with SARS-CoV-2 + /Experiment 1
• Uncover a microbiota signature of upper respiratory tract in patients with SARS-CoV-2 + /Experiment 2
• Uncover a microbiota signature of upper respiratory tract in patients with SARS-CoV-2 + /Experiment 2/Signature 1
• Uncover a microbiota signature of upper respiratory tract in patients with SARS-CoV-2 + /Experiment 3/Signature 1
• Uncover a microbiota signature of upper respiratory tract in patients with SARS-CoV-2 + /Experiment 4
• Metagenomic Analysis Reveals the Heterogeneity of Conjunctival Microbiota Dysbiosis in Dry Eye Disease/Experiment 1/Signature 2
• Metagenomic Analysis Reveals the Heterogeneity of Conjunctival Microbiota Dysbiosis in Dry Eye Disease/Experiment 2
• Metagenomic Analysis Reveals the Heterogeneity of Conjunctival Microbiota Dysbiosis in Dry Eye Disease/Experiment 2/Signature 1
• Metagenomic Analysis Reveals the Heterogeneity of Conjunctival Microbiota Dysbiosis in Dry Eye Disease/Experiment 6/Signature 1
• Metagenomic Analysis Reveals the Heterogeneity of Conjunctival Microbiota Dysbiosis in Dry Eye Disease/Experiment 7/Signature 1
• Metagenomic Analysis Reveals the Heterogeneity of Conjunctival Microbiota Dysbiosis in Dry Eye Disease/Experiment 7/Signature 2
• Metagenomic Analysis Reveals the Heterogeneity of Conjunctival Microbiota Dysbiosis in Dry Eye Disease/Experiment 8
• Metagenomic Analysis Reveals the Heterogeneity of Conjunctival Microbiota Dysbiosis in Dry Eye Disease/Experiment 8/Signature 1
• Metagenomic Analysis Reveals the Heterogeneity of Conjunctival Microbiota Dysbiosis in Dry Eye Disease/Experiment 8/Signature 2
• Temporal changes in fecal microbiota of patients infected with COVID-19: a longitudinal cohort/Experiment 1
• Temporal changes in fecal microbiota of patients infected with COVID-19: a longitudinal cohort/Experiment 1/Signature 1
• Temporal changes in fecal microbiota of patients infected with COVID-19: a longitudinal cohort/Experiment 1/Signature 2
• Temporal changes in fecal microbiota of patients infected with COVID-19: a longitudinal cohort/Experiment 2
• Temporal changes in fecal microbiota of patients infected with COVID-19: a longitudinal cohort/Experiment 2/Signature 1
• Temporal changes in fecal microbiota of patients infected with COVID-19: a longitudinal cohort/Experiment 2/Signature 2
• Gut microbiome and atrial fibrillation-results from a large population-based study
• Gut microbiome and atrial fibrillation-results from a large population-based study/Experiment 1/Signature 1
• Gut microbiome and atrial fibrillation-results from a large population-based study/Experiment 1/Signature 2
• Gut microbiome and atrial fibrillation-results from a large population-based study/Experiment 2/Signature 1
• Gut microbiome and atrial fibrillation-results from a large population-based study/Experiment 2/Signature 2
• Multi-omics profiles of the intestinal microbiome in irritable bowel syndrome and its bowel habit subtypes
• Multi-omics profiles of the intestinal microbiome in irritable bowel syndrome and its bowel habit subtypes/Experiment 1
• Multi-omics profiles of the intestinal microbiome in irritable bowel syndrome and its bowel habit subtypes/Experiment 1/Signature 1
• Multi-omics profiles of the intestinal microbiome in irritable bowel syndrome and its bowel habit subtypes/Experiment 1/Signature 2
• Metagenomic sequencing reveals altered gut microbial compositions and gene functions in patients with non-segmental vitiligo/Experiment 1
• COVID-19 mRNA vaccine-mediated antibodies in human breast milk and their association with breast milk microbiota composition/Experiment 1
• COVID-19 mRNA vaccine-mediated antibodies in human breast milk and their association with breast milk microbiota composition/Experiment 1/Signature 1
• COVID-19 mRNA vaccine-mediated antibodies in human breast milk and their association with breast milk microbiota composition/Experiment 1/Signature 2
• COVID-19 mRNA vaccine-mediated antibodies in human breast milk and their association with breast milk microbiota composition/Experiment 2
• COVID-19 mRNA vaccine-mediated antibodies in human breast milk and their association with breast milk microbiota composition/Experiment 2/Signature 1
• COVID-19 mRNA vaccine-mediated antibodies in human breast milk and their association with breast milk microbiota composition/Experiment 2/Signature 2
• COVID-19 mRNA vaccine-mediated antibodies in human breast milk and their association with breast milk microbiota composition/Experiment 3/Signature 1
• COVID-19 mRNA vaccine-mediated antibodies in human breast milk and their association with breast milk microbiota composition/Experiment 3/Signature 2
• COVID-19 mRNA vaccine-mediated antibodies in human breast milk and their association with breast milk microbiota composition/Experiment 4
• COVID-19 mRNA vaccine-mediated antibodies in human breast milk and their association with breast milk microbiota composition/Experiment 4/Signature 1
• COVID-19 mRNA vaccine-mediated antibodies in human breast milk and their association with breast milk microbiota composition/Experiment 4/Signature 2
• COVID-19 mRNA vaccine-mediated antibodies in human breast milk and their association with breast milk microbiota composition/Experiment 5
• COVID-19 mRNA vaccine-mediated antibodies in human breast milk and their association with breast milk microbiota composition/Experiment 5/Signature 1
• COVID-19 mRNA vaccine-mediated antibodies in human breast milk and their association with breast milk microbiota composition/Experiment 5/Signature 2
• COVID-19 mRNA vaccine-mediated antibodies in human breast milk and their association with breast milk microbiota composition/Experiment 6
• COVID-19 mRNA vaccine-mediated antibodies in human breast milk and their association with breast milk microbiota composition/Experiment 6/Signature 1
• COVID-19 mRNA vaccine-mediated antibodies in human breast milk and their association with breast milk microbiota composition/Experiment 6/Signature 2
• Association Between Breastmilk Microbiota and Food Allergy in Infants/Experiment 1/Signature 1
• Association Between Breastmilk Microbiota and Food Allergy in Infants/Experiment 1/Signature 2
• Sex-specific differences in intestinal microbiota associated with cardiovascular diseases/Experiment 1/Signature 1
• Sex-specific differences in intestinal microbiota associated with cardiovascular diseases/Experiment 1/Signature 2
• Sex-specific differences in intestinal microbiota associated with cardiovascular diseases/Experiment 3/Signature 2
• Sex-specific differences in intestinal microbiota associated with cardiovascular diseases/Experiment 4/Signature 1
• Sex-specific differences in intestinal microbiota associated with cardiovascular diseases/Experiment 4/Signature 2
• Changes and significance of gut microbiota in children with focal epilepsy before and after treatment/Experiment 1
• Changes and significance of gut microbiota in children with focal epilepsy before and after treatment/Experiment 1/Signature 3
• Changes and significance of gut microbiota in children with focal epilepsy before and after treatment/Experiment 2
• Changes and significance of gut microbiota in children with focal epilepsy before and after treatment/Experiment 2/Signature 1
• Changes and significance of gut microbiota in children with focal epilepsy before and after treatment/Experiment 3
• Changes and significance of gut microbiota in children with focal epilepsy before and after treatment/Experiment 3/Signature 1
• Changes and significance of gut microbiota in children with focal epilepsy before and after treatment/Experiment 3/Signature 2
• Changes and significance of gut microbiota in children with focal epilepsy before and after treatment/Experiment 4/Signature 1
• Changes and significance of gut microbiota in children with focal epilepsy before and after treatment/Experiment 5/Signature 1
• Changes and significance of gut microbiota in children with focal epilepsy before and after treatment/Experiment 6
• Changes and significance of gut microbiota in children with focal epilepsy before and after treatment/Experiment 6/Signature 1
• Comparison of changes in fecal microbiota of calves with and without dam
• Comparison of changes in fecal microbiota of calves with and without dam/Experiment 1/Signature 1
• Comparison of changes in fecal microbiota of calves with and without dam/Experiment 1/Signature 2
• Comparison of changes in fecal microbiota of calves with and without dam/Experiment 2/Signature 1
• Comparison of changes in fecal microbiota of calves with and without dam/Experiment 2/Signature 2
• Comparison of changes in fecal microbiota of calves with and without dam/Experiment 3/Signature 1
• Comparison of changes in fecal microbiota of calves with and without dam/Experiment 3/Signature 2
• Vaginal Microbiome Metagenome Inference Accuracy: Differential Measurement Error according to Community Composition/Experiment 1
• Trans-ethnic gut microbiota signatures of type 2 diabetes in Denmark and India/Experiment 4
• Trans-ethnic gut microbiota signatures of type 2 diabetes in Denmark and India/Experiment 5
• Trans-ethnic gut microbiota signatures of type 2 diabetes in Denmark and India/Experiment 6
• Trans-ethnic gut microbiota signatures of type 2 diabetes in Denmark and India/Experiment 7
• Smoking and salivary microbiota: a cross-sectional analysis of an Italian alpine population/Experiment 1
• Smoking and salivary microbiota: a cross-sectional analysis of an Italian alpine population/Experiment 1/Signature 1
• Smoking and salivary microbiota: a cross-sectional analysis of an Italian alpine population/Experiment 1/Signature 2
• Learning machine approach reveals microbial signatures of diet and sex in dog/Experiment 1/Signature 1
• Learning machine approach reveals microbial signatures of diet and sex in dog/Experiment 1/Signature 2
• Learning machine approach reveals microbial signatures of diet and sex in dog/Experiment 2/Signature 1
• Learning machine approach reveals microbial signatures of diet and sex in dog/Experiment 3/Signature 1
• Learning machine approach reveals microbial signatures of diet and sex in dog/Experiment 3/Signature 2
• Learning machine approach reveals microbial signatures of diet and sex in dog/Experiment 4/Signature 1
• Learning machine approach reveals microbial signatures of diet and sex in dog/Experiment 4/Signature 2
• Taxonomic Characterization and Short-Chain Fatty Acids Production of the Obese Microbiota/Experiment 1/Signature 1
• Taxonomic Characterization and Short-Chain Fatty Acids Production of the Obese Microbiota/Experiment 1/Signature 2
• Association between inflammation, lipopolysaccharide binding protein, and gut microbiota composition in a New Hampshire Bhutanese refugee population with a high burden of type 2 diabetes
• Geography, niches, and transportation influence bovine respiratory microbiome and health/Experiment 1/Signature 1
• Geography, niches, and transportation influence bovine respiratory microbiome and health/Experiment 2
• Geography, niches, and transportation influence bovine respiratory microbiome and health/Experiment 2/Signature 1
• Geography, niches, and transportation influence bovine respiratory microbiome and health/Experiment 3
• Geography, niches, and transportation influence bovine respiratory microbiome and health/Experiment 4/Signature 1
• Geography, niches, and transportation influence bovine respiratory microbiome and health/Experiment 5/Signature 1
• Geography, niches, and transportation influence bovine respiratory microbiome and health/Experiment 6/Signature 1
• Geography, niches, and transportation influence bovine respiratory microbiome and health/Experiment 7
• Geography, niches, and transportation influence bovine respiratory microbiome and health/Experiment 7/Signature 1
• Geography, niches, and transportation influence bovine respiratory microbiome and health/Experiment 8/Signature 1
• Geography, niches, and transportation influence bovine respiratory microbiome and health/Experiment 9/Signature 1
• Geography, niches, and transportation influence bovine respiratory microbiome and health/Experiment 10
• Geography, niches, and transportation influence bovine respiratory microbiome and health/Experiment 10/Signature 1
• Geography, niches, and transportation influence bovine respiratory microbiome and health/Experiment 10/Signature 2
• Microbiome Survey of the Inflamed and Noninflamed Gut at Different Compartments Within the Gastrointestinal Tract of Inflammatory Bowel Disease Patients/Experiment 1/Signature 1
• Microbiome Survey of the Inflamed and Noninflamed Gut at Different Compartments Within the Gastrointestinal Tract of Inflammatory Bowel Disease Patients/Experiment 2/Signature 1
• Microbiome Survey of the Inflamed and Noninflamed Gut at Different Compartments Within the Gastrointestinal Tract of Inflammatory Bowel Disease Patients/Experiment 2/Signature 2
• Microbiome Survey of the Inflamed and Noninflamed Gut at Different Compartments Within the Gastrointestinal Tract of Inflammatory Bowel Disease Patients/Experiment 3
• Microbiome Survey of the Inflamed and Noninflamed Gut at Different Compartments Within the Gastrointestinal Tract of Inflammatory Bowel Disease Patients/Experiment 3/Signature 1
• Microbiome Survey of the Inflamed and Noninflamed Gut at Different Compartments Within the Gastrointestinal Tract of Inflammatory Bowel Disease Patients/Experiment 3/Signature 2
• Analysis of Conjunctival Sac Microbiome in Dry Eye Patients With and Without Sjögren's Syndrome/Experiment 1/Signature 1
• Analysis of Conjunctival Sac Microbiome in Dry Eye Patients With and Without Sjögren's Syndrome/Experiment 1/Signature 2
• Analysis of Conjunctival Sac Microbiome in Dry Eye Patients With and Without Sjögren's Syndrome/Experiment 2
• Analysis of Conjunctival Sac Microbiome in Dry Eye Patients With and Without Sjögren's Syndrome/Experiment 2/Signature 1
• Analysis of Conjunctival Sac Microbiome in Dry Eye Patients With and Without Sjögren's Syndrome/Experiment 2/Signature 2
• Analysis of Conjunctival Sac Microbiome in Dry Eye Patients With and Without Sjögren's Syndrome/Experiment 3/Signature 1
• Analysis of Conjunctival Sac Microbiome in Dry Eye Patients With and Without Sjögren's Syndrome/Experiment 3/Signature 2
• Tear film microbiome in Sjogren's and non-Sjogren's aqueous deficiency dry eye/Experiment 3/Signature 2
• The gut microbiome in social anxiety disorder: evidence of altered composition and function/Experiment 1
• The influence of liver transplantation on the interplay between gut microbiome and bile acid homeostasis in children with biliary atresia/Experiment 1
• The influence of liver transplantation on the interplay between gut microbiome and bile acid homeostasis in children with biliary atresia/Experiment 1/Signature 1
• The influence of liver transplantation on the interplay between gut microbiome and bile acid homeostasis in children with biliary atresia/Experiment 1/Signature 2
• The influence of liver transplantation on the interplay between gut microbiome and bile acid homeostasis in children with biliary atresia/Experiment 2
• The influence of liver transplantation on the interplay between gut microbiome and bile acid homeostasis in children with biliary atresia/Experiment 2/Signature 1
• The influence of liver transplantation on the interplay between gut microbiome and bile acid homeostasis in children with biliary atresia/Experiment 2/Signature 2
• Differences in gut microbiota between allergic rhinitis, atopic dermatitis, and skin urticaria: A pilot study/Experiment 1/Signature 1
• Differences in gut microbiota between allergic rhinitis, atopic dermatitis, and skin urticaria: A pilot study/Experiment 1/Signature 2
• Differences in gut microbiota between allergic rhinitis, atopic dermatitis, and skin urticaria: A pilot study/Experiment 2
• Differences in gut microbiota between allergic rhinitis, atopic dermatitis, and skin urticaria: A pilot study/Experiment 2/Signature 1
• Differences in gut microbiota between allergic rhinitis, atopic dermatitis, and skin urticaria: A pilot study/Experiment 2/Signature 2
• Gut Dysbiosis and Abnormal Bile Acid Metabolism in Colitis-Associated Cancer/Experiment 1
• Gut Dysbiosis and Abnormal Bile Acid Metabolism in Colitis-Associated Cancer/Experiment 1/Signature 1
• Gut Dysbiosis and Abnormal Bile Acid Metabolism in Colitis-Associated Cancer/Experiment 1/Signature 2
• Mucosal Microbiome in Patients with Early Bowel Polyps: Inferences from Short-Read and Long-Read 16S rRNA Sequencing/Experiment 1
• Mucosal Microbiome in Patients with Early Bowel Polyps: Inferences from Short-Read and Long-Read 16S rRNA Sequencing/Experiment 1/Signature 1
• Mucosal Microbiome in Patients with Early Bowel Polyps: Inferences from Short-Read and Long-Read 16S rRNA Sequencing/Experiment 1/Signature 2
• Mucosal Microbiome in Patients with Early Bowel Polyps: Inferences from Short-Read and Long-Read 16S rRNA Sequencing/Experiment 2/Signature 1
• Mucosal Microbiome in Patients with Early Bowel Polyps: Inferences from Short-Read and Long-Read 16S rRNA Sequencing/Experiment 2/Signature 2
• Association between Gut Microbiota and Breast Cancer: Diet as a Potential Modulating Factor/Experiment 1/Signature 1
• Association between Gut Microbiota and Breast Cancer: Diet as a Potential Modulating Factor/Experiment 1/Signature 2
• Study of microbiome changes in patients with ulcerative colitis in the Central European part of Russia/Experiment 1/Signature 1
• Study of microbiome changes in patients with ulcerative colitis in the Central European part of Russia/Experiment 1/Signature 2
• Gut Microbiota Associated with Clinical Relapse in Patients with Quiescent Ulcerative Colitis/Experiment 1/Signature 1
• Gut Microbiota Associated with Clinical Relapse in Patients with Quiescent Ulcerative Colitis/Experiment 1/Signature 2
• Gut Microbiota Associated with Clinical Relapse in Patients with Quiescent Ulcerative Colitis/Experiment 2/Signature 1
• Identifying microbial signatures for patients with postmenopausal osteoporosis using gut microbiota analyses and feature selection approaches/Experiment 1
• Microbiome features associated with performance measures in athletic and non-athletic individuals: A case-control study/Experiment 1/Signature 1
• Microbiome features associated with performance measures in athletic and non-athletic individuals: A case-control study/Experiment 2/Signature 1
• Microbiome features associated with performance measures in athletic and non-athletic individuals: A case-control study/Experiment 3/Signature 1
• Microbiome features associated with performance measures in athletic and non-athletic individuals: A case-control study/Experiment 3/Signature 2
• Microbiome features associated with performance measures in athletic and non-athletic individuals: A case-control study/Experiment 4/Signature 1
• Microbiome features associated with performance measures in athletic and non-athletic individuals: A case-control study/Experiment 4/Signature 2
• Microbiome features associated with performance measures in athletic and non-athletic individuals: A case-control study/Experiment 5/Signature 1
• Microbiome features associated with performance measures in athletic and non-athletic individuals: A case-control study/Experiment 6/Signature 1
• Microbiome features associated with performance measures in athletic and non-athletic individuals: A case-control study/Experiment 6/Signature 2
• Microbiome features associated with performance measures in athletic and non-athletic individuals: A case-control study/Experiment 7/Signature 1
• Microbiome features associated with performance measures in athletic and non-athletic individuals: A case-control study/Experiment 8/Signature 1
• Microbiome features associated with performance measures in athletic and non-athletic individuals: A case-control study/Experiment 9/Signature 1
• Microbiome features associated with performance measures in athletic and non-athletic individuals: A case-control study/Experiment 10/Signature 1
• Patients with Acne Vulgaris Have a Distinct Gut Microbiota in Comparison with Healthy Controls
• Patients with Acne Vulgaris Have a Distinct Gut Microbiota in Comparison with Healthy Controls/Experiment 1
• Patients with Acne Vulgaris Have a Distinct Gut Microbiota in Comparison with Healthy Controls/Experiment 1/Signature 1
• Patients with Acne Vulgaris Have a Distinct Gut Microbiota in Comparison with Healthy Controls/Experiment 1/Signature 2
• Favorable subgingival plaque microbiome shifts are associated with clinical treatment for peri-implant diseases/Experiment 2/Signature 1
• Favorable subgingival plaque microbiome shifts are associated with clinical treatment for peri-implant diseases/Experiment 3/Signature 1
• Favorable subgingival plaque microbiome shifts are associated with clinical treatment for peri-implant diseases/Experiment 4/Signature 1
• Favorable subgingival plaque microbiome shifts are associated with clinical treatment for peri-implant diseases/Experiment 5/Signature 1
• Favorable subgingival plaque microbiome shifts are associated with clinical treatment for peri-implant diseases/Experiment 6/Signature 1
• Substantial overlap between symptomatic and asymptomatic genitourinary microbiota states/Experiment 1
• Substantial overlap between symptomatic and asymptomatic genitourinary microbiota states/Experiment 1/Signature 1
• Substantial overlap between symptomatic and asymptomatic genitourinary microbiota states/Experiment 1/Signature 2
• Substantial overlap between symptomatic and asymptomatic genitourinary microbiota states/Experiment 2/Signature 1
• Substantial overlap between symptomatic and asymptomatic genitourinary microbiota states/Experiment 2/Signature 2
• Substantial overlap between symptomatic and asymptomatic genitourinary microbiota states/Experiment 3/Signature 1
• Substantial overlap between symptomatic and asymptomatic genitourinary microbiota states/Experiment 4/Signature 1
• Substantial overlap between symptomatic and asymptomatic genitourinary microbiota states/Experiment 4/Signature 2
• Exploring the relationship between the gut microbiome and mental health outcomes in a posttraumatic stress disorder cohort relative to trauma-exposed controls/Experiment 1
• Exploring the relationship between the gut microbiome and mental health outcomes in a posttraumatic stress disorder cohort relative to trauma-exposed controls/Experiment 2
• Exploring the relationship between the gut microbiome and mental health outcomes in a posttraumatic stress disorder cohort relative to trauma-exposed controls/Experiment 2/Signature 1
• Exploring the relationship between the gut microbiome and mental health outcomes in a posttraumatic stress disorder cohort relative to trauma-exposed controls/Experiment 2/Signature 2
• Exploring the relationship between the gut microbiome and mental health outcomes in a posttraumatic stress disorder cohort relative to trauma-exposed controls/Experiment 3/Signature 1
• Upper respiratory tract microbiome profiles in SARS-CoV-2 Delta and Omicron infected patients exhibit variant specific patterns and robust prediction of disease groups/Experiment 1/Signature 1
• Upper respiratory tract microbiome profiles in SARS-CoV-2 Delta and Omicron infected patients exhibit variant specific patterns and robust prediction of disease groups/Experiment 1/Signature 2
• Upper respiratory tract microbiome profiles in SARS-CoV-2 Delta and Omicron infected patients exhibit variant specific patterns and robust prediction of disease groups/Experiment 2
• Upper respiratory tract microbiome profiles in SARS-CoV-2 Delta and Omicron infected patients exhibit variant specific patterns and robust prediction of disease groups/Experiment 2/Signature 1
• Upper respiratory tract microbiome profiles in SARS-CoV-2 Delta and Omicron infected patients exhibit variant specific patterns and robust prediction of disease groups/Experiment 3/Signature 1
• Upper respiratory tract microbiome profiles in SARS-CoV-2 Delta and Omicron infected patients exhibit variant specific patterns and robust prediction of disease groups/Experiment 3/Signature 2
• Alterations of the Gut Microbiota in Patients with Diabetic Nephropathy/Experiment 1/Signature 1
• Alterations of the Gut Microbiota in Patients with Diabetic Nephropathy/Experiment 2/Signature 1
• Alterations of the Gut Microbiota in Patients with Diabetic Nephropathy/Experiment 3
• Ascaris suum infection was associated with a worm-independent reduction in microbial diversity and altered metabolic potential in the porcine gut microbiome/Experiment 1/Signature 1
• Ascaris suum infection was associated with a worm-independent reduction in microbial diversity and altered metabolic potential in the porcine gut microbiome/Experiment 1/Signature 2
• Ascaris suum infection was associated with a worm-independent reduction in microbial diversity and altered metabolic potential in the porcine gut microbiome/Experiment 2/Signature 1
• Ascaris suum infection was associated with a worm-independent reduction in microbial diversity and altered metabolic potential in the porcine gut microbiome/Experiment 2/Signature 2
• Ascaris suum infection was associated with a worm-independent reduction in microbial diversity and altered metabolic potential in the porcine gut microbiome/Experiment 3/Signature 2
• Ascaris suum infection was associated with a worm-independent reduction in microbial diversity and altered metabolic potential in the porcine gut microbiome/Experiment 4/Signature 1
• Increased Abundance of Achromobacter xylosoxidans and Bacillus cereus in Upper Airway Transcriptionally Active Microbiome of COVID-19 Mortality Patients Indicates Role of Co-Infections in Disease Severity and Outcome/Experiment 1
• Increased Abundance of Achromobacter xylosoxidans and Bacillus cereus in Upper Airway Transcriptionally Active Microbiome of COVID-19 Mortality Patients Indicates Role of Co-Infections in Disease Severity and Outcome/Experiment 1/Signature 1
• Increased Abundance of Achromobacter xylosoxidans and Bacillus cereus in Upper Airway Transcriptionally Active Microbiome of COVID-19 Mortality Patients Indicates Role of Co-Infections in Disease Severity and Outcome/Experiment 2/Signature 1
• Increased Abundance of Achromobacter xylosoxidans and Bacillus cereus in Upper Airway Transcriptionally Active Microbiome of COVID-19 Mortality Patients Indicates Role of Co-Infections in Disease Severity and Outcome/Experiment 3/Signature 1
• Increased Abundance of Achromobacter xylosoxidans and Bacillus cereus in Upper Airway Transcriptionally Active Microbiome of COVID-19 Mortality Patients Indicates Role of Co-Infections in Disease Severity and Outcome/Experiment 4/Signature 1
• Increased Abundance of Achromobacter xylosoxidans and Bacillus cereus in Upper Airway Transcriptionally Active Microbiome of COVID-19 Mortality Patients Indicates Role of Co-Infections in Disease Severity and Outcome/Experiment 4/Signature 2
• Increased Abundance of Achromobacter xylosoxidans and Bacillus cereus in Upper Airway Transcriptionally Active Microbiome of COVID-19 Mortality Patients Indicates Role of Co-Infections in Disease Severity and Outcome/Experiment 5/Signature 1
• PandaGUT provides new insights into bacterial diversity, function, and resistome landscapes with implications for conservation
• PandaGUT provides new insights into bacterial diversity, function, and resistome landscapes with implications for conservation/Experiment 1
• Alterations in the Gut Microbiota and Metabolomics of Seafarers after a Six-Month Sea Voyage/Experiment 1/Signature 1
• Alterations in the Gut Microbiota and Metabolomics of Seafarers after a Six-Month Sea Voyage/Experiment 1/Signature 2
• Effects of proton pump inhibitor on the human gut microbiome profile in multi-ethnic groups in Singapore
• Effects of proton pump inhibitor on the human gut microbiome profile in multi-ethnic groups in Singapore/Experiment 1
• Effects of proton pump inhibitor on the human gut microbiome profile in multi-ethnic groups in Singapore/Experiment 1/Signature 1
• Effects of proton pump inhibitor on the human gut microbiome profile in multi-ethnic groups in Singapore/Experiment 1/Signature 2
• Effects of proton pump inhibitor on the human gut microbiome profile in multi-ethnic groups in Singapore/Experiment 3/Signature 1
• Effects of proton pump inhibitor on the human gut microbiome profile in multi-ethnic groups in Singapore/Experiment 3/Signature 2
• Effects of proton pump inhibitor on the human gut microbiome profile in multi-ethnic groups in Singapore/Experiment 4
• Effects of proton pump inhibitor on the human gut microbiome profile in multi-ethnic groups in Singapore/Experiment 4/Signature 1
• Effects of proton pump inhibitor on the human gut microbiome profile in multi-ethnic groups in Singapore/Experiment 4/Signature 2
• Effects of proton pump inhibitor on the human gut microbiome profile in multi-ethnic groups in Singapore/Experiment 6
• Effects of proton pump inhibitor on the human gut microbiome profile in multi-ethnic groups in Singapore/Experiment 6/Signature 1
• Effects of proton pump inhibitor on the human gut microbiome profile in multi-ethnic groups in Singapore/Experiment 7/Signature 1
• Effects of proton pump inhibitor on the human gut microbiome profile in multi-ethnic groups in Singapore/Experiment 7/Signature 2
• Characterisation of the koala (Phascolarctos cinereus) pouch microbiota in a captive population reveals a dysbiotic compositional profile associated with neonatal mortality
• Characterisation of the koala (Phascolarctos cinereus) pouch microbiota in a captive population reveals a dysbiotic compositional profile associated with neonatal mortality/Experiment 1/Signature 1
• Characterisation of the koala (Phascolarctos cinereus) pouch microbiota in a captive population reveals a dysbiotic compositional profile associated with neonatal mortality/Experiment 1/Signature 2
• Genomic investigations of acute munitions exposures on the health and skin microbiome composition of leopard frog (Rana pipiens) tadpoles
• Genomic investigations of acute munitions exposures on the health and skin microbiome composition of leopard frog (Rana pipiens) tadpoles/Experiment 3/Signature 1
• Genomic investigations of acute munitions exposures on the health and skin microbiome composition of leopard frog (Rana pipiens) tadpoles/Experiment 3/Signature 2
• Abundance alteration of nondominant species in fecal-associated microbiome of patients with SAPHO syndrome/Experiment 1/Signature 1
• Abundance alteration of nondominant species in fecal-associated microbiome of patients with SAPHO syndrome/Experiment 1/Signature 2
• Characterization of microbial communities from gut microbiota of hypercholesterolemic and control subjects
• Characterization of microbial communities from gut microbiota of hypercholesterolemic and control subjects/Experiment 1
• Characterization of microbial communities from gut microbiota of hypercholesterolemic and control subjects/Experiment 1/Signature 1
• Characterization of microbial communities from gut microbiota of hypercholesterolemic and control subjects/Experiment 1/Signature 2
• Dental Biofilm Microbiota Dysbiosis Is Associated With the Risk of Acute Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation/Experiment 1/Signature 1
• Dental Biofilm Microbiota Dysbiosis Is Associated With the Risk of Acute Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation/Experiment 1/Signature 2
• Dental Biofilm Microbiota Dysbiosis Is Associated With the Risk of Acute Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation/Experiment 2
• Dental Biofilm Microbiota Dysbiosis Is Associated With the Risk of Acute Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation/Experiment 3
• Characterization of microbial communities in the chicken oviduct and the origin of chicken embryo gut microbiota/Experiment 1/Signature 1
• Characterization of microbial communities in the chicken oviduct and the origin of chicken embryo gut microbiota/Experiment 1/Signature 2
• Different Characteristics in Gut Microbiome between Advanced Adenoma Patients and Colorectal Cancer Patients by Metagenomic Analysis/Experiment 1/Signature 1
• Different Characteristics in Gut Microbiome between Advanced Adenoma Patients and Colorectal Cancer Patients by Metagenomic Analysis/Experiment 1/Signature 2
• Differences in gut microbiota structure in patients with stages 4-5 chronic kidney disease/Experiment 1
• Differences in gut microbiota structure in patients with stages 4-5 chronic kidney disease/Experiment 1/Signature 1
• Differences in gut microbiota structure in patients with stages 4-5 chronic kidney disease/Experiment 1/Signature 2
• Differences in the Composition of Gut Microbiota between Patients with Parkinson's Disease and Healthy Controls: A Cohort Study/Experiment 1/Signature 1
• Differences in the Composition of Gut Microbiota between Patients with Parkinson's Disease and Healthy Controls: A Cohort Study/Experiment 1/Signature 2
• Gut Microbiota Regulate Motor Deficits and Neuroinflammation in a Model of Parkinson's Disease/Experiment 1/Signature 1
• Gut Microbiota Regulate Motor Deficits and Neuroinflammation in a Model of Parkinson's Disease/Experiment 1/Signature 2
• Gut Microbiota Regulate Motor Deficits and Neuroinflammation in a Model of Parkinson's Disease/Experiment 2/Signature 2
• Alterations of conjunctival microbiota associated with orthokeratology lens wearing in myopic children/Experiment 1
• Evaluation of fecal microbiota transplantation in Parkinson's disease patients with constipation/Experiment 1/Signature 1
• Evaluation of fecal microbiota transplantation in Parkinson's disease patients with constipation/Experiment 1/Signature 2
• Evaluation of fecal microbiota transplantation in Parkinson's disease patients with constipation/Experiment 2/Signature 2
• Evaluation of fecal microbiota transplantation in Parkinson's disease patients with constipation/Experiment 3/Signature 1
• Evaluation of fecal microbiota transplantation in Parkinson's disease patients with constipation/Experiment 3/Signature 2
• Evaluation of fecal microbiota transplantation in Parkinson's disease patients with constipation/Experiment 4
• Evaluation of fecal microbiota transplantation in Parkinson's disease patients with constipation/Experiment 4/Signature 1
• Evaluation of fecal microbiota transplantation in Parkinson's disease patients with constipation/Experiment 4/Signature 2
• Evaluation of fecal microbiota transplantation in Parkinson's disease patients with constipation/Experiment 5
• Evaluation of fecal microbiota transplantation in Parkinson's disease patients with constipation/Experiment 5/Signature 1
• Evaluation of fecal microbiota transplantation in Parkinson's disease patients with constipation/Experiment 5/Signature 2
• Gut Microbiota Alterations and Their Functional Differences in Depression According to Enterotypes in Asian Individuals/Experiment 1
• Gut Microbiota Alterations and Their Functional Differences in Depression According to Enterotypes in Asian Individuals/Experiment 1/Signature 1
• Gut Microbiota Alterations and Their Functional Differences in Depression According to Enterotypes in Asian Individuals/Experiment 1/Signature 2
• Gut Microbiota Alterations and Their Functional Differences in Depression According to Enterotypes in Asian Individuals/Experiment 2
• Gut Microbiota Alterations and Their Functional Differences in Depression According to Enterotypes in Asian Individuals/Experiment 2/Signature 1
• Gut Microbiota Alterations and Their Functional Differences in Depression According to Enterotypes in Asian Individuals/Experiment 2/Signature 2
• Gut Microbiota Alterations and Their Functional Differences in Depression According to Enterotypes in Asian Individuals/Experiment 3
• Influence of aerobic exercise training on mice gut microbiota in Parkinson's disease/Experiment 1/Signature 1
• Influence of aerobic exercise training on mice gut microbiota in Parkinson's disease/Experiment 2/Signature 1
• Influence of aerobic exercise training on mice gut microbiota in Parkinson's disease/Experiment 3/Signature 1
• Diagnosis of Crohn's disease and ulcerative colitis using the microbiome/Experiment 1
• Diagnosis of Crohn's disease and ulcerative colitis using the microbiome/Experiment 1/Signature 1
• Diagnosis of Crohn's disease and ulcerative colitis using the microbiome/Experiment 1/Signature 2
• Diagnosis of Crohn's disease and ulcerative colitis using the microbiome/Experiment 2
• Diagnosis of Crohn's disease and ulcerative colitis using the microbiome/Experiment 2/Signature 1
• Diagnosis of Crohn's disease and ulcerative colitis using the microbiome/Experiment 2/Signature 2
• Diagnosis of Crohn's disease and ulcerative colitis using the microbiome/Experiment 3
• Diagnosis of Crohn's disease and ulcerative colitis using the microbiome/Experiment 3/Signature 1
• Diagnosis of Crohn's disease and ulcerative colitis using the microbiome/Experiment 3/Signature 2
• Diagnosis of Crohn's disease and ulcerative colitis using the microbiome/Experiment 4/Signature 1
• Diagnosis of Crohn's disease and ulcerative colitis using the microbiome/Experiment 5/Signature 1
• Diagnosis of Crohn's disease and ulcerative colitis using the microbiome/Experiment 5/Signature 2
• Diagnosis of Crohn's disease and ulcerative colitis using the microbiome/Experiment 6
• Diagnosis of Crohn's disease and ulcerative colitis using the microbiome/Experiment 6/Signature 1
• Diagnosis of Crohn's disease and ulcerative colitis using the microbiome/Experiment 6/Signature 2
• Diagnosis of Crohn's disease and ulcerative colitis using the microbiome/Experiment 7
• Diagnosis of Crohn's disease and ulcerative colitis using the microbiome/Experiment 7/Signature 1
• Diagnosis of Crohn's disease and ulcerative colitis using the microbiome/Experiment 7/Signature 2
• Diagnosis of Crohn's disease and ulcerative colitis using the microbiome/Experiment 8
• Diagnosis of Crohn's disease and ulcerative colitis using the microbiome/Experiment 8/Signature 1
• Diagnosis of Crohn's disease and ulcerative colitis using the microbiome/Experiment 8/Signature 2
• Diagnosis of Crohn's disease and ulcerative colitis using the microbiome/Experiment 9
• Diagnosis of Crohn's disease and ulcerative colitis using the microbiome/Experiment 9/Signature 1
• Diagnosis of Crohn's disease and ulcerative colitis using the microbiome/Experiment 9/Signature 2
• A metagenomic study of the gut microbiome in Behcet's disease/Experiment 1
• A metagenomic study of the gut microbiome in Behcet's disease/Experiment 1/Signature 1
• A metagenomic study of the gut microbiome in Behcet's disease/Experiment 1/Signature 2
• A metagenomic study of the gut microbiome in Behcet's disease/Experiment 2
• A metagenomic study of the gut microbiome in Behcet's disease/Experiment 2/Signature 1
• A metagenomic study of the gut microbiome in Behcet's disease/Experiment 2/Signature 2
• A metagenomic study of the gut microbiome in Behcet's disease/Experiment 3
• A metagenomic study of the gut microbiome in Behcet's disease/Experiment 3/Signature 1
• A metagenomic study of the gut microbiome in Behcet's disease/Experiment 3/Signature 2
• A metagenomic study of the gut microbiome in Behcet's disease/Experiment 4/Signature 1
• A metagenomic study of the gut microbiome in Behcet's disease/Experiment 4/Signature 2
• Intestinal microbiome and metabolome signatures in patients with chronic granulomatous disease/Experiment 1/Signature 1
• Intestinal microbiome and metabolome signatures in patients with chronic granulomatous disease/Experiment 1/Signature 2
• Intestinal microbiome and metabolome signatures in patients with chronic granulomatous disease/Experiment 4/Signature 1
• Intestinal microbiome and metabolome signatures in patients with chronic granulomatous disease/Experiment 4/Signature 2
• Intestinal microbiome and metabolome signatures in patients with chronic granulomatous disease/Experiment 5/Signature 1
• Intestinal microbiome and metabolome signatures in patients with chronic granulomatous disease/Experiment 5/Signature 2
• Intestinal microbiome and metabolome signatures in patients with chronic granulomatous disease/Experiment 6/Signature 1
• Gut microbiota regulate Alzheimer's disease pathologies and cognitive disorders via PUFA-associated neuroinflammation/Experiment 1/Signature 1
• Gut microbiota regulate Alzheimer's disease pathologies and cognitive disorders via PUFA-associated neuroinflammation/Experiment 1/Signature 2
• Association of fecal short-chain fatty acids with clinical severity and gut microbiota in essential tremor and its difference from Parkinson's disease/Experiment 1/Signature 1
• Association of fecal short-chain fatty acids with clinical severity and gut microbiota in essential tremor and its difference from Parkinson's disease/Experiment 1/Signature 2
• Association of fecal short-chain fatty acids with clinical severity and gut microbiota in essential tremor and its difference from Parkinson's disease/Experiment 2
• Association of fecal short-chain fatty acids with clinical severity and gut microbiota in essential tremor and its difference from Parkinson's disease/Experiment 2/Signature 2
• Longitudinal and Comparative Analysis of Gut Microbiota of Tunisian Newborns According to Delivery Mode/Experiment 1
• Longitudinal and Comparative Analysis of Gut Microbiota of Tunisian Newborns According to Delivery Mode/Experiment 1/Signature 1
• Longitudinal and Comparative Analysis of Gut Microbiota of Tunisian Newborns According to Delivery Mode/Experiment 1/Signature 2
• Longitudinal and Comparative Analysis of Gut Microbiota of Tunisian Newborns According to Delivery Mode/Experiment 2/Signature 1
• Longitudinal and Comparative Analysis of Gut Microbiota of Tunisian Newborns According to Delivery Mode/Experiment 2/Signature 2
• Longitudinal and Comparative Analysis of Gut Microbiota of Tunisian Newborns According to Delivery Mode/Experiment 3/Signature 1
• Longitudinal and Comparative Analysis of Gut Microbiota of Tunisian Newborns According to Delivery Mode/Experiment 3/Signature 2
• Longitudinal and Comparative Analysis of Gut Microbiota of Tunisian Newborns According to Delivery Mode/Experiment 4/Signature 1
• Longitudinal and Comparative Analysis of Gut Microbiota of Tunisian Newborns According to Delivery Mode/Experiment 4/Signature 2
• Longitudinal and Comparative Analysis of Gut Microbiota of Tunisian Newborns According to Delivery Mode/Experiment 5/Signature 1
• Longitudinal and Comparative Analysis of Gut Microbiota of Tunisian Newborns According to Delivery Mode/Experiment 6/Signature 2
• Alterations in gut microbiota and metabolite profiles in patients with infantile cholestasis/Experiment 1/Signature 1
• Alterations in gut microbiota and metabolite profiles in patients with infantile cholestasis/Experiment 1/Signature 2
• Gut microbiota are related to Parkinson's disease and clinical phenotype/Experiment 1
• Gut microbiota are related to Parkinson's disease and clinical phenotype/Experiment 1/Signature 1
• Systematic analysis of gut microbiome reveals the role of bacterial folate and homocysteine metabolism in Parkinson's disease/Experiment 1
• Systematic analysis of gut microbiome reveals the role of bacterial folate and homocysteine metabolism in Parkinson's disease/Experiment 1/Signature 1
• Systematic analysis of gut microbiome reveals the role of bacterial folate and homocysteine metabolism in Parkinson's disease/Experiment 1/Signature 2
• Systematic analysis of gut microbiome reveals the role of bacterial folate and homocysteine metabolism in Parkinson's disease/Experiment 2/Signature 2
• Characteristics of gut microbiota in patients with asthenozoospermia: a Chinese pilot study
• Characteristics of gut microbiota in patients with asthenozoospermia: a Chinese pilot study/Experiment 1
• Characteristics of gut microbiota in patients with asthenozoospermia: a Chinese pilot study/Experiment 1/Signature 1
• Characteristics of gut microbiota in patients with asthenozoospermia: a Chinese pilot study/Experiment 1/Signature 2
• Pivotal interplays between fecal metabolome and gut microbiome reveal functional signatures in cerebral ischemic stroke
• Pivotal interplays between fecal metabolome and gut microbiome reveal functional signatures in cerebral ischemic stroke/Experiment 1
• Pivotal interplays between fecal metabolome and gut microbiome reveal functional signatures in cerebral ischemic stroke/Experiment 1/Signature 1
• Pivotal interplays between fecal metabolome and gut microbiome reveal functional signatures in cerebral ischemic stroke/Experiment 1/Signature 2
• Short chain fatty acids and gut microbiota differ between patients with Parkinson's disease and age-matched controls/Experiment 1/Signature 1
• Short chain fatty acids and gut microbiota differ between patients with Parkinson's disease and age-matched controls/Experiment 1/Signature 2
• Short chain fatty acids and gut microbiota differ between patients with Parkinson's disease and age-matched controls/Experiment 2/Signature 1
• Study 944/Experiment 2/Signature 2
• Integrated Multi-Cohort Analysis of the Parkinson's Disease Gut Metagenome/Experiment 1
• Integrated Multi-Cohort Analysis of the Parkinson's Disease Gut Metagenome/Experiment 1/Signature 1
• Integrated Multi-Cohort Analysis of the Parkinson's Disease Gut Metagenome/Experiment 1/Signature 2
• Integrated Multi-Cohort Analysis of the Parkinson's Disease Gut Metagenome/Experiment 2/Signature 1
• Integrated Multi-Cohort Analysis of the Parkinson's Disease Gut Metagenome/Experiment 2/Signature 2
• Dysbiosis of Oral Microbiota and Metabolite Profiles Associated with Type 2 Diabetes Mellitus/Experiment 1/Signature 1
• Dysbiosis of Oral Microbiota and Metabolite Profiles Associated with Type 2 Diabetes Mellitus/Experiment 1/Signature 2
• Dysbiosis of Oral Microbiota and Metabolite Profiles Associated with Type 2 Diabetes Mellitus/Experiment 2/Signature 1
• Exploring nasopharyngeal microbiota profile in children affected by SARS-CoV-2 infection/Experiment 1
• Effect of Parkinson's disease and related medications on the composition of the fecal bacterial microbiota/Experiment 1/Signature 1
• Effect of Parkinson's disease and related medications on the composition of the fecal bacterial microbiota/Experiment 1/Signature 2
• Effect of Parkinson's disease and related medications on the composition of the fecal bacterial microbiota/Experiment 2/Signature 1
• Effect of Parkinson's disease and related medications on the composition of the fecal bacterial microbiota/Experiment 4/Signature 1
• Effect of Parkinson's disease and related medications on the composition of the fecal bacterial microbiota/Experiment 4/Signature 2
• Effect of Parkinson's disease and related medications on the composition of the fecal bacterial microbiota/Experiment 8/Signature 1
• Effect of Parkinson's disease and related medications on the composition of the fecal bacterial microbiota/Experiment 11/Signature 1
• Effect of Parkinson's disease and related medications on the composition of the fecal bacterial microbiota/Experiment 12/Signature 2
• Effect of Parkinson's disease and related medications on the composition of the fecal bacterial microbiota/Experiment 13/Signature 1
• Effect of Parkinson's disease and related medications on the composition of the fecal bacterial microbiota/Experiment 14/Signature 1
• The Interaction between Intratumoral Microbiome and Immunity Is Related to the Prognosis of Ovarian Cancer/Experiment 1/Signature 1
• The Interaction between Intratumoral Microbiome and Immunity Is Related to the Prognosis of Ovarian Cancer/Experiment 1/Signature 2
• Dysbiosis of the Beneficial Gut Bacteria in Patients with Parkinson's Disease from India/Experiment 1/Signature 1
• Dysbiosis of the Beneficial Gut Bacteria in Patients with Parkinson's Disease from India/Experiment 1/Signature 2
• The Gut Microbiome Is Associated with Clinical Response to Anti-PD-1/PD-L1 Immunotherapy in Gastrointestinal Cancer/Experiment 1/Signature 1
• The Gut Microbiome Is Associated with Clinical Response to Anti-PD-1/PD-L1 Immunotherapy in Gastrointestinal Cancer/Experiment 1/Signature 2
• The Gut Microbiome Is Associated with Clinical Response to Anti-PD-1/PD-L1 Immunotherapy in Gastrointestinal Cancer/Experiment 2/Signature 1
• The Gut Microbiome Is Associated with Clinical Response to Anti-PD-1/PD-L1 Immunotherapy in Gastrointestinal Cancer/Experiment 2/Signature 2
• The Gut Microbiome Is Associated with Clinical Response to Anti-PD-1/PD-L1 Immunotherapy in Gastrointestinal Cancer/Experiment 3/Signature 1
• The Gut Microbiome Is Associated with Clinical Response to Anti-PD-1/PD-L1 Immunotherapy in Gastrointestinal Cancer/Experiment 3/Signature 2
• The Gut Microbiome Is Associated with Clinical Response to Anti-PD-1/PD-L1 Immunotherapy in Gastrointestinal Cancer/Experiment 4/Signature 1
• The Gut Microbiome Is Associated with Clinical Response to Anti-PD-1/PD-L1 Immunotherapy in Gastrointestinal Cancer/Experiment 4/Signature 2
• The Gut Microbiome Is Associated with Clinical Response to Anti-PD-1/PD-L1 Immunotherapy in Gastrointestinal Cancer/Experiment 5/Signature 1
• The Gut Microbiome Is Associated with Clinical Response to Anti-PD-1/PD-L1 Immunotherapy in Gastrointestinal Cancer/Experiment 5/Signature 2
• Nutritional Intake and Gut Microbiome Composition Predict Parkinson's Disease/Experiment 1
• Exploring the Relevance between Gut Microbiota-Metabolites Profile and Chronic Kidney Disease with Distinct Pathogenic Factor/Experiment 1
• Exploring the Relevance between Gut Microbiota-Metabolites Profile and Chronic Kidney Disease with Distinct Pathogenic Factor/Experiment 1/Signature 1
• Exploring the Relevance between Gut Microbiota-Metabolites Profile and Chronic Kidney Disease with Distinct Pathogenic Factor/Experiment 1/Signature 2
• Exploring the Relevance between Gut Microbiota-Metabolites Profile and Chronic Kidney Disease with Distinct Pathogenic Factor/Experiment 2
• Exploring the Relevance between Gut Microbiota-Metabolites Profile and Chronic Kidney Disease with Distinct Pathogenic Factor/Experiment 3
• Exploring the Relevance between Gut Microbiota-Metabolites Profile and Chronic Kidney Disease with Distinct Pathogenic Factor/Experiment 4
• The efficacy of prevention for colon cancer based on the microbiota therapy and the antitumor mechanisms with intervention of dietary Lactobacillus/Experiment 1
• The efficacy of prevention for colon cancer based on the microbiota therapy and the antitumor mechanisms with intervention of dietary Lactobacillus/Experiment 1/Signature 1
• The efficacy of prevention for colon cancer based on the microbiota therapy and the antitumor mechanisms with intervention of dietary Lactobacillus/Experiment 1/Signature 2
• The efficacy of prevention for colon cancer based on the microbiota therapy and the antitumor mechanisms with intervention of dietary Lactobacillus/Experiment 2
• The efficacy of prevention for colon cancer based on the microbiota therapy and the antitumor mechanisms with intervention of dietary Lactobacillus/Experiment 3
• The efficacy of prevention for colon cancer based on the microbiota therapy and the antitumor mechanisms with intervention of dietary Lactobacillus/Experiment 3/Signature 1
• The efficacy of prevention for colon cancer based on the microbiota therapy and the antitumor mechanisms with intervention of dietary Lactobacillus/Experiment 3/Signature 2
• Divergent maturational patterns of the infant bacterial and fungal gut microbiome in the first year of life are associated with inter-kingdom community dynamics and infant nutrition/Experiment 1/Signature 1
• Divergent maturational patterns of the infant bacterial and fungal gut microbiome in the first year of life are associated with inter-kingdom community dynamics and infant nutrition/Experiment 2/Signature 1
• Divergent maturational patterns of the infant bacterial and fungal gut microbiome in the first year of life are associated with inter-kingdom community dynamics and infant nutrition/Experiment 2/Signature 2
• Acupuncture inhibits neuroinflammation and gut microbial dysbiosis in a mouse model of Parkinson's disease/Experiment 4
• Clinical Phenotypes of Parkinson's Disease Associate with Distinct Gut Microbiota and Metabolome Enterotypes
• Clinical Phenotypes of Parkinson's Disease Associate with Distinct Gut Microbiota and Metabolome Enterotypes/Experiment 1/Signature 1
• Clinical Phenotypes of Parkinson's Disease Associate with Distinct Gut Microbiota and Metabolome Enterotypes/Experiment 1/Signature 2
• Clinical Phenotypes of Parkinson's Disease Associate with Distinct Gut Microbiota and Metabolome Enterotypes/Experiment 2/Signature 2
• Clinical Phenotypes of Parkinson's Disease Associate with Distinct Gut Microbiota and Metabolome Enterotypes/Experiment 3/Signature 1
• Virulence genes are a signature of the microbiome in the colorectal tumor microenvironment/Experiment 1
• Virulence genes are a signature of the microbiome in the colorectal tumor microenvironment/Experiment 1/Signature 1
• Virulence genes are a signature of the microbiome in the colorectal tumor microenvironment/Experiment 1/Signature 2
• Altered gut microbiota in Parkinson's disease patients with motor complications/Experiment 1
• Altered gut microbiota in Parkinson's disease patients with motor complications/Experiment 1/Signature 1
• Altered gut microbiota in Parkinson's disease patients with motor complications/Experiment 1/Signature 2
• Gut Microbiota is Altered in Patients with Alzheimer's Disease/Experiment 1/Signature 1
• The Airway Microbiota Signatures of Infection and Rejection in Lung Transplant Recipients
• Alteration in gut mycobiota of patients with polycystic ovary syndrome/Experiment 1
• Alteration in gut mycobiota of patients with polycystic ovary syndrome/Experiment 1/Signature 1
• Alteration in gut mycobiota of patients with polycystic ovary syndrome/Experiment 1/Signature 2
• Airway Microbiome and Serum Metabolomics Analysis Identify Differential Candidate Biomarkers in Allergic Rhinitis/Experiment 1/Signature 1
• Airway Microbiome and Serum Metabolomics Analysis Identify Differential Candidate Biomarkers in Allergic Rhinitis/Experiment 1/Signature 2